



Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents

Joseph T. Flynn, MD, MS, FAAP,^a David C. Kaelber, MD, PhD, MPH, FAAP, FACP, FACMI,^b Carissa M. Baker-Smith, MD, MS, MPH, FAAP, FAHA,^c Douglas Blowey, MD,^d Aaron E. Carroll, MD, MS, FAAP,^e Stephen R. Daniels, MD, PhD, FAAP,^f Sarah D. de Ferranti, MD, MPH, FAAP,^g Janis M. Dionne, MD, FRCPC,^h Bonita Falkner, MD,ⁱ Susan K. Flinn, MA,^j Samuel S. Gidding, MD,^k Celeste Goodwin,^l Michael G. Leu, MD, MS, MHS, FAAP,^m Makia E. Powers, MD, MPH, FAAP,ⁿ Corinna Rea, MD, MPH, FAAP,^o Joshua Samuels, MD, MPH, FAAP,^p Madeline Simasek, MD, MSCP, FAAP,^q Vidhu V. Thaker, MD, FAAP,^r Elaine M. Urbina, MD, MS, FAAP,^s SUBCOMMITTEE ON SCREENING AND MANAGEMENT OF HIGH BLOOD PRESSURE IN CHILDREN

These pediatric hypertension guidelines are an update to the 2004 “Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents.” Significant changes in these guidelines include (1) the replacement of the term “prehypertension” with the term “elevated blood pressure,” (2) new normative pediatric blood pressure (BP) tables based on normal-weight children, (3) a simplified screening table for identifying BPs needing further evaluation, (4) a simplified BP classification in adolescents ≥ 13 years of age that aligns with the forthcoming American Heart Association and American College of Cardiology adult BP guidelines, (5) a more limited recommendation to perform screening BP measurements only at preventive care visits, (6) streamlined recommendations on the initial evaluation and management of abnormal BPs, (7) an expanded role for ambulatory BP monitoring in the diagnosis and management of pediatric hypertension, and (8) revised recommendations on when to perform echocardiography in the evaluation of newly diagnosed hypertensive pediatric patients (generally only before medication initiation), along with a revised definition of left ventricular hypertrophy. These guidelines include 30 Key Action Statements and 27 additional recommendations derived from a comprehensive review of almost 15 000 published articles between January 2004 and July 2016. Each Key Action Statement includes level of evidence, benefit-harm relationship, and strength of recommendation. This clinical practice guideline, endorsed by the American Heart Association, is intended to foster a patient- and family-centered approach to care, reduce unnecessary and costly medical interventions, improve patient diagnoses and outcomes, support implementation, and provide direction for future research.

abstract

FREE

^aDr. Robert O. Hickman Endowed Chair in Pediatric Nephrology, Division of Nephrology, Department of Pediatrics, University of Washington and Seattle Children's Hospital, Seattle, Washington; ^bDepartments of Pediatrics, Internal Medicine, Population and Quantitative Health Sciences, Center for Clinical Informatics Research and Education, Case Western Reserve University and MetroHealth System, Cleveland, Ohio; ^cDivision of Pediatric Cardiology, School of Medicine, University of Maryland, Baltimore, Maryland; ^dChildren's Mercy Hospital, University of Missouri-Kansas City and Children's Mercy Integrated Care Solutions, Kansas City, Missouri; ^eDepartment of Pediatrics, School of Medicine, Indiana University, Bloomington, Indiana; ^fDepartment of Pediatrics, School of Medicine, University of Colorado-Denver and Pediatrician in Chief, Children's Hospital Colorado, Aurora, Colorado; ^gDirector, Preventive Cardiology Clinic, Boston Children's Hospital, Department of Pediatrics, Harvard Medical School, Boston, Massachusetts; ^hDivision of Nephrology, Department of Pediatrics, University of British Columbia and British Columbia Children's Hospital, Vancouver, British Columbia, Canada; ⁱDepartments of Medicine and Pediatrics, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania; ^jConsultant, American Academy of Pediatrics, Washington, District of Columbia; ^kCardiology Division Head, Nemours Cardiac Center, Alfred I. duPont Hospital for Children, Wilmington, Delaware; ^lNational Pediatric Blood Pressure Awareness Foundation, Prairieville, Louisiana; ^mDepartments of Pediatrics and Biomedical Informatics and Medical Education, University of Washington, University of Washington Medicine and Information Technology Services, and Seattle Children's Hospital,

To cite: Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. *Pediatrics*. 2017;140(3):e20171904

1. INTRODUCTION

1. Scope of the Clinical Practice Guideline

Interest in childhood hypertension (HTN) has increased since the 2004 publication of the “Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents” (Fourth Report).¹ Recognizing ongoing evidence gaps and the need for an updated, thorough review of the relevant literature, the American Academy of Pediatrics (AAP) and its Council on Quality Improvement and Patient Safety developed this practice guideline to provide an update on topics relevant to the diagnosis, evaluation, and management of pediatric HTN. It is primarily directed at clinicians caring for children and adolescents in the outpatient setting. This guideline is endorsed by the American Heart Association.

When it was not possible to identify sufficient evidence, recommendations are based on the consensus opinion of the expert members of the Screening and Management of High Blood Pressure in Children Clinical Practice Guideline Subcommittee (henceforth, “the subcommittee”). The subcommittee intends to regularly update this guideline as new evidence becomes available. Implementation tools for this guideline are available on the AAP Web site (<https://www.aap.org/en-us/about-the-aap/Committees-Councils-Sections/coqips/Pages/Implementation-Guide.aspx>).

1.1 Methodology

The subcommittee was co-chaired by a pediatric nephrologist and a general pediatrician and consisted of 17 members, including a parent representative. All subcommittee members were asked to disclose relevant financial or proprietary conflicts of interest for members or their family members at the start of and throughout the guideline

preparation process. Potential conflicts of interest were addressed and resolved by the AAP. A detailed list of subcommittee members and affiliations can be found in the Consortium section at the end of this article. A listing of subcommittee members with conflicts of interest will be included in the forthcoming technical report.

The subcommittee epidemiologist created a detailed content outline, which was reviewed and approved by the subcommittee. The outline contained a list of primary and secondary topics generated to guide a thorough literature search and meet the goal of providing an up-to-date systemic review of the literature pertaining to the diagnosis, management, and treatment of pediatric HTN as well as the prevalence of pediatric HTN and its associated comorbidities.

Of the topics covered in the outline, ~80% were researched by using a Patient, Intervention/Indicator, Comparison, Outcome, and Time (PICOT) format to address the following key questions:

1. How should systemic HTN (eg, primary HTN, renovascular HTN, white coat hypertension [WCH], and masked hypertension [MH]) in children be diagnosed, and what is the optimal approach to diagnosing HTN in children and adolescents?
2. What is the recommended workup for pediatric HTN? How do we best identify the underlying etiologies of secondary HTN in children?
3. What is the optimal goal systolic blood pressure (SBP) and/or diastolic blood pressure (DBP) for children and adolescents?
4. In children 0 to 18 years of age, how does treatment with lifestyle versus antihypertensive agents influence indirect measures of cardiovascular disease (CVD) risk, such as carotid intima-media

thickness (cIMT), flow-mediated dilation (FMD), left ventricular hypertrophy (LVH), and other markers of vascular dysfunction?

To address these key questions, a systematic search and review of literature was performed. The initial search included articles published between the publication of the Fourth Report (January 2004) and August 2015. The process used to conduct the systematic review was consistent with the recommendations of the Institute of Medicine for systematic reviews.²

For the topics not researched by using the PICOT format, separate searches were conducted. Not all topics (eg, economic aspects of pediatric HTN) were appropriate for the PICOT format. A third and final search was conducted at the time the Key Action Statements (KASs) were generated to identify any additional relevant articles published between August 2015 and July 2016. (See Table 1 for a complete list of KASs.)

A detailed description of the methodology used to conduct the literature search and systematic review for this clinical practice guideline will be included in the forthcoming technical report. In brief, reference selection involved a multistep process. First, 2 subcommittee members reviewed the titles and abstracts of references identified for each key question. The epidemiologist provided a deciding vote when required. Next, 2 subcommittee members and the epidemiologist conducted full-text reviews of the selected articles. Although many subcommittee members have extensively published articles on topics covered in this guideline, articles were not preferentially selected on the basis of authorship.

Articles selected at this stage were mapped back to the relevant main topic in the outline. Subcommittee members were then assigned to

TABLE 1 Summary of KASs for Screening and Management of High BP in Children and Adolescents

KAS	Evidence Quality, Strength of Recommendation
1. BP should be measured annually in children and adolescents ≥ 3 y of age.	C, moderate
2. BP should be checked in all children and adolescents ≥ 3 y of age at every health care encounter if they have obesity, are taking medications known to increase BP, have renal disease, a history of aortic arch obstruction or coarctation, or diabetes.	C, moderate
3. Trained health care professionals in the office setting should make a diagnosis of HTN if a child or adolescent has auscultatory-confirmed BP readings ≥ 95 th percentile at 3 different visits.	C, moderate
4. Organizations with EHRs used in an office setting should consider including flags for abnormal BP values, both when the values are being entered and when they are being viewed.	C, weak
5. Oscillometric devices may be used for BP screening in children and adolescents. When doing so, providers should use a device that has been validated in the pediatric age group. If elevated BP is suspected on the basis of oscillometric readings, confirmatory measurements should be obtained by auscultation.	B, strong
6. ABPM should be performed for confirmation of HTN in children and adolescents with office BP measurements in the elevated BP category for 1 year or more or with stage 1 HTN over 3 clinic visits.	C, moderate
7. Routine performance of ABPM should be strongly considered in children and adolescents with high-risk conditions (see Table 12) to assess HTN severity and determine if abnormal circadian BP patterns are present, which may indicate increased risk for target organ damage.	B, moderate
8. ABPM should be performed by using a standardized approach (see Table 13) with monitors that have been validated in a pediatric population, and studies should be interpreted by using pediatric normative data.	C, moderate
9. Children and adolescents with suspected WCH should undergo ABPM. Diagnosis is based on the presence of mean SBP and DBP < 95 th percentile and SBP and DBP load $< 25\%$.	B, strong
10. Home BP monitoring should not be used to diagnose HTN, MH, or WCH but may be a useful adjunct to office and ambulatory BP measurement after HTN has been diagnosed.	C, moderate
11. Children and adolescents ≥ 6 y of age do not require an extensive evaluation for secondary causes of HTN if they have a positive family history of HTN, are overweight or obese, and/or do not have history or physical examination findings (Table 14) suggestive of a secondary cause of HTN.	C, moderate
12. Children and adolescents who have undergone coarctation repair should undergo ABPM for the detection of HTN (including MH).	B, strong
13. In children and adolescents being evaluated for high BP, the provider should obtain a perinatal history, appropriate nutritional history, physical activity history, psychosocial history, and family history and perform a physical examination to identify findings suggestive of secondary causes of HTN.	B, strong
14. Clinicians should not perform electrocardiography in hypertensive children and adolescents being evaluated for LVH.	B, strong
15-1. It is recommended that echocardiography be performed to assess for cardiac target organ damage (LV mass, geometry, and function) at the time of consideration of pharmacologic treatment of HTN.	C, moderate
15-2. LVH should be defined as LV mass > 51 g/m ^{2.7} (boys and girls) for children and adolescents older than age 8 y and defined by LV mass > 115 g/BSA for boys and LV mass > 95 g/BSA for girls.	
15-3. Repeat echocardiography may be performed to monitor improvement or progression of target organ damage at 6- to 12-mo intervals. Indications to repeat echocardiography include persistent HTN despite treatment, concentric LV hypertrophy, or reduced LV ejection fraction.	
15-4. In patients without LV target organ injury at initial echocardiographic assessment, repeat echocardiography at yearly intervals may be considered in those with stage 2 HTN, secondary HTN, or chronic stage 1 HTN incompletely treated (noncompliance or drug resistance) to assess for the development of worsening LV target organ injury.	
16. Doppler renal ultrasonography may be used as a noninvasive screening study for the evaluation of possible RAS in normal-wt children and adolescents ≥ 8 y of age who are suspected of having renovascular HTN and who will cooperate with the procedure.	C, moderate
17. In children and adolescents suspected of having RAS, either CTA or MRA may be performed as noninvasive imaging studies. Nuclear renography is less useful in pediatrics and should generally be avoided.	D, weak
18. Routine testing for MA is not recommended for children and adolescents with primary HTN.	C, moderate
19. In children and adolescents diagnosed with HTN, the treatment goal with nonpharmacologic and pharmacologic therapy should be a reduction in SBP and DBP to < 90 th percentile and $< 130/80$ mm Hg in adolescents ≥ 13 years old.	C, moderate
20. At the time of diagnosis of elevated BP or HTN in a child or adolescent, clinicians should provide advice on the DASH diet and recommend moderate to vigorous physical activity at least 3 to 5 d per week (30–60 min per session) to help reduce BP.	C, weak
21. In hypertensive children and adolescents who have failed lifestyle modifications (particularly those who have LV hypertrophy on echocardiography, symptomatic HTN, or stage 2 HTN without a clearly modifiable factor [eg, obesity]), clinicians should initiate pharmacologic treatment with an ACE inhibitor, ARB, long-acting calcium channel blocker, or thiazide diuretic.	B, moderate
22. ABPM may be used to assess treatment effectiveness in children and adolescents with HTN, especially when clinic and/or home BP measurements indicate insufficient BP response to treatment.	B, moderate
23-1. Children and adolescents with CKD should be evaluated for HTN at each medical encounter.	B, strong
23-2. Children or adolescents with both CKD and HTN should be treated to lower 24-hr MAP < 50 th percentile by ABPM.	
23-3. Regardless of apparent control of BP with office measures, children and adolescents with CKD and a history of HTN should have BP assessed by ABPM at least yearly to screen for MH.	
24. Children and adolescents with CKD and HTN should be evaluated for proteinuria.	B, strong
25. Children and adolescents with CKD, HTN, and proteinuria should be treated with an ACE inhibitor or ARB.	B, strong

TABLE 1 Continued

KAS	Evidence Quality, Strength of Recommendation
26. Children and adolescents with T1DM or T2DM should be evaluated for HTN at each medical encounter and treated if BP \geq 95th percentile or $>130/80$ mm Hg in adolescents ≥ 13 y of age.	C, moderate
27. In children and adolescents with acute severe HTN and life-threatening symptoms, immediate treatment with short-acting antihypertensive medication should be initiated, and BP should be reduced by no more than 25% of the planned reduction over the first 8 h.	Expert opinion, D, weak
28. Children and adolescents with HTN may participate in competitive sports once hypertensive target organ effects and cardiovascular risk have been assessed.	C, moderate
29. Children and adolescents with HTN should receive treatment to lower BP below stage 2 thresholds before participation in competitive sports.	C, moderate
30. Adolescents with elevated BP or HTN (whether they are receiving antihypertensive treatment) should typically have their care transitioned to an appropriate adult care provider by 22 y of age (recognizing that there may be individual cases in which this upper age limit is exceeded, particularly in the case of youth with special health care needs). There should be a transfer of information regarding HTN etiology and past manifestations and complications of the patient's HTN.	X, strong

writing teams that evaluated the evidence quality for selected topics and generated appropriate KASs in accordance with an AAP grading matrix (see Fig 1 and the detailed discussion in the forthcoming technical report).³ Special working groups were created to address 2 specific topics for which evidence was lacking and expert opinion was required to generate KASs, "Definition of HTN" and "Definition of LVH." References for any topics not covered by the key questions were selected on the basis of additional literature searches and reviewed by the epidemiologist and subcommittee members assigned to the topic. When applicable, searches were conducted by using the PICOT format.

In addition to the 30 KASs listed above, this guideline also contains 27 additional recommendations that are based on the consensus expert opinion of the subcommittee members. These recommendations, along with their locations in the document, are listed in Table 2.

2. EPIDEMIOLOGY AND CLINICAL SIGNIFICANCE

2.1 Prevalence of HTN in Children

Information on the prevalence of high blood pressure (BP) in children is largely derived from data from the NHANES and typically is based on a single BP measurement session. These surveys, conducted

since 1988, indicate that there has been an increase in the prevalence of childhood high BP, including both HTN and elevated BP.^{4,5} High BP is consistently greater in boys (15%–19%) than in girls (7%–12%). The prevalence of high BP is higher among Hispanic and non-Hispanic African American children compared with non-Hispanic white children, with higher rates among adolescents than among younger children.⁶

However, in a clinical setting and with repeated BP measurements, the prevalence of confirmed HTN is lower in part because of inherent BP variability as well as an adjustment to the experience of having BP measured (also known as the accommodation effect). Therefore, the actual prevalence of clinical HTN in children and adolescents is $\sim 3.5\%$.^{7,8} The prevalence of persistently elevated BP (formerly termed "prehypertension," including BP values from the 90th to 94th percentiles or between 120/80 and 130/80 mm Hg in adolescents) is also $\sim 2.2\%$ to 3.5% , with higher rates among children and adolescents who have overweight and obesity.^{7,9}

Data on BP tracking from childhood to adulthood demonstrate that higher BP in childhood correlates with higher BP in adulthood and the onset of HTN in young adulthood. The strength of the tracking relationship is stronger in older children and adolescents.¹⁰

Trajectory data on BP (including repeat measurements from early childhood into midadulthood) confirm the association of elevated BP in adolescence with HTN in early adulthood¹¹ and that normal BP in childhood is associated with a lack of HTN in midadulthood.¹¹

2.2 Awareness, Treatment, and Control of HTN in Children

Of the 32.6% of US adults who have HTN, almost half (17.2%) are not aware they have HTN; even among those who are aware of their condition, only approximately half (54.1%) have controlled BP.¹² Unfortunately, there are no large studies in which researchers have systematically studied BP awareness or control in youth, although an analysis of prescribing patterns from a nationwide prescription drug provider found an increase in the number of prescriptions written for high BP in youth from 2004 to 2007.¹³

The SEARCH for Diabetes in Youth study found that only 7.4% of youth with type 1 diabetes mellitus (T1DM) and 31.9% of youth with type 2 diabetes mellitus (T2DM) demonstrated knowledge of their BP status.¹⁴ Even after becoming aware of the diagnosis, only 57.1% of patients with T1DM and 40.6% of patients with T2DM achieved good BP control.¹⁴ The HEALTHY Primary Prevention Trial of Risk Factors for

TABLE 2 Additional Consensus Opinion Recommendations and Text Locations

Recommendation	CPG Section(s)
1. Follow the revised classification scheme in Table 3 for childhood BP levels, including the use of the term “elevated BP,” the new definition of stage 2 HTN, and the use of similar BP levels as adults for adolescents ≥ 13 y of age.	3.1
2. Use simplified BP tables (Table 4) to screen for BP values that may require further evaluation by a clinician.	3.2a
3. Use reference data on neonatal BP from ref 80 to identify elevated BP values in neonates up to 44 wk postmenstrual age and BP curves from the 1987 Second Task Force report to identify elevated BP values in infants 1–12 mo of age.	3.3
4. Use the standardized technique for measuring BP by auscultation described in Table 7 and Fig 2 (including appropriate cuff size, extremity, and patient positioning) to obtain accurate BP values.	4.1
5. If the initial BP at an office visit is elevated, as described in Fig 3, obtain 2 additional BP measurements at the same visit and average them; use the averaged auscultatory BP measurement to determine the patient’s BP category.	4.1
6. Oscillometric devices are used to measure BP in infants and toddlers until they are able to cooperate with auscultatory BP. Follow the same rules for BP measurement technique and cuff size as for older children.	4.1a
7. Measure BP at every health care encounter in children <3 y of age if they have an underlying condition listed in Table 9 that increases their risk for HTN.	4.2
8. After a patient’s BP has been categorized, follow Table 11 for when to obtain repeat BP readings, institute lifestyle changes, or proceed to a workup for HTN.	4.3
9. When an oscillometric BP reading is elevated, obtain repeat readings, discard the first reading, and average subsequent readings to approximate auscultatory BP.	4.5
10. Wrist and forearm BP measurements should not be used in children and adolescents for the diagnosis or management of HTN.	4.6
11. Use ABPM to evaluate high-risk patients (those with obesity, CKD, or repaired aortic coarctation) for potential MH.	4.7a, 4.8
12. Routine use of BP readings obtained in the school setting is not recommended for diagnosis of HTN in children and adolescents.	4.10
13. Use the history and physical examination to identify possible underlying causes of HTN, such as heart disease, kidney disease, renovascular disease, endocrine HTN (Table 15), drug-induced HTN (Table 8), and OSAS-associated HTN (Table 18).	5.2–5.4, 5.7, 9.2
14. Suspect monogenic HTN in patients with a family history of early-onset HTN, hypokalemia, suppressed plasma renin, or an elevated ARR.	5.8
15. Obtain laboratory studies listed in Table 10 to evaluate for underlying secondary causes of HTN when indicated.	6.4
16. Routine use of vascular imaging, such as carotid intimal-media measurements or PWV measurements, is not recommended in the evaluation of HTN in children and adolescents.	6.7
17. Suspect renovascular HTN in selected children and adolescents with stage 2 HTN, significant diastolic HTN, discrepant kidney sizes on ultrasound, hypokalemia on screening laboratories, or an epigastric and/or upper abdominal bruit on physical examination.	6.8a
18. Routine measurement of serum UA is not recommended for children and adolescents with elevated BP.	6.9
19. Offer intensive weight-loss programs to hypertensive children and adolescents with obesity; consider using MI as an adjunct to the treatment of obesity.	7.2c
20. Follow-up children and adolescents treated with antihypertensive medications every 4–6 wk until BP is controlled, then extend the interval. Follow-up every 3–6 mo is appropriate for patients treated with lifestyle modification only.	7.3c
21. Evaluate and treat children and adolescents with apparent treatment-resistant HTN in a similar manner to that recommended for adults with resistant HTN.	7.4
22. Treat hypertensive children and adolescents with dyslipidemia according to current, existing pediatric lipid guidelines.	9.1
23. Use ABPM to evaluate for potential HTN in children and adolescents with known or suspected OSAS.	9.2
24. Racial, ethnic, and sex differences need not be considered in the evaluation and management of children and adolescents with HTN.	10
25. Use ABPM to evaluate BP in pediatric heart- and kidney-transplant recipients.	11.3

Type 2 Diabetes in Middle-School Youth, which examined a school-based intervention designed to reduce cardiovascular (CV) risk among middle school students, found the prevalence of stage 1 or 2 HTN to be $\sim 9.5\%$.¹⁵ There was no significant reduction in HTN in the control group after the intervention; the intervention group saw a reduction in the prevalence of HTN of $\sim 1\%$, leaving 8.5% with BP still above the ideal range.

Researchers in a number of small, single-center studies have evaluated BP control in children and adolescents with HTN. One study found that lifestyle change and medications produced adequate BP control in 46 of 65 youth (70%) with HTN.¹⁶ Another study in which researchers used ambulatory blood pressure monitoring (ABPM) to assess BP control among a group of 38 children (of whom 84% had chronic kidney disease [CKD]) found that only 13 children (34%) achieved adequate BP control even among those who received more than 1 drug.¹⁷ A similar study found that additional drugs did increase rates of BP control in children with CKD, however.¹⁸

2.3 Prevalence of HTN Among Children With Various Chronic Conditions

It is well recognized that HTN rates are higher in children with certain chronic conditions, including children with obesity, sleep-disordered breathing (SDB), CKD, and those born preterm. These are described below.

2.3a Children With Obesity

HTN prevalence ranges from 3.8% to 24.8% in youth with overweight and obesity. Rates of HTN increase in a graded fashion with increasing adiposity.^{19–24} Similar relationships are seen between HTN and increasing waist circumference.^{4,25,26} Systematic reviews of 63 studies on BMI²⁷ and 61 studies on various measures

TABLE 2 Continued

Recommendation	CPG Section(s)
26. Reasonable strategies for HTN prevention include the maintenance of a normal BMI, consuming a DASH-type diet, avoidance of excessive sodium consumption, and regular vigorous physical activity.	13.2
27. Provide education about HTN to patients and their parents to improve patient involvement in their care and better achieve therapeutic goals.	15.2, 15.3

Based on the expert opinion of the subcommittee members (level of evidence = D; strength of recommendations = weak). CPG, clinical practice guideline.

of abdominal adiposity²⁸ have shown associations between these conditions and HTN. Obesity is also associated with a lack of circadian variability of BP,^{29,30} with up to 50% of children who have obesity not experiencing the expected nocturnal BP dip.^{31–33}

Studies have shown that childhood obesity is also related to the development of future HTN.²² Elevated BMI as early as infancy is associated with higher future BP.³⁴ This risk appears to increase with obesity severity; there is a fourfold increase in BP among those with severe obesity (BMI >99th percentile) versus a twofold increase in those with obesity (BMI 95th–98th percentiles) compared with normal-weight children and adolescents.³⁵

Collectively, the results of these cross-sectional and longitudinal studies firmly establish an increasing prevalence of HTN with increasing BMI percentile. The study results also underscore the importance of monitoring BP in all children with overweight and/or obesity at every clinical encounter.

Obesity in children with HTN may be accompanied by additional cardiometabolic risk factors (eg, dyslipidemia and disordered glucose metabolism)^{36,37} that may have their own effects on BP or may represent comorbid conditions arising from the same adverse lifestyle behaviors.^{25,38} Some argue that the presence of multiple risk factors, including obesity and HTN, leads to far greater increases in CV risk than is explained by the individual risk factors alone. Although this phenomenon has been

hard to demonstrate definitively, the Strong Heart Study did show that American Indian adolescents with multiple cardiometabolic risk factors had a higher prevalence of LVH (43.2% vs 11.7%), left atrial dilation (63.1% vs 21.9%; $P < .001$), and reduced LV systolic and diastolic function compared with those without multiple cardiometabolic risk factors.³⁹ Notably, both obesity and HTN were drivers of these CV abnormalities, with obesity being a stronger determinant of cardiac abnormalities than HTN (odds ratio, 4.17 vs 1.03).

2.3b Children With SDB

SDB occurs on a spectrum that includes (1) primary snoring, (2) sleep fragmentation, and (3) obstructive sleep apnea syndrome (OSAS). Researchers in numerous studies have identified an association between SDB and HTN in the pediatric population.^{40–42} Studies suggest that children who sleep 7 hours or less per night are at increased risk for HTN.⁴³ Small studies of youth with sleep disorders have found the prevalence of high BP to range between 3.6% and 14%.^{40,41} The more severe the OSAS, the more likely a child is to have HTN.^{44,45} Even inadequate duration of sleep and poor-quality sleep have been associated with elevated BP.⁴³

2.3c Children With CKD

There are well-established pathophysiologic links between childhood HTN and CKD. Certain forms of CKD can lead to HTN, and untreated HTN can lead to CKD in adults, although evidence for the

latter in pediatric patients is lacking. Among children and adolescents with CKD, ~50% are known to be hypertensive.^{46–48} In children and adolescents with end-stage renal disease (either those on dialysis or after transplant), ~48% to 79% are hypertensive, with 20% to 70% having uncontrolled HTN.^{49–53} Almost 20% of pediatric HTN may be attributable to CKD.⁵⁴

2.3d Children With History of Prematurity

Abnormal birth history—including preterm birth and low birth weight—has been identified as a risk factor for HTN and other CVD in adults⁵⁵; only low birth weight has been associated with elevated BP in the pediatric age range.⁵⁶ One retrospective cohort study showed a prevalence of HTN of 7.3% among 3 year olds who were born preterm.⁵⁷ Researchers in another retrospective case series noted a high prevalence of HTN in older children with a history of preterm birth.⁵⁸ It also appears that preterm birth may result in abnormal circadian BP patterns in childhood.⁵⁹ These data are intriguing but limited. Further study is needed to determine how often preterm birth results in childhood HTN.

2.4 Importance of Diagnosing HTN in Children and Adolescents

Numerous studies have shown that elevated BP in childhood increases the risk for adult HTN and metabolic syndrome.^{10,60–62} Youth with higher BP levels in childhood are also more likely to have persistent HTN as adults.^{60,63} One recent study found that adolescents with elevated BP progressed to HTN at a rate of 7% per year, and elevated BMI predicted sustained BP elevations.⁶⁴ In addition, young patients with HTN are likely to experience accelerated vascular aging. Both autopsy⁶⁵ and imaging studies⁶⁶ have demonstrated BP-related CV damage in youth. These intermediate markers of CVD (eg, increased LV mass,⁶⁷ cIMT,⁶⁸ and

pulse wave velocity [PWV]⁶⁹) are known to predict CV events in adults, making it crucial to diagnose and treat HTN early.

Eighty million US adults (1 in 3) have HTN, which is a major contributor to CVD.¹² Key contributors to CV health have been identified by the American Heart Association (AHA) as “Life’s Simple 7,” including 4 ideal health behaviors (not smoking, normal BMI, physical activity at goal levels, and a healthy diet) and 3 ideal health factors (untreated, normal total cholesterol; normal fasting blood glucose; and normal untreated BP, defined in childhood as ≤ 90 th percentile or $<120/80$ mm Hg). Notably, elevated BP is the least common abnormal health factor in children and adolescents⁷⁰; 89% of youth (ages 12–19 years) are in the ideal BP category.⁶

Given the prevalence of known key contributors in youth (ie, tobacco exposure, obesity, inactivity, and nonideal diet^{12,71}), adult CVD likely has its origins in childhood. One-third of US adolescents report having tried a cigarette in the past 30 days.⁷² Almost half (40%–48%) of teenagers have elevated BMI, and the rates of severe obesity (BMI >99 th percentile) continue to climb, particularly in girls and adolescents.^{73–75} Physical activity measured by accelerometry shows less than half of school-aged boys and only one-third of school-aged girls meet the goal for ideal physical activity levels.⁷² More than 80% of youth 12 to 19 years of age have a poor diet (as defined by AHA metrics for ideal CV health); only ~10% eat adequate fruits and vegetables, and only ~15% consume <1500 mg per day of sodium, both of which are key dietary determinants of HTN.⁷⁶

Finally, measuring BP at routine well-child visits enables the early detection of primary HTN as well as the detection of asymptomatic HTN secondary to another underlying

TABLE 3 Updated Definitions of BP Categories and Stages

For Children Aged 1–13 y	For Children Aged ≥ 13 y
Normal BP: <90 th percentile	Normal BP: $<120/80$ mm Hg
Elevated BP: ≥ 90 th percentile to <95 th percentile or 120/80 mm Hg to <95 th percentile (whichever is lower)	Elevated BP: 120/80 to 129/89 mm Hg
Stage 1 HTN: ≥ 95 th percentile to <95 th percentile + 12 mm Hg, or 130/80 to 139/89 mm Hg (whichever is lower)	Stage 1 HTN: 130/80 to 139/89 mm Hg
Stage 2 HTN: ≥ 95 th percentile + 12 mm Hg, or $\geq 140/90$ mm Hg (whichever is lower)	Stage 2 HTN: $\geq 140/90$ mm Hg

disorder. Early detection of HTN is vital given the greater relative prevalence of secondary causes of HTN in children compared with adults.

3. DEFINITION OF HTN

3.1 Definition of HTN (1–18 Years of Age)

Given the lack of outcome data, the current definition of HTN in children and adolescents is based on the normative distribution of BP in healthy children.¹ Because it is a major determinant of BP in growing children, height has been incorporated into the normative data since the publication of the 1996 Working Group Report.¹ BP levels should be interpreted on the basis of sex, age, and height to avoid misclassification of children who are either extremely tall or extremely short. It should be noted that the normative data were collected by using an auscultatory technique,¹ which may provide different values than measurement obtained by using oscillometric devices or from ABPM.

In the Fourth Report, “normal blood pressure” was defined as SBP and DBP values <90 th percentile (on the basis of age, sex, and height percentiles). For the preadolescent, “prehypertension” was defined as SBP and/or DBP ≥ 90 th percentile and <95 th percentile (on the basis of age, sex, and height tables). For adolescents, “prehypertension” was defined as BP $\geq 120/80$ mm Hg to <95 th percentile, or ≥ 90 th and <95 th percentile, whichever was

lower. HTN was defined as average clinic measured SBP and/or DBP ≥ 95 th percentile (on the basis of age, sex, and height percentiles) and was further classified as stage 1 or stage 2 HTN.

There are still no data to identify a specific level of BP in childhood that leads to adverse CV outcomes in adulthood. Therefore, the subcommittee decided to maintain a statistical definition for childhood HTN. The staging criteria have been revised for stage 1 and stage 2 HTN for ease of implementation compared with the Fourth Report. For children ≥ 13 years of age, this staging scheme will seamlessly interface with the 2017 AHA and American College of Cardiology (ACC) adult HTN guideline.* Additionally, the term “prehypertension” has been replaced by the term “elevated blood pressure,” to be consistent with the AHA and ACC guideline and convey the importance of lifestyle measures to prevent the development of HTN (see Table 3).

3.2 New BP Tables

New normative BP tables based on normal-weight children are included with these guidelines (see Tables 4 and 5). Similar to the tables in the

*Whelton PK, Carey RM, Aronow WS, et al. ACC/AHA/APPA/ABC/ACPM/AGS/APHA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation and management of high blood pressure in adults: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Hypertension*. 2017. In press.

Fourth Report,¹ they include SBP and DBP values arranged by age, sex, and height (and height percentile). These values are based on auscultatory measurements obtained from ~50 000 children and adolescents. A new feature in these tables is that the BP values are categorized according to the scheme presented in Table 3 as normal (50th percentile), elevated BP (>90th percentile), stage 1 HTN (≥ 95 th percentile), and stage 2 HTN (≥ 95 th percentile + 12 mm Hg). Additionally, actual heights in centimeters and inches are provided.

Unlike the tables in the Fourth Report,¹ the BP values in these tables do not include children and adolescents with overweight and obesity (ie, those with a BMI ≥ 85 th percentile); therefore, they represent normative BP values for normal-weight youth. The decision to create these new tables was based on evidence of the strong association of both overweight and obesity with elevated BP and HTN. Including patients with overweight and obesity in normative BP tables was thought to create bias. The practical effect of this change is that the BP values in Tables 4 and 5 are several millimeters of mercury lower than in the similar tables in the Fourth Report.¹ These tables are based on the same population data excluding participants with overweight and obesity, and the same methods used in the Fourth Report.¹ The methods and results have been published elsewhere.⁷⁷ For researchers and others interested in the equations used to calculate the tables' BP values, detailed methodology and the Statistical Analysis System (SAS) code can be found at: <http://sites.google.com/a/channing.harvard.edu/bernardrosner/pediatric-blood-pressure/childhood-blood-pressure>.

There are slight differences between the actual percentile-based values in these tables and the cut-points in Table 3, particularly for teenagers ≥ 13 years of age. Clinicians should

understand that the scheme in Table 3 was chosen to align with the new adult guideline and facilitate the management of older adolescents with high BP. The percentile-based values in Tables 4 and 5 are provided to aid researchers and others interested in a more precise classification of BP.

3.2a. Simplified BP Table

This guideline includes a new, simplified table for initial BP screening (see Table 6) based on the 90th percentile BP for age and sex for children at the 5th percentile of height, which gives the values in the table a negative predictive value of >99%.⁷⁸ This simplified table is designed as a screening tool only for the identification of children and adolescents who need further evaluation of their BP starting with repeat BP measurements. It should not be used to diagnose elevated BP or HTN by itself. To diagnose elevated BP or HTN, it is important to locate the actual cutoffs in the complete BP tables because the SBP and DBP cutoffs may be as much as 9 mm Hg higher depending on a child's age and length or height. A typical-use case for this simplified table is for nursing staff to quickly identify BP that may need further evaluation by a clinician. For adolescents ≥ 13 years of age, a threshold of 120/80 mm Hg is used in the simplified table regardless of sex to align with adult guidelines for the detection of elevated BP.

3.3 Definition of HTN in the Neonate and Infant (0–1 Year of Age)

Although a reasonably strict definition of HTN has been developed for older children, it is more difficult to define HTN in neonates given the well-known changes in BP that occur during the first few weeks of life.⁷⁹ These BP changes can be significant in preterm infants, in whom BP depends on a variety of factors, including postmenstrual age, birth weight, and maternal conditions.⁸⁰

In an attempt to develop a more standardized approach to the HTN definition in preterm and term neonates, Dionne et al⁷⁹ compiled available data on neonatal BP and generated a summary table of BP values, including values for the 95th and 99th percentiles for infants from 26 to 44 weeks' postmenstrual age. The authors proposed that by using these values, a similar approach to that used to identify older children with elevated BP can be followed in neonates, even in those who are born preterm.

At present, no alternative data have been developed, and no outcome data are available on the consequences of high BP in this population; thus, it is reasonable to use these compiled BP values in the assessment of elevated BP in newborn infants. Of note, the 1987 "Report of the Second Task Force on Blood Pressure Control in Children" published curves of normative BP values in older infants up to 1 year of age.⁸¹ These normative values should continue to be used given the lack of more contemporary data for this age group.

4. MEASUREMENT OF BP

4.1 BP Measurement Technique

BP in childhood may vary considerably between visits and even during the same visit. There are many potential etiologies for isolated elevated BP in children and adolescents, including such factors as anxiety and recent caffeine intake.⁸² BP generally decreases with repeated measurements during a single visit,⁸³ although the variability may not be large enough to affect BP classification.⁸⁴ BP measurements can also vary across visits^{64,85}; one study in adolescents found that only 56% of the sample had the same HTN stage on 3 different occasions.⁸ Therefore, it is important to obtain multiple measurements over time before diagnosing HTN.

TABLE 4 BP Levels for Boys by Age and Height Percentile

Age (y)	BP Percentile	SBP (mm Hg)					DBP (mm Hg)								
		Height Percentile or Measured Height					Height Percentile or Measured Height								
		5%	10%	25%	50%	75%	90%	95%	5%	10%	25%	50%	75%	90%	95%
1	Height (in)	30.4	30.8	31.6	32.4	33.3	34.1	34.6	30.4	30.8	31.6	32.4	33.3	34.1	34.6
	Height (cm)	77.2	78.3	80.2	82.4	84.6	86.7	87.9	77.2	78.3	80.2	82.4	84.6	86.7	87.9
	50th	85	85	86	86	87	88	88	40	40	40	41	41	42	42
	90th	98	99	99	100	100	101	101	52	52	53	53	54	54	54
	95th	102	102	103	103	104	105	105	54	54	55	55	56	57	57
2	95th + 12 mm Hg	114	114	115	115	116	117	117	66	66	67	67	68	69	69
	Height (in)	33.9	34.4	35.3	36.3	37.3	38.2	38.8	33.9	34.4	35.3	36.3	37.3	38.2	38.8
	Height (cm)	86.1	87.4	89.6	92.1	94.7	97.1	98.5	86.1	87.4	89.6	92.1	94.7	97.1	98.5
	50th	87	87	88	89	89	90	91	43	43	44	44	45	46	46
	90th	100	100	101	102	103	103	104	55	55	56	56	57	58	58
3	95th	104	105	105	106	107	107	108	57	58	58	59	60	61	61
	95th + 12 mm Hg	116	117	117	118	119	119	120	69	70	70	71	72	73	73
	Height (in)	36.4	37	37.9	39	40.1	41.1	41.7	36.4	37	37.9	39	40.1	41.1	41.7
	Height (cm)	92.5	93.9	96.3	99	101.8	104.3	105.8	92.5	93.9	96.3	99	101.8	104.3	105.8
	50th	88	89	89	90	91	92	92	45	46	46	47	48	49	49
4	90th	101	102	102	103	104	105	105	58	58	59	59	60	61	61
	95th	106	106	107	107	108	109	109	60	61	61	62	63	64	64
	95th + 12 mm Hg	118	118	119	119	120	121	121	72	73	73	74	75	76	76
	Height (in)	38.8	39.4	40.5	41.7	42.9	43.9	44.5	38.8	39.4	40.5	41.7	42.9	43.9	44.5
	Height (cm)	98.5	100.2	102.9	105.9	108.9	111.5	113.2	98.5	100.2	102.9	105.9	108.9	111.5	113.2
5	50th	90	90	91	92	93	94	94	48	49	49	50	51	52	52
	90th	102	103	104	105	105	106	107	60	61	62	62	63	64	64
	95th	107	107	108	108	109	110	110	63	64	65	66	67	68	68
	95th + 12 mm Hg	119	119	120	120	121	122	122	75	76	77	78	79	79	80
	Height (in)	41.1	41.8	43.0	44.3	45.5	46.7	47.4	41.1	41.8	43.0	44.3	45.5	46.7	47.4
6	Height (cm)	104.4	106.2	109.1	112.4	115.7	118.6	120.3	104.4	106.2	109.1	112.4	115.7	118.6	120.3
	50th	91	92	93	94	95	96	96	51	51	52	53	54	55	55
	90th	103	104	105	106	107	108	108	63	64	65	65	66	67	67
	95th	107	108	109	109	110	111	112	66	67	68	69	70	70	71
	95th + 12 mm Hg	119	120	121	121	122	123	124	78	79	80	81	82	82	83
7	Height (in)	43.4	44.2	45.4	46.8	48.2	49.4	50.2	43.4	44.2	45.4	46.8	48.2	49.4	50.2
	Height (cm)	110.3	112.2	115.3	118.9	122.4	125.6	127.5	110.3	112.2	115.3	118.9	122.4	125.6	127.5
	50th	93	93	94	95	96	97	98	54	54	55	56	57	57	58
	90th	105	105	106	107	109	110	110	66	66	67	68	68	69	69
	95th	108	109	110	111	112	113	114	69	70	70	71	72	72	73
7	95th + 12 mm Hg	120	121	122	123	124	125	126	81	82	82	83	84	84	85
	Height (in)	45.7	46.5	47.8	49.3	50.8	52.1	52.9	45.7	46.5	47.8	49.3	50.8	52.1	52.9
	Height (cm)	116.1	118	121.4	125.1	128.9	132.4	134.5	116.1	118	121.4	125.1	128.9	132.4	134.5
	50th	94	94	95	97	98	98	99	56	56	57	58	58	59	59
	90th	106	107	108	109	110	111	111	68	68	69	70	70	71	71
7	95th	110	110	111	112	114	115	116	71	71	72	73	73	74	74
	95th + 12 mm Hg	122	122	123	124	126	127	128	83	83	84	85	85	86	86

TABLE 4 Continued

Age (y)	BP Percentile	SBP (mm Hg)								DBP (mm Hg)							
		Height Percentile or Measured Height								Height Percentile or Measured Height							
		5%	10%	25%	50%	75%	90%	95%	5%	10%	25%	50%	75%	90%	95%		
8	Height (in)	47.8	48.6	50	51.6	53.2	54.6	55.5	47.8	48.6	50	51.6	53.2	54.6	55.5		
	Height (cm)	121.4	123.5	127	131	135.1	138.8	141	121.4	123.5	127	131	135.1	138.8	141		
	50th	95	96	97	98	99	99	100	57	57	58	59	59	60	60		
	90th	107	108	109	110	111	112	112	69	70	70	71	72	72	73		
	95th	111	112	112	114	115	116	117	72	73	73	74	75	75	75		
9	95th + 12 mmHg	123	124	124	126	127	128	129	84	85	85	86	87	87	87		
	Height (in)	49.6	50.5	52	53.7	55.4	56.9	57.9	49.6	50.5	52	53.7	55.4	56.9	57.9		
	Height (cm)	126	128.3	132.1	136.3	140.7	144.7	147.1	126	128.3	132.1	136.3	140.7	144.7	147.1		
	50th	96	97	98	99	100	101	101	57	58	59	60	61	62	62		
	90th	107	108	109	110	112	113	114	70	71	72	73	74	74	74		
10	95th	112	112	113	115	116	118	119	74	74	75	76	76	77	77		
	95th + 12 mm Hg	124	124	125	127	128	130	131	86	86	87	88	88	89	89		
	Height (in)	51.3	52.2	53.8	55.6	57.4	59.1	60.1	51.3	52.2	53.8	55.6	57.4	59.1	60.1		
	Height (cm)	130.2	132.7	136.7	141.3	145.9	150.1	152.7	130.2	132.7	136.7	141.3	145.9	150.1	152.7		
	50th	97	98	99	100	101	102	103	59	60	61	62	63	63	64		
11	90th	108	109	111	112	113	115	116	72	73	74	74	75	75	76		
	95th	112	113	114	116	118	120	121	76	76	77	77	78	78	78		
	95th + 12 mm Hg	124	125	126	128	130	132	133	88	88	89	89	90	90	90		
	Height (in)	53	54	55.7	57.6	59.6	61.3	62.4	53	54	55.7	57.6	59.6	61.3	62.4		
	Height (cm)	134.7	137.3	141.5	146.4	151.3	155.8	158.6	134.7	137.3	141.5	146.4	151.3	155.8	158.6		
12	50th	99	99	101	102	103	104	106	61	61	62	63	63	63	63		
	90th	110	111	112	114	116	117	118	74	74	75	75	75	76	76		
	95th	114	114	116	118	120	123	124	77	78	78	78	78	78	78		
	95th + 12 mmHg	126	126	128	130	132	135	136	89	90	90	90	90	90	90		
	Height (in)	55.2	56.3	58.1	60.1	62.2	64	65.2	55.2	56.3	58.1	60.1	62.2	64	65.2		
13	Height (cm)	140.3	143	147.5	152.7	157.9	162.6	165.5	140.3	143	147.5	152.7	157.9	162.6	165.5		
	50th	101	101	102	104	106	108	109	61	62	62	62	62	63	63		
	90th	113	114	115	117	119	121	122	75	75	75	75	75	76	76		
	95th	116	117	118	121	124	126	128	78	78	78	78	78	79	79		
	95th + 12 mm Hg	128	129	130	133	136	138	140	90	90	90	90	90	91	91		
14	Height (in)	57.9	59.1	61	63.1	65.2	67.1	68.3	57.9	59.1	61	63.1	65.2	67.1	68.3		
	Height (cm)	147	150	154.9	160.3	165.7	170.5	173.4	147	150	154.9	160.3	165.7	170.5	173.4		
	50th	103	104	105	108	110	111	112	61	60	61	62	63	64	65		
	90th	115	116	118	121	124	126	126	74	74	74	75	76	77	77		
	95th	119	120	122	125	128	130	131	78	78	78	78	80	81	81		
14	95th + 12 mm Hg	131	132	134	137	140	142	143	90	90	90	90	92	93	93		
	Height (in)	60.6	61.8	63.8	65.9	68.0	69.8	70.9	60.6	61.8	63.8	65.9	68.0	69.8	70.9		
	Height (cm)	153.8	156.9	162	167.5	172.7	177.4	180.1	153.8	156.9	162	167.5	172.7	177.4	180.1		
	50th	105	106	109	111	112	113	113	60	60	62	64	65	66	67		
	90th	119	120	123	126	127	128	129	74	74	75	77	78	79	80		
14	95th	123	125	127	130	132	133	134	77	78	79	81	82	83	84		
	95th + 12 mm Hg	135	137	139	142	144	145	146	89	90	91	93	94	95	96		

TABLE 4 Continued

Age (y)	BP Percentile	SBP (mm Hg)								DBP (mm Hg)							
		Height Percentile or Measured Height								Height Percentile or Measured Height							
		5%	10%	25%	50%	75%	90%	95%	5%	10%	25%	50%	75%	90%	95%		
15	Height (in)	62.6	63.8	65.7	67.8	69.8	71.5	72.5	62.6	63.8	65.7	67.8	69.8	71.5	72.5		
	Height (cm)	159	162	166.9	172.2	177.2	181.6	184.2	159	162	166.9	172.2	177.2	181.6	184.2		
	50th	108	110	112	113	114	114	114	61	62	64	65	66	67	68		
	90th	123	124	126	128	129	130	130	75	76	78	79	80	81	81		
	95th	127	129	131	132	134	135	135	78	79	81	83	84	85	85		
16	95th + 12 mm Hg	139	141	143	144	146	147	147	90	91	93	95	96	97	97		
	Height (in)	63.8	64.9	66.8	68.8	70.7	72.4	73.4	63.8	64.9	66.8	68.8	70.7	72.4	73.4		
	Height (cm)	162.1	165	169.6	174.6	179.5	183.8	186.4	162.1	165	169.6	174.6	179.5	183.8	186.4		
	50th	111	112	114	115	115	116	116	63	64	66	67	68	69	69		
	90th	126	127	128	129	131	131	132	77	78	79	80	81	82	82		
17	95th	130	131	133	134	135	136	137	80	81	83	84	85	86	86		
	95th + 12 mm Hg	142	143	145	146	147	148	149	92	93	95	96	97	98	98		
	Height (in)	64.5	65.5	67.3	69.2	71.1	72.8	73.8	64.5	65.5	67.3	69.2	71.1	72.8	73.8		
	Height (cm)	163.8	166.5	170.9	175.8	180.7	184.9	187.5	163.8	166.5	170.9	175.8	180.7	184.9	187.5		
	50th	114	115	116	117	117	118	118	65	66	67	68	69	70	70		
	90th	128	129	130	131	132	133	134	78	79	80	81	82	82	83		
	95th	132	133	134	135	137	138	138	81	82	84	85	86	86	87		
	95th + 12 mm Hg	144	145	146	147	149	150	150	93	94	96	97	98	98	99		

Use percentile values to stage BP readings according to the scheme in Table 3 (elevated BP: ≥ 90 th percentile; stage 1 HTN: ≥ 95 th percentile; and stage 2 HTN: ≥ 95 th percentile + 12 mm Hg). The 50th, 90th, and 95th percentiles were derived by using quantile regression on the basis of normal-weight children (BMI <85th percentile).⁷⁷

TABLE 5 BP Levels for Girls by Age and Height Percentile

Age (y)	BP Percentile	SBP (mm Hg)										DBP (mm Hg)										
		Height Percentile or Measured Height										Height Percentile or Measured Height										
		5%	10%	25%	50%	75%	90%	95%	5%	10%	25%	50%	75%	90%	95%							
1	Height (in)	29.7	30.2	30.9	31.8	32.7	33.4	33.9	29.7	30.2	30.9	31.8	32.7	33.4	33.9	29.7	30.2	30.9	31.8	32.7	33.4	33.9
	Height (cm)	75.4	76.6	78.6	80.8	83	84.9	86.1	75.4	76.6	78.6	80.8	83	84.9	86.1	75.4	76.6	78.6	80.8	83	84.9	86.1
	50th	84	85	86	86	87	88	88	41	42	42	43	44	45	46	41	42	42	43	44	45	46
	90th	98	99	99	100	101	102	102	54	55	56	56	57	58	58	54	55	56	56	57	58	58
	95th	101	102	102	103	104	105	105	59	59	60	60	61	62	62	59	59	60	60	61	62	62
2	95th + 12 mm Hg	113	114	114	115	116	117	117	71	71	72	72	73	74	74	71	71	72	72	73	74	74
	Height (in)	33.4	34	34.9	35.9	36.9	37.8	38.4	33.4	34	34.9	35.9	36.9	37.8	38.4	33.4	34	34.9	35.9	36.9	37.8	38.4
	Height (cm)	84.9	86.3	88.6	91.1	93.7	96	97.4	84.9	86.3	88.6	91.1	93.7	96	97.4	84.9	86.3	88.6	91.1	93.7	96	97.4
	50th	87	87	88	89	90	91	91	45	46	47	48	49	50	51	45	46	47	48	49	50	51
	90th	101	101	102	103	104	105	106	58	58	59	60	61	62	62	58	58	59	60	61	62	62
3	95th	104	105	106	106	107	108	109	62	63	63	64	65	66	66	62	63	63	64	65	66	66
	95th + 12 mm Hg	116	117	118	118	119	120	121	74	75	75	76	77	78	78	74	75	75	76	77	78	78
	Height (in)	35.8	36.4	37.3	38.4	39.6	40.6	41.2	35.8	36.4	37.3	38.4	39.6	40.6	41.2	35.8	36.4	37.3	38.4	39.6	40.6	41.2
	Height (cm)	91	92.4	94.9	97.6	100.5	103.1	104.6	91	92.4	94.9	97.6	100.5	103.1	104.6	91	92.4	94.9	97.6	100.5	103.1	104.6
	50th	88	89	89	90	91	92	93	48	48	48	49	50	51	53	48	48	49	50	51	53	53
4	90th	102	103	104	104	105	106	107	60	61	61	62	63	64	65	60	61	61	62	63	64	65
	95th	106	106	107	108	109	110	110	64	65	65	66	67	68	69	64	65	65	66	67	68	69
	95th + 12 mm Hg	118	118	119	120	121	122	122	76	77	77	78	79	80	81	76	77	77	78	79	80	81
	Height (in)	38.3	38.9	39.9	41.1	42.4	43.5	44.2	38.3	38.9	39.9	41.1	42.4	43.5	44.2	38.3	38.9	39.9	41.1	42.4	43.5	44.2
	Height (cm)	97.2	98.8	101.4	104.5	107.6	110.5	112.2	97.2	98.8	101.4	104.5	107.6	110.5	112.2	97.2	98.8	101.4	104.5	107.6	110.5	112.2
5	50th	89	90	91	92	93	94	94	50	51	51	53	54	55	55	50	51	51	53	54	55	55
	90th	103	104	105	106	107	108	108	62	63	64	65	66	67	67	62	63	64	65	66	67	67
	95th	107	108	109	109	110	111	112	66	67	68	69	70	71	71	66	67	68	69	70	71	71
	95th + 12 mm Hg	119	120	121	121	122	123	124	78	79	80	81	82	83	83	78	79	80	81	82	83	83
	Height (in)	40.8	41.5	42.6	43.9	45.2	46.5	47.3	40.8	41.5	42.6	43.9	45.2	46.5	47.3	40.8	41.5	42.6	43.9	45.2	46.5	47.3
6	Height (cm)	103.6	105.3	108.2	111.5	114.9	118.1	120	103.6	105.3	108.2	111.5	114.9	118.1	120	103.6	105.3	108.2	111.5	114.9	118.1	120
	50th	90	91	92	93	94	95	96	52	52	53	55	56	57	57	52	52	53	55	56	57	57
	90th	104	105	106	107	108	109	110	64	65	66	67	68	69	70	64	65	66	67	68	69	70
	95th	108	109	109	110	111	112	113	68	69	70	71	72	73	73	68	69	70	71	72	73	73
	95th + 12 mm Hg	120	121	121	122	123	124	125	80	81	82	83	84	85	85	80	81	82	83	84	85	85
7	Height (in)	43.3	44	45.2	46.6	48.1	49.4	50.3	43.3	44	45.2	46.6	48.1	49.4	50.3	43.3	44	45.2	46.6	48.1	49.4	50.3
	Height (cm)	110	111.8	114.9	118.4	122.1	125.6	127.7	110	111.8	114.9	118.4	122.1	125.6	127.7	110	111.8	114.9	118.4	122.1	125.6	127.7
	50th	92	92	93	94	96	97	97	54	54	55	56	57	58	59	54	54	55	56	57	58	59
	90th	105	106	107	108	109	110	111	67	67	68	69	70	71	71	67	67	68	69	70	71	71
	95th	109	109	110	111	112	113	114	70	71	72	72	73	74	74	70	71	72	72	73	74	74
7	95th + 12 mm Hg	121	121	122	123	124	125	126	82	83	84	84	85	86	86	82	83	84	84	85	86	86
	Height (in)	45.6	46.4	47.7	49.2	50.7	52.1	53	45.6	46.4	47.7	49.2	50.7	52.1	53	45.6	46.4	47.7	49.2	50.7	52.1	53
	Height (cm)	115.9	117.8	121.1	124.9	128.8	132.5	134.7	115.9	117.8	121.1	124.9	128.8	132.5	134.7	115.9	117.8	121.1	124.9	128.8	132.5	134.7
	50th	92	93	94	95	97	98	99	55	55	56	57	58	59	60	55	55	56	57	58	59	60
	90th	106	106	107	109	110	111	112	68	68	69	70	71	72	72	68	68	69	70	71	72	72
7	95th	109	110	111	112	113	114	115	72	72	73	73	74	75	75	72	73	73	73	74	74	75
	95th + 12 mm Hg	121	122	123	124	125	126	127	84	84	85	85	86	87	87	84	84	85	85	86	86	87

TABLE 5 Continued

Age (y)	BP Percentile	SBP (mm Hg)					DBP (mm Hg)								
		Height Percentile or Measured Height					Height Percentile or Measured Height								
		5%	10%	25%	50%	75%	90%	95%	5%	10%	25%	50%	75%	90%	95%
8	Height (in)	47.6	48.4	49.8	51.4	53	54.5	55.5	47.6	48.4	49.8	51.4	53	54.5	55.5
	Height (cm)	121	123	126.5	130.6	134.7	138.5	140.9	121	123	126.5	130.6	134.7	138.5	140.9
	50th	93	94	95	97	98	99	100	56	56	57	59	60	61	61
	90th	107	107	108	110	111	112	113	69	70	71	72	72	73	73
	95th	110	111	112	113	115	116	117	72	73	74	74	75	75	75
9	95th + 12 mmHg	122	123	124	125	127	128	129	84	85	86	86	87	87	87
	Height (in)	49.3	50.2	51.7	53.4	55.1	56.7	57.7	49.3	50.2	51.7	53.4	55.1	56.7	57.7
	Height (cm)	125.3	127.6	131.3	135.6	140.1	144.1	146.6	125.3	127.6	131.3	135.6	140.1	144.1	146.6
	50th	95	95	97	98	99	100	101	57	58	59	60	60	61	61
	90th	108	108	109	111	112	113	114	71	71	72	73	73	73	73
10	95th	112	112	113	114	116	117	118	74	74	75	75	75	75	75
	95th + 12 mmHg	124	124	125	126	128	129	130	86	86	87	87	87	87	87
	Height (in)	51.1	52	53.7	55.5	57.4	59.1	60.2	51.1	52	53.7	55.5	57.4	59.1	60.2
	Height (cm)	129.7	132.2	136.3	141	145.8	150.2	152.8	129.7	132.2	136.3	141	145.8	150.2	152.8
	50th	96	97	98	99	101	102	103	58	59	59	60	61	61	62
11	90th	109	110	111	112	113	115	116	72	73	73	73	73	73	73
	95th	113	114	114	116	117	119	120	75	75	76	76	76	76	76
	95th + 12 mmHg	125	126	126	128	129	131	132	87	87	88	88	88	88	88
	Height (in)	53.4	54.5	56.2	58.2	60.2	61.9	63	53.4	54.5	56.2	58.2	60.2	61.9	63
	Height (cm)	135.6	138.3	142.8	147.8	152.8	157.3	160	135.6	138.3	142.8	147.8	152.8	157.3	160
12	50th	98	99	101	102	104	105	106	60	60	60	61	62	63	64
	90th	111	112	113	114	116	118	120	74	74	74	74	74	75	75
	95th	115	116	117	118	120	123	124	76	77	77	77	77	77	77
	95th + 12 mmHg	127	128	129	130	132	135	136	88	89	89	89	89	89	89
	Height (in)	56.2	57.3	59	60.9	62.8	64.5	65.5	56.2	57.3	59	60.9	62.8	64.5	65.5
13	Height (cm)	142.8	145.5	149.9	154.8	159.6	163.8	166.4	142.8	145.5	149.9	154.8	159.6	163.8	166.4
	50th	102	102	104	105	107	108	108	61	61	61	62	64	65	65
	90th	114	115	116	118	120	122	122	75	75	75	75	76	76	76
	95th	118	119	120	122	124	125	126	78	78	78	78	79	79	79
	95th + 12 mmHg	130	131	132	134	136	137	138	90	90	90	90	91	91	91
14	Height (in)	58.3	59.3	60.9	62.7	64.5	66.1	67	58.3	59.3	60.9	62.7	64.5	66.1	67
	Height (cm)	148.1	150.6	154.7	159.2	163.7	167.8	170.2	148.1	150.6	154.7	159.2	163.7	167.8	170.2
	50th	104	105	106	107	108	108	109	62	62	63	64	65	65	66
	90th	116	117	119	121	122	123	123	75	75	75	76	76	76	76
	95th	121	122	123	124	126	126	127	79	79	79	79	80	80	81
14	95th + 12 mmHg	133	134	135	136	138	138	139	91	91	91	91	92	92	93
	Height (in)	59.3	60.2	61.8	63.5	65.2	66.8	67.7	59.3	60.2	61.8	63.5	65.2	66.8	67.7
	Height (cm)	150.6	153	156.9	161.3	165.7	169.7	172.1	150.6	153	156.9	161.3	165.7	169.7	172.1
	50th	105	106	107	108	109	109	109	63	63	64	65	66	66	66
	90th	118	118	120	122	123	123	123	76	76	76	76	77	77	77
14	95th	123	123	124	125	126	127	127	80	80	80	80	81	81	82
	95th + 12 mmHg	135	135	136	137	138	139	139	92	92	92	92	93	93	94

TABLE 5 Continued

Age (y)	BP Percentile	SBP (mm Hg)							DBP (mm Hg)						
		Height Percentile or Measured Height							Height Percentile or Measured Height						
		5%	10%	25%	50%	75%	90%	95%	5%	10%	25%	50%	75%	90%	95%
15	Height (in)	59.7	60.6	62.2	63.9	65.6	67.2	68.1	59.7	60.6	62.2	63.9	65.6	67.2	68.1
	Height (cm)	151.7	154	157.9	162.3	166.7	170.6	173	151.7	154	157.9	162.3	166.7	170.6	173
	50th	105	106	107	108	109	109	109	64	64	64	65	66	67	67
	90th	118	119	121	122	123	123	124	76	76	76	77	77	78	78
	95th	124	124	125	126	127	127	128	80	80	80	81	82	82	82
16	95th + 12 mmHg	136	136	137	138	139	139	140	92	92	92	93	94	94	94
	Height (in)	59.9	60.8	62.4	64.1	65.8	67.3	68.3	59.9	60.8	62.4	64.1	65.8	67.3	68.3
	Height (cm)	152.1	154.5	158.4	162.8	167.1	171.1	173.4	152.1	154.5	158.4	162.8	167.1	171.1	173.4
	50th	106	107	108	109	109	110	110	64	64	65	66	66	67	67
	90th	119	120	122	123	124	124	124	76	76	76	77	78	78	78
17	95th	124	125	125	127	127	128	128	80	80	80	81	82	82	82
	95th + 12 mm Hg	136	137	137	139	139	140	140	92	92	92	93	94	94	94
	Height (in)	60.0	60.9	62.5	64.2	65.9	67.4	68.4	60.0	60.9	62.5	64.2	65.9	67.4	68.4
	Height (cm)	152.4	154.7	158.7	163.0	167.4	171.3	173.7	152.4	154.7	158.7	163.0	167.4	171.3	173.7
	50th	107	108	109	110	110	110	111	64	64	65	66	66	67	67
	90th	120	121	123	124	124	125	125	76	76	77	77	78	78	78
	95th	125	125	126	127	128	128	128	80	80	80	81	82	82	82
	95th + 12 mmHg	137	137	138	139	140	140	140	92	92	92	93	94	94	94

Use percentile values to stage BP readings according to the scheme in Table 3 (elevated BP: ≥ 90 th percentile; stage 1 HTN: ≥ 95 th percentile; and stage 2 HTN: ≥ 95 th percentile + 12 mm Hg). The 50th, 90th, and 95th percentiles were derived by using quantile regression on the basis of normal-weight children (BMI <85th percentile).⁷⁷

The initial BP measurement may be oscillometric (on a calibrated machine that has been validated for use in the pediatric population) or auscultatory (by using a mercury or aneroid sphygmomanometer^{86,87}). (Validation status for oscillometric BP devices, including whether they are validated in the pediatric age group, can be checked at www.dableducational.org.) BP should be measured in the right arm by using standard measurement practices unless the child has atypical aortic arch anatomy, such as right aortic arch and aortic coarctation or left aortic arch with aberrant right subclavian artery (see Table 7). Other important aspects of proper BP measurement are illustrated in an AAP video available at <http://youtu.be/JLzkNBpqi0>. Care should be taken that providers follow an accurate and consistent measurement technique.^{88,89}

An appropriately sized cuff should be used for accurate BP measurement.⁸³ Researchers in 3 studies in the United Kingdom and 1 in Brazil documented the lack of availability of an appropriately sized cuff in both the inpatient and outpatient settings.^{91–94} Pediatric offices should have access to a wide range of cuff sizes, including a thigh cuff for use in children and adolescents with severe obesity. For children in whom the appropriate cuff size is difficult to determine, the midarm circumference (measured as the midpoint between the acromion of the scapula and olecranon of the elbow, with the shoulder in a neutral position and the elbow flexed to 90°^{86,95,96}) should be obtained for an accurate determination of the correct cuff size (see Fig 2 and Table 7).⁹⁵

If the initial BP is elevated (≥ 90 th percentile), providers should perform 2 additional oscillometric or auscultatory BP measurements at the same visit and average them. If using auscultation, this averaged measurement is used to determine the child's BP category (ie, normal,

TABLE 6 Screening BP Values Requiring Further Evaluation

Age, y	BP, mm Hg			
	Boys		Girls	
	Systolic	DBP	Systolic	DBP
1	98	52	98	54
2	100	55	101	58
3	101	58	102	60
4	102	60	103	62
5	103	63	104	64
6	105	66	105	67
7	106	68	106	68
8	107	69	107	69
9	107	70	108	71
10	108	72	109	72
11	110	74	111	74
12	113	75	114	75
≥13	120	80	120	80

elevated BP, stage 1 HTN, or stage 2 HTN). If the averaged oscillometric reading is ≥ 90 th percentile, 2 auscultatory measurements should be taken and averaged to define the BP category (see Fig 3).

4.1a Measurement of BP in the Neonate

Multiple methods are available for the measurement of BP in hospitalized neonates, including direct intra-arterial measurements using indwelling catheters as well as indirect measurements using the oscillometric technique. In the office, however, the oscillometric technique typically is used at least until the infant is able to cooperate with manual BP determination (which also depends on the ability of the individual measuring the BP to obtain auscultatory BP in infants

and toddlers). Normative values for neonatal and infant BP have generally been determined in the right upper arm with the infant supine, and a similar approach should be followed in the outpatient setting.

As with older children, proper cuff size is important in obtaining accurate BP readings in neonates. The cuff bladder length should encircle 80% to 100% of the arm circumference; a cuff bladder with a width-to-arm circumference ratio of 0.45 to 0.55 is recommended.^{79,97,98}

Offices that will be obtaining BP measurements in neonates need to have a variety of cuff sizes available. In addition, the oscillometric device used should be validated in neonates and programmed to have an initial inflation value appropriate for infants (generally ≤ 120 mm Hg). Auscultation becomes technically feasible once the infant's upper arm is large enough for the smallest cuff available for auscultatory devices. Measurements are best taken when the infant is in a calm state; multiple readings may be needed if the first




FIGURE 1
AAP grading matrix.

TABLE 7 Best BP Measurement Practices

1. The child should be seated in a quiet room for 3–5 min before measurement, with the back supported and feet uncrossed on the floor.
2. BP should be measured in the right arm for consistency, for comparison with standard tables, and to avoid a falsely low reading from the left arm in the case of coarctation of the aorta. The arm should be at heart level,⁹⁰ supported, and uncovered above the cuff. The patient and observer should not speak while the measurement is being taken.
3. The correct cuff size should be used. The bladder length should be 80%–100% of the circumference of the arm, and the width should be at least 40%.
4. For an auscultatory BP, the bell of the stethoscope should be placed over the brachial artery in the antecubital fossa, and the lower end of the cuff should be 2–3 cm above the antecubital fossa. The cuff should be inflated to 20–30 mm Hg above the point at which the radial pulse disappears. Overinflation should be avoided. The cuff should be deflated at a rate of 2–3 mm Hg per second. The first (phase I Korotkoff) and last (phase V Korotkoff) audible sounds should be taken as SBP and DBP. If the Korotkoff sounds are heard to 0 mm Hg, the point at which the sound is muffled (phase IV Korotkoff) should be taken as the DBP, or the measurement repeated with less pressure applied over the brachial artery. The measurement should be read to the nearest 2 mm Hg.
5. To measure BP in the legs, the patient should be in the prone position, if possible. An appropriately sized cuff should be placed midthigh and the stethoscope placed over the popliteal artery. The SBP in the legs is usually 10%–20% higher than the brachial artery pressure.

Adapted from Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. *Circulation*. 2005;111(5):697–716.




FIGURE 2

Determination of proper BP cuff size.⁹⁵ A, Marking spine extending from acromion process. B, Correct tape placement for upper arm length. C, Incorrect tape placement for upper arm length. D, Marking upper arm length midpoint.

reading is elevated, similar to the technique recommended for older children.^{99,100}

4.2 BP Measurement Frequency

It remains unclear what age is optimal to begin routine BP measurement in children, although available data suggest that prevention and intervention efforts should begin at a young age.^{10,60,101–106} The subcommittee believes that the recommendation to measure BP in

the ambulatory setting beginning at 3 years of age should remain unchanged.¹ For otherwise healthy children, however, BP need only be measured annually rather than during every health care encounter.

Some children should have BP measured at every health encounter, specifically those with obesity (BMI ≥ 95 percentile),^{5,27,107–109} renal disease,⁴⁶ diabetes,^{110,111} aortic arch obstruction or coarctation, or those who are taking medications known

to increase BP (see Table 8 and the “Secondary Causes: Medication-related” section of this guideline).^{112,113}

Children younger than 3 years should have BP measurements taken at well-child care visits if they are at increased risk for developing HTN (see Table 9).¹

Key Action Statement 1

BP should be measured annually in children and adolescents ≥ 3 years of age (grade C, moderate recommendation).

Key Action Statement 2

BP should be checked in all children and adolescents ≥ 3 years of age at every health care encounter if they have obesity, are taking medications known to increase BP, have renal disease, a history of aortic arch obstruction or coarctation, or diabetes (see Table 9) (grade C, moderate recommendation).

4.3 Patient Management on the Basis of Office BP

4.3a Normal BP

If BP is normal or normalizes after repeat readings (ie, BP < 90 th percentile), then no additional action is needed. Practitioners should measure the BP at the next routine well-child care visit.

4.3b Elevated BP

1. If the BP reading is at the elevated BP level (Table 3), lifestyle interventions should be recommended (ie, healthy diet, sleep, and physical activity); the measurement should be repeated in 6 months by auscultation. Nutrition and/or weight management referral should be considered as appropriate;
2. If BP remains at the elevated BP level after 6 months, upper and lower extremity BP should be checked (right arm, left arm, and 1 leg), lifestyle counseling should be repeated, and BP should be

Key Action Statement 1. BP should be measured annually in children and adolescents ≥ 3 years of age (grade C, moderate recommendation).

Aggregate Evidence Quality	Grade C
Benefits	Early detection of asymptomatic HTN; prevention of short- and long-term HTN-related morbidity
Risks, harm, cost	Overtesting, misclassification, unnecessary treatment, discomfort from BP measurement procedure, time involved in measuring BP
Benefit-harm assessment	Benefit of annual BP measurement exceeds potential harm
Intentional vagueness	None
Role of patient preferences	Increased visit time, discomfort of cuff
Exclusions	None
Strength	Moderate recommendation
Key references	10,60,102,103

Key Action Statement 2. BP should be checked in all children and adolescents ≥ 3 years of age at every health care encounter if they have obesity, are taking medications known to increase BP, have renal disease, a history of aortic arch obstruction or coarctation, or diabetes (see Table 9) (grade C, moderate recommendation).

Aggregate Evidence Quality	Grade C
Benefits	Early detection of HTN and prevention of CV morbidity in predisposed children and adolescents
Risks, harm, cost	Time for and difficulty of conducting measurements
Benefit-harm assessment	Benefits exceed harm
Intentional vagueness	Frequency of evaluation
Role of patient preferences	Increased visit time, discomfort of cuff
Exclusions	Children and adolescents who are not at increased risk for HTN
Strength	Moderate recommendation
Key references	27,46,107,110–112

rechecked in 6 months (ie, at the next well-child care visit) by auscultation;

- If BP continues at the elevated BP level after 12 months (eg, after 3 auscultatory measurements), ABPM should be ordered (if available), and diagnostic evaluation should be conducted

(see Table 10 for a list of screening tests and the populations in which they should be performed). Consider subspecialty referral (ie, cardiology or nephrology) (see Table 11); and

- If BP normalizes at any point, return to annual BP screening at well-child care visits.

4.3c Stage 1 HTN

- If the BP reading is at the stage 1 HTN level (Table 3) and

the patient is asymptomatic, provide lifestyle counseling and recheck the BP in 1 to 2 weeks by auscultation;

- If the BP reading is still at the stage 1 level, upper and lower extremity BP should be checked (right arm, left arm, and 1 leg), and BP should be rechecked in 3 months by auscultation. Nutrition and/or weight management referral should be considered as appropriate; and
- If BP continues to be at the stage 1 HTN level after 3 visits, ABPM should be ordered (if available), diagnostic evaluation should be conducted, and treatment should be initiated. Subspecialty referral should be considered (see Table 11).

4.3d Stage 2 HTN

- If the BP reading is at the stage 2 HTN level (Table 3), upper and lower extremity BP should be checked (right arm, left arm, and 1 leg), lifestyle recommendations given, and the BP measurement should be repeated within 1 week. Alternatively, the patient could be referred to subspecialty care within 1 week;
- If the BP reading is still at the stage 2 HTN level when repeated, then diagnostic evaluation, including ABPM, should be conducted and treatment should be initiated, or the patient should

TABLE 8 Common Associated With Elevated BP in Children

Common Associated With Elevated BP in Children	Pharmacologic Agents
Over-the-counter drugs	Decongestants Caffeine Nonsteroidal anti-inflammatory drugs
Prescription drugs	Alternative therapies, herbal and nutritional supplements Stimulants for attention-deficit/hyperactivity disorder Hormonal contraception Steroids Tricyclic antidepressants
Illicit drugs	Amphetamines Cocaine

Adapted from the Fourth Report.¹

TABLE 9 Conditions Under Which Children Younger Than 3 Years Should Have BP Measured

History of prematurity <32 week's gestation or small for gestational age, very low birth weight, other neonatal complications requiring intensive care, umbilical artery line
Congenital heart disease (repaired or unrepaired)
Recurrent urinary tract infections, hematuria, or proteinuria
Known renal disease or urologic malformations
Family history of congenital renal disease
Solid-organ transplant
Malignancy or bone marrow transplant
Treatment with drugs known to raise BP
Other systemic illnesses associated with HTN (neurofibromatosis, tuberous sclerosis, sickle cell disease, ¹¹⁴ etc)
Evidence of elevated intracranial pressure

Adapted from Table 3 in the Fourth Report.¹

Key Action Statement 3. Trained health care professionals in the office setting should make a diagnosis of HTN if a child or adolescent has auscultatory-confirmed BP readings \geq 95th percentile on 3 different visits (grade C, moderate recommendation).

Aggregate Evidence Quality	Grade C
Benefits	Early detection of HTN; prevention of CV morbidity in predisposed children and adolescents; identification of secondary causes of HTN
Risks, harm, cost	Overtesting, misclassification, unnecessary treatment, discomfort from BP measurement, time involved in taking BP
Benefit-harm assessment	Benefits of repeated BP measurement exceeds potential harm
Intentional vagueness	None
Role of patient preferences	Families may have varying levels of concern about elevated BP readings and may request evaluation on a different time line
Exclusions	None
Strength	Moderate recommendation
Key references	8,84,85

be referred to subspecialty care within 1 week (see Table 11); and

3. If the BP reading is at the stage 2 HTN level and the patient is symptomatic, or the BP is >30 mm Hg above the 95th percentile (or >180/120 mm Hg in an adolescent), refer to an immediate source of care, such as an emergency department (ED).

Key Action Statement 3

Trained health care professionals in the office setting should make a diagnosis of HTN if a child or adolescent has auscultatory-confirmed BP readings \geq 95th percentile on 3 different visits (grade C, moderate recommendation).

4.4 Use of Electronic Health Records

Studies have demonstrated that primary care providers frequently fail to measure BP and often underdiagnose HTN.^{85,115,116}

One analysis using nationally representative survey data found that providers measured BP at only 67% of preventive visits for children 3 to 18 years of age. Older children and children with overweight or obesity were more likely to be screened.¹¹⁷ In a large cohort study of 14 187 children, 507 patients met the criteria for HTN, but only 131 (26%) had the diagnosis documented in their electronic health records (EHRs). Elevated BP was only recognized in 11% of cases.⁷

It is likely that the low rates of screening and diagnosis of pediatric HTN are related, at least in part, to the need to use detailed reference tables incorporating age, sex, and height to classify BP levels.¹¹⁸ Studies have shown that using health information technology can increase adherence to clinical guidelines and improve practitioner performance.^{119–121} In fact, applying

Key Action Statement 4. Organizations with EHRs used in an office setting should consider including flags for abnormal BP values both when the values are being entered and when they are being viewed (grade C, weak recommendation).

Aggregate Evidence Quality	Grade C
Benefits	Improved rate of screening and recognition of elevated BP
Risks, harm, cost	Cost of EHR development, alert fatigue
Benefit-harm assessment	Benefit of EHR flagging of elevated BP outweighs harm from development cost and potential for alert fatigue
Intentional vagueness	None
Role of patient preferences	None
Exclusions	None
Strength	Weak recommendation (because of a lack of pediatric data)
Key references	7,117,120,125

decision support in conjunction with an EHR in adult populations has also been associated with improved BP screening, recognition, medication prescribing, and control; pediatric data are limited, however.^{122–125} Some studies failed to show improvement in BP screening or control,^{122,126} but given the inherent complexity in the interpretation of pediatric BP measurements, EHRs should be designed to flag abnormal values both at the time of measurement and on entry into the EHR.

Key Action Statement 4

Organizations with EHRs used in an office setting should consider including flags for abnormal BP values both when the values are being entered and when they are being viewed (grade C, weak recommendation).

4.5 Oscillometric Versus Auscultatory (Manual) BP Measurement

Although pediatric normative BP data are based on auscultatory measurements, oscillometric BP devices have become commonplace in health care settings.¹²⁷ Ease of use, a lack of digit preference, and automation are all perceived benefits of using oscillometric devices. Unlike auscultatory measurement, however, oscillometric devices measure the oscillations transmitted from disrupted arterial flow by using the cuff as a transducer to determine mean arterial pressure (MAP). Rather than directly measuring any pressure that correlates to SBP or DBP, the device uses a proprietary algorithm to calculate these values from the directly measured MAP.¹²⁷ Because the algorithms vary for different brands of oscillometric devices, there is no standard oscillometric BP.¹²⁸

Researchers in several studies have evaluated the accuracy of oscillometric devices^{127,129–134} and compared auscultatory and




FIGURE 3
Modified BP measurement algorithm.

oscillometric readings' ability to predict target organ damage.¹³⁵ These studies demonstrated that oscillometric devices systematically overestimate SBP and DBP compared with values obtained by auscultation.^{129,133} BP status potentially can be misclassified because of the different values obtained by these 2 methods, which may be magnified in the office setting.^{86,88,129} Target organ damage (such as increased LV mass and elevated PWV) was best predicted by BPs obtained by auscultation.¹³⁵

A major issue with oscillometric devices is that there appears to be great within-visit variation with inaccurately high readings obtained on initial measurement.¹³⁶ An elevated initial oscillometric reading should be ignored and

TABLE 10 Screening Tests and Relevant Populations

Patient Population	Screening Tests
All patients	Urinalysis Chemistry panel, including electrolytes, blood urea nitrogen, and creatinine Lipid profile (fasting or nonfasting to include high-density lipoproteins and total cholesterol) Renal ultrasonography in those <6 y of age or those with abnormal urinalysis or renal function
In the obese (BMI >95th percentile) child or adolescent, in addition to the above	Hemoglobin A1c (accepted screen for diabetes) Aspartate transaminase and alanine transaminase (screen for fatty liver) Fasting lipid panel (screen for dyslipidemia)
Optional tests to be obtained on the basis of history, physical examination, and initial studies	Fasting serum glucose for those at high risk for diabetes mellitus Thyroid-stimulating hormone Drug screen Sleep study (if loud snoring, daytime sleepiness, or reported history of apnea) Complete blood count, especially in those with growth delay or abnormal renal function

Adapted from Wiesen J, Adkins M, Fortune S, et al. Evaluation of pediatric patients with mild-to-moderate hypertension: yield of diagnostic testing. *Pediatrics*. 2008;122(5). Available at: www.pediatrics.org/cgi/content/full/122/5/e988.

repeat measures averaged to approximate values obtained by auscultation.

Key Action Statement 5

Oscillometric devices may be used for BP screening in children

TABLE 11 Patient Evaluation and Management According to BP Level

BP Category (See Table 3)	BP Screening Schedule	Lifestyle Counseling (Weight and Nutrition)	Check Upper and Lower Extremity BP	ABPM ^a	Diagnostic Evaluation ^b	Initiate Treatment ^c	Consider Subspecialty Referral
Normal	Annual	X	—	—	—	—	—
Elevated BP	Initial	X	—	—	—	—	—
	Second measurement: repeat in 6 mo	X	X	—	—	—	—
	Third measurement: repeat in 6 mo	X	—	X	X	—	X
Stage 1 HTN	Initial	X	—	—	—	—	—
	Second measurement: repeat in 1–2 wk	X	X	—	—	—	—
	Third measurement: repeat in 3 mo	X	—	X	X	X	X
Stage 2 HTN ^d	Initial	X	X	—	—	—	—
	Second measurement: repeat, refer to specialty care within 1 wk	X	—	X	X	X	X

X, recommended intervention; —, not applicable.

^a ABPM is done to confirm HTN before initiating a diagnostic evaluation.^b See Table 15 for recommended studies.^c Treatment may be initiated by a primary care provider or subspecialist.^d If the patient is symptomatic or BP is >30 mm Hg above the 95th percentile (or >180/120 mm Hg in an adolescent), send to an ED.

and adolescents. When doing so, providers should use a device that has been validated in the pediatric age group. If elevated BP is suspected on the basis of oscillometric readings, confirmatory measurements should be obtained by auscultation (grade B, strong recommendation).

4.6 Forearm and/or Wrist BP Measurement

Wrist monitors have several potential advantages when compared with arm devices. They are smaller; they can be placed more easily; and, because wrist diameter is less affected by BMI, they do not need to be modified for patients with obesity.^{83,137} Several studies in adults have found excellent reproducibility of wrist

BP measurements, equivalence to readings obtained by mercury sphygmomanometers or ABPM, and better correlation with left

Key Action Statement 5. Oscillometric devices may be used for BP screening in children and adolescents. When doing so, providers should use a device that has been validated in the pediatric age group. If elevated BP is suspected on the basis of oscillometric readings, confirmatory measurements should be obtained by auscultation (grade B, strong recommendation).

Aggregate Evidence Quality	Grade B
Benefits	Use of auscultatory readings prevents potential misclassification of patients as hypertensive because of inaccuracy of oscillometric devices
Risks, harm, cost	Auscultation requires more training and experience and has flaws such as digit preference
Benefit–harm assessment	Benefit exceeds harm
Intentional vagueness	None
Role of patient preferences	Patients may prefer the convenience of oscillometric monitors
Exclusions	None
Strength	Strong recommendation
Key references	86,88,128–136

ventricular mass index (LVMI) than systolic office BP.^{138,139}

Although many wrist devices have been validated in adults,^{140–142} some studies have shown greater variation and decreased accuracy in the resulting measurements.^{143–146} These negative outcomes may possibly result from differences in the number of measurements taken,¹³⁹ the position of the wrist in relation to the heart,¹⁴⁷ flexion or extension of the wrist during measurement,¹⁴⁸ or differences in pulse pressure.¹⁴⁹ Technologies are being developed to help standardize wrist position.^{150,151}

Few studies using wrist monitors have been conducted in children. One study in adolescents compared a wrist digital monitor with a mercury sphygmomanometer and found high agreement between systolic measurements but lower agreement for diastolic measurements, which was clinically relevant.¹⁵² Researchers in 2 small studies conducted in PICUs compared wrist monitors with indwelling arterial lines and found good agreement between the 2 measurement modalities.^{153,154} No large comparative studies or formal validation studies of wrist monitors have been conducted in children, however. Because of limited data, the use of wrist and forearm monitors is not recommended in the diagnosis or

TABLE 12 High-Risk Conditions for Which ABPM May Be Useful

Condition	Rationale
Secondary HTN	Severe ambulatory HTN or nocturnal HTN indicates higher likelihood of secondary HTN ^{161,167}
CKD or structural renal abnormalities	Evaluate for MH or nocturnal HTN, ^{168–172} better control delays progression of renal disease ¹⁷³
T1DM and T2DM	Evaluate for abnormal ABPM patterns, ^{174,175} better BP control delays the development of MA ^{176–178}
Solid-organ transplant	Evaluate for MH or nocturnal HTN, better control BP ^{179–188}
Obesity	Evaluate for WCH and MH ^{23,189–192}
OSAS	Evaluate for nondipping and accentuated morning BP surge ^{43,46,193,194}
Aortic coarctation (repaired)	Evaluate for sustained HTN and MH ^{58,112,113}
Genetic syndromes associated with HTN (neurofibromatosis, Turner syndrome, Williams syndrome, coarctation of the aorta)	HTN associated with increased arterial stiffness may only be manifest with activity during ABPM ^{58,195}
Treated hypertensive patients	Confirm 24-h BP control ¹⁵⁵
Patient born prematurely	Evaluate for nondipping ¹⁹⁶
Research, clinical trials	To reduce sample size ¹⁹⁷

TABLE 13 Recommended Procedures for the Application of ABPM

Procedure	Recommendation
Device	Should be validated by the Association for the Advancement of Medical Instrumentation or the British Hypertension Society for use in children May be oscillometric or auscultatory
Application	Trained personnel should apply the monitor Correct cuff size should be selected Right and left arm and a lower extremity BP should be obtained to rule out coarctation of the aorta Use nondominant arm unless there is large difference in size between the left arm and right arm, then apply to the arm with the higher BP Take readings every 15–20 min during the day and every 20–30 min at night Compare (calibrate) the device to resting BP measured by the same technique (oscillometric or auscultatory) Record time of medications, activity, and sleep
Assessment	A physician who is familiar with pediatric ABPM should interpret the results Interpret only recordings of adequate quality. Minimum of 1 reading per hour; 40–50 for a full day, 65%–75% of all possible recordings Edit outliers by inspecting for biologic plausibility, edit out calibration measures Calculate mean BP, BP load (% of readings above threshold), and dipping (% decline in BP from wake to sleep) Interpret with pediatric ABPM normal data by sex and height Use AHA staging schema ¹⁵⁵ Consider interpretation of 24-h, daytime, and nighttime MAP, especially in patients with CKD ^{173,198}

Adapted from Flynn JT, Daniels SR, Hayman LL, et al; American Heart Association Atherosclerosis, Hypertension and Obesity in Youth Committee of the Council on Cardiovascular Disease in the Young. Update: ambulatory blood pressure monitoring in children and adolescents: a scientific statement from the American Heart Association. *Hypertension*. 2014;63(5):1116–1135.

management of HTN in children and adolescents at this time.

4.7 ABPM

An ambulatory BP monitor consists of a BP cuff attached to a box slightly larger than a cell phone, which records BP periodically (usually every 20–30 minutes) throughout the day and night; these data are later downloaded to a computer for analysis.¹⁵⁵

ABPM has been recommended by the US Preventive Services Task Force for the confirmation of HTN in adults before starting treatment.¹⁵⁶ Although a growing number of

pediatric providers have access to ABPM, there are still gaps in access and knowledge regarding the optimal application of ABPM to the evaluation of children's BP.^{155,157} For example, there are currently no reference data for children whose height is <120 cm. Because no outcome data exist linking ABPM data from childhood to hard CV events in adulthood, recommendations either rely largely on surrogate outcome markers or are extrapolated from adult studies.

However, sufficient data exist to demonstrate that ABPM is more accurate for the diagnosis of HTN than clinic-measured

BP,^{158,159} is more predictive of future BP,¹⁶⁰ and can assist in the detection of secondary HTN.¹⁶¹ Furthermore, increased LVMI and LVH correlate more strongly with ABPM parameters than casual BP.^{162–166} In addition, ABPM is more reproducible than casual or home BP measurements.¹⁵⁹ For these reasons, the routine application of ABPM is recommended, when available, as indicated below (see also Tables 12 and 13). Obtaining ABPM may require referral to a specialist.

Key Action Statement 6

ABPM should be performed for the confirmation of HTN in children

and adolescents with office BP measurements in the elevated BP category for 1 year or more or with stage 1 HTN over 3 clinic visits (grade C, moderate recommendation).

For technical reasons, ABPM may need to be limited to children ≥ 5 years of age who can tolerate the procedure and those for whom reference data are available.

Key Action Statement 7

The routine performance of ABPM should be strongly considered in children and adolescents with high-risk conditions (see Table 12) to assess HTN severity and determine if abnormal circadian BP patterns are present, which may indicate increased risk for target organ damage (grade B, moderate recommendation).

Key Action Statement 8

ABPM should be performed by using a standardized approach (see Table 13) with monitors that have been validated in a pediatric population, and studies should be interpreted by using pediatric normative data (grade C, moderate recommendation).

4.7a Masked Hypertension

MH occurs when patients have normal office BP but elevated BP on ABPM, and it has been found in 5.8% of unselected children studied by ABPM.¹⁹⁹ There is growing evidence

that compared with those with normal 24-hour BP, these patients have significant risk for end organ hypertensive damage.^{200,203} Patients who are at risk of MH include patients with obesity and secondary forms of HTN, such as CKD or repaired aortic coarctation. MH is particularly prevalent in patients with CKD⁴⁸ and is associated with target organ damage.²⁰³ Children with CKD should be periodically evaluated using ABPM for MH as part of routine CKD management.^{201,204–206}

4.7b White Coat Hypertension

WCH is defined as BP ≥ 95 th percentile in the office or clinical setting but < 95 th percentile outside of the office or clinical setting. WCH is diagnosed by ABPM when the mean SBP and DBP are < 95 th percentile and SBP and DBP load are $< 25\%$; load is defined as the percentage of valid ambulatory BP measurements above a set threshold value (eg, 95th percentile) for age, sex, and height.^{155,156,206} It is estimated that up to half of children who are evaluated for elevated office BP have WCH.^{207,208}

In adults, compared with normotension, WCH is associated with only a slightly increased risk of adverse outcomes but at a much lower risk compared with those

with established HTN.²⁰⁹ Most (but not all) studies suggest that WCH is not associated with increased LV mass.^{200,207,210} Although the distinction between WCH and true HTN is important, abnormal BP response to exercise and increased LVM has been found to occur in children with WCH.²⁰⁷ Furthermore, the identification of WCH may reduce costs by reducing the number of additional tests performed and decreasing the number of children who are exposed to antihypertensive medications.²⁰⁸ Children and adolescents with WCH should have screening BP measured at regular well-child care visits with consideration of a repeat ABPM in 1 to 2 years.

Key Action Statement 9

Children and adolescents with suspected WCH should undergo ABPM. Diagnosis is based on the presence of mean SBP and DBP < 95 th percentile and SBP and DBP load $< 25\%$ (grade B, strong recommendation).

4.8 Measurement in Children With Obesity

Accurate BP measurement can be challenging in individuals with obesity.^{23,211,212} Elevated BMI in children and adolescents is associated with an increase in the midarm circumference,⁹⁶ requiring the use of a larger cuff to obtain accurate BP measurements.⁸³ During NHANES 2007–2010, among children 9 to 11 years of age with obesity, one-third of boys and one-quarter of girls required an adult BP cuff, and a fraction required a large adult cuff or an adult thigh cuff for an accurate measurement of BP.²¹³ Researchers in studies of adults have also noted the influence of the conical upper arm shape on BP measurements in people with obesity.^{214,215} ABPM is a valuable tool in the diagnosis of HTN in children with obesity because of the discrepancies between casual and

Key Action Statement 6. ABPM should be performed for the confirmation of HTN in children and adolescents with office BP measurements in the elevated BP category for 1 year or more or with stage 1 HTN over 3 clinic visits (grade C, moderate recommendation).

Aggregate Evidence Quality	Grade C
Benefits	Avoids unnecessarily exposing youth with WCH to extensive diagnostic testing or medication
Risks, harm, cost	Risk of discomfort to patient. Some insurance plans may not reimburse for the test
Benefit–harm assessment	The risk of ABPM is lower than the risk of unnecessary treatment. The use of ABPM has also been shown to be more cost-effective than other approaches to diagnosing HTN
Intentional vagueness	None
Role of patient preferences	Some patients may prefer repeat office or home measurements to ABPM
Exclusions	None
Strength	Moderate recommendation
Key references	23,155,158,159

Key Action Statement 7. The routine performance of ABPM should be strongly considered in children and adolescents with high-risk conditions (see Table 12) to assess HTN severity and determine if abnormal circadian BP patterns are present, which may indicate increased risk for target organ damage (grade B, moderate recommendation).

Aggregate Evidence Quality	Grade B
Benefits	Improved 24-h control of BP improves outcomes. Recognition of MH or nocturnal HTN might lead to therapeutic changes that will limit end organ damage
Risks, harm, cost	Risk of discomfort to patient. Some insurance plans may not reimburse for the test. The risk of diagnosing and labeling a patient as having MH or nocturnal HTN might lead to increased anxiety and cost of evaluation
Benefit–harm assessment	The risk of ABPM is much lower than the risk of inadequate treatment
Intentional vagueness	Frequency at which normal or abnormal ABPM should be repeated is not known
Role of patient preferences	Some patients may prefer repeat office or home measurements to ABPM
Exclusions	None
Strength	Moderate recommendation
Key references	47,155,199–202

Key Action Statement 8. ABPM should be performed by using a standardized approach (see Table 13) with monitors that have been validated in a pediatric population, and studies should be interpreted by using pediatric normative data (grade C, moderate recommendation).

Aggregate Evidence Quality	Grade C
Benefits	Validated monitors applied and interpreted correctly will provide the most accurate results
Risks, harm, cost	Risk of discomfort to patient. Some insurance plans may not reimburse for the test. Monitors validated in the pediatric population and expertise in reading pediatric ABPM may not be universally available
Benefit–harm assessment	There is substantial evidence showing incorrect application or interpretation reduces the accuracy of results
Intentional vagueness	None
Role of patient preferences	Some patients may prefer repeat office or home measurements to ABPM
Exclusions	None
Strength	Moderate recommendation
Key references	155

ambulatory BP^{23,33} and the higher prevalence of MH.^{26,29,155,216,217}

4.9. At-Home Measurement

Home measurement (or self-monitoring) of BP has advantages over both office and ambulatory monitoring, including convenience and the ability to obtain repeated measurements over time.^{83,218} Furthermore, automated devices with memory capacity are straightforward to use and avoid potential problems, such as observer bias, inaccurate reporting, and terminal digit preference (ie, overreporting of certain digits, like 0, as the terminal digit in recording BP).^{219,220}

Numerous studies have shown that it is feasible for families to conduct repeated measurements at home.^{221–223} Home BP measurements appear to be more reproducible than those conducted in the office, likely because of the familiarity of the home environment and greater comfort with repeated measurements.^{159,223,224} Inaccuracies occur when measurements obtained at home are either excluded or inappropriately recorded.²¹⁹ Inconsistencies in home, office, and ambulatory BP measurements seem to be influenced by both age and HTN status, with ABPM tending to be higher than home BP measurements

in children.^{222,225–227} Home BP measurements show no consistent pattern when compared with office measurements.^{228–230}

There are several practical concerns with the use of home BP measurement, however. The only normative data available are from the relatively small Arsakeion School study.²³¹ In addition, only a few automated devices have been validated for use in the pediatric population, and available cuff sizes for them are limited. Furthermore, there is no consensus regarding how many home measurements across what period of time are needed to evaluate BP.

Key Action Statement 10

Home BP monitoring should not be used to diagnose HTN, MH, or WCH but may be a useful adjunct to office and ambulatory BP measurement after HTN has been diagnosed (grade C, moderate recommendation).

4.10 School Measurement and the Role of School-Based Health Professionals

There is limited evidence to support school-based measurement of children's BP.^{8,232} Observational studies demonstrate that school measurements can be reliable²³³ and that longitudinal follow-up is feasible.^{8,232,234} Available data do not distinguish between the efficacy of school-based screening programs in which measurements are obtained by trained clinical personnel (not a school nurse) versus measurements obtained by the school nurse. Because of insufficient evidence and a lack of established protocols, the routine use of school-based measurements to diagnose HTN cannot be recommended. However, school-based BP measurement can be a useful tool to identify children who require formal evaluation as well as a helpful adjunct in the monitoring of diagnosed HTN. Note: School-based health clinics are considered part of

Key Action Statement 9. Children and adolescents with suspected WCH should undergo ABPM. Diagnosis is based on the presence of mean SBP and DBP <95th percentile and SBP and DBP load <25% (grade B, strong recommendation).

Aggregate Evidence Quality	Grade B (Evidence Level A in Adults)
Benefits	Improved diagnosis of WCH and the benefit of fewer additional laboratory tests and/or treatment of primary HTN. Costs might be reduced if the treatment of those misdiagnosed as hypertensive is prevented
Risks, harm, cost	Additional costs; costs may not be covered by insurance companies. The ambulatory BP monitor is uncomfortable for some patients
Benefit-harm assessment	Benefit exceeds risk
Intentional vagueness	None
Role of patient preferences	Important; some patients may not want to undergo ABPM. Benefits of the procedure should be reviewed with families to assist in decision-making
Exclusions	None
Strength	Strong recommendation
Key references	206

Key Action Statement 10. Home BP monitoring should not be used to diagnose HTN, MH, or WCH but may be a useful adjunct to office and ambulatory BP measurement after HTN has been diagnosed (grade C, moderate recommendation).

Aggregate Evidence Quality	Grade C
Benefits	Convenient, cost-effective, widely available, can be used over time
Risks, harm, cost	Risk of inaccurate diagnosis. Unclear what norms or schedule should be used. Few validated devices in children, and cuff sizes are limited
Benefit-harm assessment	Benefits outweigh harm when used as an adjunctive measurement technique
Intentional vagueness	None
Role of patient preferences	Patients may find home BP more convenient and accessible than office or ambulatory BP
Exclusions	None
Strength	Moderate recommendation
Key references	159,221–225,227,230

systems of pediatric primary care, and these comments would not apply to them.

5. PRIMARY AND SECONDARY CAUSES OF HTN

5.1 Primary HTN

Primary HTN is now the predominant diagnosis for hypertensive children and adolescents seen in referral centers in the United States,^{235,236} although single-center studies from outside the United States still find primary HTN to be uncommon.²³⁷ Although prospective, multicenter studies are generally lacking, at least one large study in which researchers used insurance claims data confirmed that primary HTN is significantly

more common than secondary HTN among American youth.²³⁸

General characteristics of children with primary HTN include older age (≥ 6 years),^{239,240} positive family history (in a parent and/or grandparent) of HTN,^{236,237,240} and overweight and/or obesity.^{16,236,237,239} Severity of BP elevation has not differed significantly between children with primary and secondary HTN in some studies,^{235,237} but DBP elevation appears to be more predictive of secondary HTN,^{239,240} whereas systolic HTN appears to be more predictive of primary HTN.^{236,239}

Key Action Statement 11

Children and adolescents ≥ 6 years of age do not require an extensive

evaluation for secondary causes of HTN if they have a positive family history of HTN, are overweight or obese, and/or do not have history or physical examination findings (Table 14) suggestive of a secondary cause of HTN (grade C, moderate recommendation).

5.2 Secondary Causes: Renal and/or Renovascular

Renal disease and renovascular disease are among the most common secondary causes of HTN in children. Renal parenchymal disease and renal structural abnormalities accounted for 34% to 79% of patients with secondary HTN in 3 retrospective, single-center case series, and renovascular disease was present in 12% to 13%.^{101,240,241} The literature suggests that renal disease is a more common cause of HTN in younger children.²³⁹ Renal disorders (including vascular problems) accounted for 63% to 74% of children <6 years of age who were enrolled in 3 recent clinical trials of angiotensin receptor blockers (ARBs).^{239,242–244} No increased frequency was seen in younger patients in a recent single-center case series, however.¹⁰¹ It is appropriate to have a high index of suspicion for renal and renovascular disease in hypertensive pediatric patients, particularly in those <6 years of age.

5.3 Secondary Causes: Cardiac, Including Aortic Coarctation

Coarctation of the aorta is a congenital abnormality of the aortic arch characterized by discrete narrowing of the aortic arch, generally at the level of the aortic isthmus. It is usually associated with HTN and right arm BP that is 20 mm Hg (or more) greater than the lower extremity BP. Repair in infants is often surgical; adolescents may be treated with angioplasty or stenting. Long-segment narrowing of the abdominal aorta can also cause HTN and should be considered in children with refractory

Key Action Statement 11. Children and adolescents ≥ 6 years of age do not require an extensive evaluation for secondary causes of HTN if they have a positive family history of HTN, are overweight or obese, and/or do not have history or physical examination findings (Table 14) suggestive of a secondary cause of HTN (grade C, moderate recommendation).

Aggregate Evidence Quality	Grade C
Benefits	Avoidance of unnecessary diagnostic evaluation
Risks, harm, cost	Potential to miss some children with secondary HTN
Benefit-harm assessment	Benefit equals harm
Intentional vagueness	Not applicable
Role of patient preferences	Some families may want further testing performed
Exclusions	Hypertensive children < 6 y of age
Strength	Moderate recommendation
Key references	16,129,235–240

HTN and a gradient between the upper and lower extremities in which the upper extremity SBP exceeds the lower extremity SBP by 20 mm Hg.²⁴⁵ Of note, children with abdominal aortic obstruction may have neurofibromatosis, Williams syndrome, Alagille syndrome, or Takayasu arteritis.

Patients with coarctation can remain hypertensive or develop HTN even after early and successful repair, with reported prevalence varying from 17% to 77%.¹¹² HTN can be a manifestation of recoarctation. Recoarctation in repaired patients should be assessed for by using 4 extremity BP measurements and echocardiography. HTN can also occur without recoarctation.²⁴⁶ The prevalence of HTN increases over time after successful coarctation repair.¹¹²

Routine office BP measurement alone is often insufficient for diagnosing HTN after coarctation repair.^{113,246} Children who have undergone coarctation repair may have normal in-office BP but high BP out of the office, which is consistent with MH.^{58,112} Of children with a history of aortic coarctation, ~45% have MH at ~1 to 14 years after coarctation repair.^{58,113} Children with a history of repaired aortic coarctation and normal in-office BP are at risk for LVH,⁵⁸ HTN, and MH.^{58,112}

ABPM has emerged as the gold standard for diagnosing HTN among individuals who have undergone coarctation repair, and it is likely

more useful than casual BP.^{58,245–247} Screening is recommended as a part of usual care on an annual basis beginning, at most, 12 years after coarctation repair. Earlier screening may be considered on the basis of risk factors and clinician discretion.

Key Action Statement 12

Children and adolescents who have undergone coarctation repair should undergo ABPM for the detection of HTN (including MH) (grade B, strong recommendation).

5.4 Secondary Causes: Endocrine HTN

HTN resulting from hormonal excess accounts for a relatively small proportion of children with secondary HTN. Although rare (with a prevalence ranging from 0.05% to 6% in children^{101,237,239,240}), an accurate diagnosis of endocrine HTN provides the clinician with a unique treatment opportunity to render a

surgical cure or achieve a dramatic response with pharmacologic therapy.²⁴⁸ Known endocrine causes with associated molecular defects (when known) are summarized in Table 15.

5.5 Secondary Causes: Environmental Exposures

Several environmental exposures have been associated with higher childhood BP, although most studies are limited to small case series. Among the most prominent are lead, cadmium, mercury, and phthalates.

- **Lead:** Long-term exposure to lead in adults has been associated with higher BP in population studies^{295,296} and in studies of industrial workers with high lead exposure,²⁹⁷ although findings have not been consistent.²⁹⁸ At least 1 cross-sectional study of 122 children demonstrated that children with higher blood lead concentrations had higher BP; lower socioeconomic status was also seen in this group, which may have confounded the BP results.²⁹⁹ Furthermore, in a randomized study of lead-exposed children, those who received chelation with succimer did not have lower BP than in those who received a placebo.³⁰⁰
- **Cadmium:** Environmental cadmium exposure has been linked to higher BP levels and the development of HTN in adults, particularly among women.^{296,301–303} Although cross-sectional studies have

Key Action Statement 12. Children and adolescents who have undergone coarctation repair should undergo ABPM for the detection of HTN (including MH) (grade B, strong recommendation).

Aggregate Evidence Quality	Grade B (Aggregate Level of Evidence Equals B, Given 3 Studies With Similar Findings)
Benefits	Early detection of HTN
Risks, harm, cost	Additional costs related to the placement of ABPM
Benefit-harm assessment	Benefits exceed harms
Intentional vagueness	Frequency of measurement. Because the development of HTN after coarctation repair is influenced by many factors, the ideal onset of screening for HTN (including MH) is unknown
Role of patient preferences	None
Exclusions	Individuals with a history of residual aortic arch obstruction
Strength	Strong recommendation
Key references	58,112,113

TABLE 14 Examples of Physical Examination Findings and History Suggestive of Secondary HTN or Related to End Organ Damage Secondary to HTN

Body System	Finding, History	Possible Etiology
Vital signs	Tachycardia	Hyperthyroidism PCC Neuroblastoma
	Decreased lower extremity pulses; drop in BP from upper to lower extremities	Coarctation of the aorta
Eyes	Proptosis	Hyperthyroidism
	Retinal changes ^a	Severe HTN, more likely to be associated with secondary HTN
Ear, nose, throat	Adenotonsillar hypertrophy	SDB
	History of snoring	Sleep apnea
Height, weight	Growth retardation	Chronic renal failure
	Obesity (high BMI)	Cushing syndrome
Head, neck	Truncal obesity	Insulin resistance syndrome
	Elfin facies	Williams syndrome
	Moon facies	Cushing syndrome
	Thyromegaly, goiter	Hyperthyroidism
Skin	Webbed neck	Turner syndrome
	Pallor, flushing, diaphoresis	PCC
	Acne, hirsutism, striae	Cushing syndrome
	Café-au-lait spots	Anabolic steroid abuse
Hematologic	Adenoma sebaceum	Neurofibromatosis
	Malar rash	Tuberous sclerosis
	Acanthosis nigricans	Systemic lupus
	Pallor	T2DM
Chest, cardiac	Sickle cell anemia	Renal disease
	Chest pain	Heart disease
	Palpitations	
	Exertional dyspnea	
Abdomen	Widely spaced nipples	Turner syndrome
	Heart murmur	Coarctation of the aorta
	Friction rub	Systemic lupus (pericarditis)
	Apical heave ^a	Collagen vascular disease
Genitourinary	Abdominal mass	LVH
	Epigastric, flank bruit	Wilms tumor
	Palpable kidneys	Neuroblastoma
		PCC
Extremities	Ambiguous or virilized genitalia	RAS
	Urinary tract infection	Polycystic kidney disease
	Vesicoureteral reflux	Hydronephrosis
	Hematuria, edema, fatigue	Multicystic dysplastic kidney
Neurologic, metabolic	Abdominal trauma	Congenital adrenal hyperplasia
	Joint swelling	Renal disease
	Muscle weakness	Systemic lupus
		Collagen vascular disease
Neurologic, metabolic	Hypokalemia, headache, dizziness, polyuria, nocturia	Hyperaldosteronism
	Muscle weakness, hypokalemia	Liddle syndrome
		Reninoma
		Monogenic HTN (Liddle syndrome, GRA, AME)

AME, apparent mineralocorticoid excess; GRA, glucocorticoid-remediable aldosteronism. Adapted from Flynn JT. Evaluation and management of hypertension in childhood. *Prog Pediatr Cardiol.* 2001;12(2):177–188; National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. *Pediatrics.* 2004;114(2):555–576.

^a Findings that may be indicative of end organ damage related to HTN.

confirmed potential nephrotoxicity of cadmium in children,³⁰⁴ no definite effect on BP has been demonstrated.^{304,305}

- **Mercury:** Mercury is a known nephrotoxin, particularly in its elemental form.^{306,307} Severe mercury intoxication has been linked to acute HTN in children in several case reports; patients' symptoms may resemble those seen in patients with pheochromocytoma (PCC).^{308–310}
- **Phthalates:** Antenatal and childhood exposure to phthalates has recently been associated with higher childhood BP^{311–313} but not with the development of overt HTN. Specific metabolites of these ubiquitous chemicals may have differential effects on BP,³¹³ indicating that much more detailed study is needed to completely understand the effect of such exposure.

5.6 Secondary Causes: Neurofibromatosis

Neurofibromatosis type 1 (NF-1) (also known as Von Recklinghausen disease) is a rare autosomal dominant disorder characterized by distinct clinical examination findings. These include the following: café-au-lait macules, neurofibromas, Lisch nodules of the iris, axillary freckling, optic nerve gliomas, and distinctive bone lesions. Patients with NF-1 have several unique and potential secondary causes of HTN, most commonly renal artery stenosis (RAS); coarctation of the aorta, middle aortic syndrome, and PCC are also well described.^{314–319}

Additionally, an increased incidence of idiopathic HTN has been documented in patients with NF-1, as high as 6.1% in a recent pediatric case series, which is a much greater incidence than in the general population.³²⁰ PCC has also been well described in patients with NF-1, although exact incidences are difficult

TABLE 15 Endocrine Causes of HTN

Name of Disorder	Genetic Mutation	Mode of Inheritance	Clinical Feature(s)	Biochemical Mechanism and Notes	Ref No(s).
Catecholamine excess PCC, paraganglioma	VHL (49%)	De novo, AD	HTN	Diagnostic test: fractionated plasma ^a and/or urine metanephrines and normetanephrines	248–254
Mineralocorticoid excess Specific etiologies addressed below Consider if: Early onset HTN Potassium level abnormalities Family history of primary aldosteronism Resistant HTN	SDHB (15%) SDHD (10%) RET		Palpitations, headache, sweating Abdominal mass Incidental radiographic finding Family screening		255,256
Congenital adrenal hyperplasia 11 β -hydroxylase deficiency	CYP11B1 (loss of function)	AR	HTN	Elevated levels of DOC, 11-deoxycortisol, androstenedione, testosterone, and DHEAS Higher prevalence in Moroccan Jews	257–259
17- α hydroxylase deficiency	CYP17 (loss of function)	AR	Hypokalemia Acne, hirsutism, and virilization in girls Pseudoprecocious puberty in boys 11% of congenital adrenal hyperplasia HTN and hypokalemia Low aldosterone and renin Undervirilized boys, sexual infantilism in girls <1% of congenital adrenal hyperplasia	Elevated DOC and corticosterone Decreased androstenedione, testosterone and DHEAS Prominent in Dutch Mennonites	260–262
Familial hyperaldosteronism Type 1	Hybrid CYP11B1 and CYP11B2 (11 β -hydroxylase—aldosterone synthase, gain of function)	AD	Young subjects with PA Family history of young strokes	Excessive, ACTH-regulated aldosterone production Prescription with low-dose dexamethasone May add low-dose spironolactone, calcium channel blocker, or potassium supplementation	263,264
Type 2	Unknown, possibly 7p22	AD (prevalence varies from 1.2% to 6%)	PA in the patient with an affected first-degree relative Unresponsive to dexamethasone May have adrenal adenoma or bilateral adrenal hyperplasia	Excessive autonomous aldosterone production	265–267
Type 3	KCNJ5 G-protein potassium channel (loss of function)	AD	Early onset severe HTN in the first family described Milder phenotypes also seen PA and HTN age <10 y Variable developmental abnormalities	Mutation leads to loss of potassium+ sensitivity causing sodium+ influx that activates Ca ⁺⁺ channels, leading to aldosterone synthesis Increased Ca ⁺⁺ channel sensitivity causing increased aldosterone synthesis	268–270
Type 4	CACNA1D coding for calcium channel (gain of function)	AD			271,272
Other genetic causes					

TABLE 15 Continued

Name of Disorder	Genetic Mutation	Mode of Inheritance	Clinical Feature(s)	Biochemical Mechanism and Notes	Ref No(s).
Carney complex	PRKARIA	AD	Skin pigmentation Pituitary and other tumors	Rare familial cause	273,274
McCune Albright syndrome	GNAS, α -subunit	Somatic	Cutaneous pigmentation Fibrous dysplasia	Tumors in the breast, thyroid, pituitary gland, or testicles may be present	275,276
Primary glucocorticoid resistance (Chrousos syndrome)	NR3C1 (loss of function glucocorticoid receptor)	AD	HTN Ambiguous genitalia Precocious puberty Androgen excess, menstrual abnormalities or infertility in women	Loss of function of glucocorticoid receptor	277–279
Apparent mineralocorticoid excess	HSD11B2 (loss of function)	AR	HTN	Reduced or absent activity of 11 β -HSD2: cortisol gains access to MR Mimicked by licorice toxicity	280,281
Liddle syndrome	SCNN1B β -subunit–SCNN1G γ -subunit (activating mutation)		Hypokalemia Low birth weight Failure to thrive Polyuria, polydipsia Severe HTN	Constitutive activation of the epithelial sodium channel causing salt retention and volume expansion	282,283
Geller syndrome	MCR (mineralocorticoid-d receptor, activating mutation)	AD	Hypokalemia Metabolic alkalosis Muscle weakness Onset of HTN <20 y Exacerbated by pregnancy	Constitutive activation of MR Also activated by progesterone	284
Pseudohypoaldosteronism type 2 (Gordon syndrome)	WNK1.4; KLHL3; CUL3; SPAK (activating mutation)	AD	Short stature Hyperkalemic and hyperchloremic metabolic acidosis Borderline HTN	Increased activity of sodium chloride cotransporter causing salt retention and volume expansion	285–287
Glucocorticoid excess Cushing syndrome, adrenocortical carcinoma, iatrogenic excess	To be discovered	—	HTN Other signs of Cushing syndrome	Likely attributable to increased DOC, sensitivity to vasoconstriction, cardiac output, activation of RAS	288–290
Other endocrine abnormalities					
Hyperthyroidism	To be discovered	—	Tachycardia	Mechanism increased cardiac output, stroke volume, and decreased peripheral resistance Initial prescription with β blockers	291,292
Hyperparathyroidism	—	—	HTN Tremors Other signs of hyperthyroidism Hypocalcemia Other signs of hyperparathyroidism	Mechanism unknown, may not remit after treatment of hyperparathyroidism	293,294

ACTH, adrenocorticotrophic hormone; AD, autosomal dominant; AR, autosomal recessive; DHEAS, dehydroepiandrosterone sulfate; DOC, deoxycortisol; MR, magnetics resonance; PA, primary hyperaldosteronism; PAC, plasma aldosterone concentration; RAS, renin angiotensin system; —, not applicable.
^a Influenced by posture, specialized center preferred.

to determine, and patients may not have classic symptoms of PCC.^{321,322}

Vascular causes of HTN and PCC all require specific treatment and follow-up, so maintaining a high index of suspicion for these disorders is important in evaluating hypertensive children and adolescents with NF-1.

5.7 Secondary Causes: Medication Related

Many over-the-counter drugs, prescription medications, alternative therapies (ie, herbal and nutritional supplements), dietary products, and recreational drugs can increase BP. Common prescription medications associated with a rise in BP include oral contraceptives,^{323–325} central nervous system stimulants,³²⁶ and corticosteroids.^{1,327} When a child has elevated BP measurements, the practitioner should inquire about the intake of pharmacologic agents (see Table 8).

Usually, the BP elevation is mild and reversible on discontinuation of the medication, but a significant increase in BP can occasionally occur with higher doses or as an idiosyncratic response. Over-the-counter cold medications that contain decongestants (eg, pseudoephedrine and phenylpropanolamine) may cause a mild increase in BP with the recommended dosing, but severe HTN has been observed as an idiosyncratic response with appropriate dosing as well as with excessive doses.

Nonsteroidal anti-inflammatory drugs may antagonize the BP-lowering effect of antihypertensive medications (specifically, angiotensin-converting enzyme [ACE] inhibitors) but do not appear to have an impact on BP in those without HTN. The commonly used supplement ephedra (ma haung) likely contains some amount of ephedrine and caffeine that can cause an unpredictable rise in BP. Recreational drugs associated with

HTN include stimulants (eg, cocaine and amphetamine derivatives) and anabolic steroids.

5.8 Monogenic HTN

Monogenic forms of HTN are uncommon, although the exact incidence is unknown. In a study of select hypertensive children without a known etiology, genetic testing for familial hyperaldosteronism type I (FH-I), or glucocorticoid-remediable aldosteronism, confirmed responsible genetic mutations in 3% of the population.²⁶³

Other monogenic forms of HTN in children include Liddle syndrome, pseudohypoaldosteronism type II (Gordon syndrome), apparent mineralocorticoid excess, familial glucocorticoid resistance, mineralocorticoid receptor activating mutation, and congenital adrenal hyperplasia (see “Secondary Causes: Endocrine Causes of Hypertension”).³²⁸ All manifest as HTN with suppressed plasma renin activity (PRA) and increased sodium absorption in the distal tubule. Other features may include serum potassium abnormalities, metabolic acid-base disturbances, and abnormal plasma aldosterone concentrations, although the clinical presentations can be highly variable.^{263,328,329} In the study of FH-I, all affected children had suppressed PRA and an aldosterone to renin ratio (ARR) (ng/dL and ng/M1 per hour, respectively) of >10; the authors suggest that an ARR >10 is an indication to perform genetic testing in a hypertensive child.²⁶³ Monogenic forms of HTN should be suspected in hypertensive children with a suppressed PRA or elevated ARR, especially if there is a family history of early-onset HTN.

6. DIAGNOSTIC EVALUATION

6.1 Patient Evaluation

As with any medical condition, appropriate diagnostic evaluation

is a critical component in the evaluation of a patient with suspected HTN. Evaluation focuses on determining possible causes of and/or comorbidities associated with HTN. Evaluation, as is detailed in the following sections, should include appropriate patient history, family history, physical examination, laboratory evaluation, and imaging.

6.2 History

The first step in the evaluation of the child or adolescent with elevated BP is to obtain a history. The various components of the history include the perinatal history, past medical history, nutritional history, activity history, and psychosocial history. Each is discussed in the following sections.

6.2a Perinatal History

As discussed, perinatal factors such as maternal HTN and low birth weight have been shown to influence later BP, even in childhood.^{56,330} Additionally, a high incidence of preterm birth among hypertensive children has recently been reported in 1 large case series.¹⁰¹ Thus, it is appropriate to obtain a history of pertinent prenatal information, including maternal pregnancy complications; gestational age; birth weight; and, if pertinent, complications occurring in the neonatal nursery and/or ICU. It is also appropriate to document pertinent procedures, such as umbilical catheter placement.

6.2b Nutritional History

High sodium intake has been linked to childhood HTN and increased LVMI and is the focus of several population health campaigns.^{4,331} In NHANES 2003–2008, among children 8 to 18 years of age ($n = 6235$), higher sodium intake (as assessed by dietary recall) was associated with a twofold increase in the combined outcome of elevated BP or HTN. The effect was threefold among participants with obesity.³³² Limited data suggest

the same effect is seen in younger children.³³³ One study found that high intake of total fat and saturated fat, as well as adiposity and central obesity, were also predictors of SBP.^{334–336}

Nutrition history is an important part of the patient assessment because it may identify dietary contributors to HTN and detect areas in which lifestyle modification may be appropriate. The important components to discuss include salt intake (including salt added in the kitchen and at the table and sodium hidden in processed and fast food), consumption of high-fat foods, and consumption of sugary beverages.^{337,338} Infrequent consumption of fruits, vegetables, and low-fat dairy products should also be identified.

6.2c Physical Activity History

A detailed history of physical activity and inactivity is an integral part of the patient assessment, not only to understand contributors to the development of HTN but also to direct lifestyle modification counseling as an important part of management.^{339–344}

6.2d Psychosocial History

Providers should obtain a psychosocial history in children and adolescents with suspected or confirmed HTN. Adverse experiences both prenatally³⁴⁵ and during childhood (including maltreatment, early onset depression, and anxiety) are associated with adult-onset HTN.^{346,347} The identification of stress may suggest a diagnosis of WCH. The psychosocial history should include questions about feelings of depression and anxiety, bullying, and body perceptions. The latter is particularly important for patients with overweight or obesity because ~70% of these children report having bullying and body perception concerns.³⁴⁸ Starting at 11 years of age, the psychosocial history should include questions about smoking,^{349,350} alcohol, and other drug use.³⁵¹

6.2e Family History

Taking and updating the family history is a quick and easy way to risk-stratify pediatric patients with an increased risk for HTN. It is important to update the family history for HTN over the course of the pediatric patient's lifetime in the practice (typically until 18–21 years of age) because first- and second-degree relatives may develop HTN during this time. All too often, the diagnosis of HTN in the pediatric patient stimulates the collection of a detailed family history of HTN, sometimes even years after the pediatric patient has had elevated BP, instead of the other way around.³⁵²

6.3 Physical Examination

A complete physical examination may provide clues to potential secondary causes of HTN and assess possible hypertensive end organ damage. The child's height, weight, calculated BMI, and percentiles for age should be determined at the start of the physical examination. Poor growth may indicate an underlying chronic illness.

At the second visit with confirmed elevated BP or stage 1 HTN or the first visit with confirmed stage 2 HTN, BP should be measured in both arms and in a leg. Normally, BP is 10 to 20 mm Hg higher in the legs than the arms. If the leg BP is lower than the arm BP, or if femoral pulses are weak or absent, coarctation of the aorta may be present. Obesity alone is an insufficient explanation for diminished femoral pulses in the presence of high BP.

The remainder of the physical examination should pursue clues found in the history and should focus on body systems and findings that may indicate secondary HTN and/or end organ damage related to HTN. Table 14 lists important physical examination findings in hypertensive children.³⁵³ These are examples of history and physical findings and do not represent all possible history and

physical examination findings. The physical examination in hypertensive children is frequently normal except for the BP elevation.

Key Action Statement 13

In children and adolescents being evaluated for high BP, the provider should obtain a perinatal history, appropriate nutritional history, physical activity history, psychosocial history, and family history and perform a physical examination to identify findings suggestive of secondary causes of HTN (grade B, strong recommendation).

6.4 Laboratory Evaluation

The purpose of the laboratory evaluation is to identify underlying secondary causes of HTN (eg, renal or endocrine disease) that would require specific treatment guided by a subspecialist. In general, such testing includes a basic set of screening tests and additional, specific tests; the latter are selected on the basis of clues obtained from the history and physical examination and/or the results of the initial screening tests.³⁵⁴ Table 10 provides a list of screening tests and the populations in which they should be performed.

6.5 Electrocardiography

Approximately one-half of adolescents with HTN have undergone electrocardiography at least once as an assessment for LVH.³⁵⁵ Unlike echocardiography, electrocardiography takes little time and is a relatively low-cost test. Electrocardiography has high specificity but poor sensitivity for identifying children and adolescents with LVH.^{356–358} The positive predictive value of electrocardiography to identify LVH is extremely low.³⁵⁹

Key Action Statement 14

Clinicians should not perform electrocardiography in hypertensive

Key Action Statement 13. In children and adolescents being evaluated for high BP, the provider should obtain a perinatal history, appropriate nutritional history, physical activity history, psychosocial history, and family history and perform a physical examination to identify findings suggestive of secondary causes of HTN (grade B, strong recommendation).

Aggregate Evidence Quality	Grade B
Benefits	Identify personal risk factors for HTN
Risks, harm, cost	None
Benefit–harm assessment	Identification of personal risk factors is useful in the assessment of childhood HTN
Intentional vagueness	None
Role of patient preferences	None
Exclusions	Children with normal BP
Strength	Strong recommendation
Key references	56,330

children and adolescents being evaluated for LVH (grade B, strong recommendation).

6.6 Imaging Evaluation, Echocardiography: Detection of Target Organ Damage

Echocardiography was identified in the Fourth Report as a tool to measure left ventricular (LV) target organ injury related to HTN in children.¹ The basis for this assessment is as follows: (1) the relationship of LV mass to BP,³⁶¹ (2) the independent and strong relationship of LVH to adverse CVD outcomes in adults,^{362–364} and (3) that a significant percentage of children and adolescents with HTN demonstrate the degree of LVH associated with adverse outcomes in adults.^{365–367} Antihypertensive treatment reduces LVH. Observational data suggest that the

regression of LVH independently predicts outcomes in adults.³⁶⁸

The best-studied measures of LV target organ injury are measures of LV structure (LV mass and the relationship of LV wall thickness or mass to LV cavity volume) and systolic function (LV ejection fraction). LV structure is usually stratified into 4 groups on the basis of LV mass (normal or hypertrophied) and relative LV wall thickness (normal or increased). These 4 are as follows: (1) normal geometry with normal LV mass and wall thickness, (2) concentric geometry with normal LV mass and increased LV wall thickness, (3) eccentric LVH with increased LV mass and normal LV wall thickness, and (4) concentric LVH with both increased LV mass and increased relative wall thickness.^{369,370}

Key Action Statement 14. Clinicians should not perform electrocardiography in hypertensive children and adolescents being evaluated for LVH (grade B, strong recommendation).

Aggregate Evidence Quality	Grade B (Aggregate of Level of Evidence Equals B Because of Multiple Level of Evidence C References With Similar Findings)
Benefits	Electrocardiography is less expensive than echocardiography or other imaging modalities for identifying LVH
Risks, harm, cost	Electrocardiography has a low sensitivity for detecting LVH
Benefit–harm assessment	The risk of concluding that a child with HTN does not have LVH on the basis of a normal electrocardiogram means that a diagnosis of end organ injury is potentially missed
Intentional vagueness	None
Role of patient preferences	Patients and families may prefer electrocardiography because of cost and convenience, but the sensitivity of the test is poor
Exclusions	None
Strength	Strong recommendation
Key references	1,355–360

The American Society of Echocardiography recommendations should be followed with regard to image acquisition and LV measurement for calculating LV ejection fraction, mass, and relative wall thickness.^{369,371} LV ejection fraction may be significantly decreased in severe or acute onset HTN with associated congestive heart failure.¹ Rarely, LV ejection fraction may be mildly depressed in chronic HTN.

Because the heart increases in size in relation to body size, indexing LV mass is required.³⁶¹ Indexing LV mass is particularly important in infants and younger children because of their rapid growth.^{372,373} Physical training increases LV mass in a healthful manner. Lean body mass is more strongly associated with LV mass than fat mass.³⁷⁰ Because body composition is not routinely measured clinically, surrogate formulae for indexing are required. It is unclear whether expected values for LV mass should be derived from reference populations of normal weight and normotensive children or should include normotensive children who have overweight or obesity. The best method for indexing LV mass in children is an area of active investigation.

For this document, the following definitions for LV target organ injury have been chosen regarding hypertrophy, relative wall thickness, and ejection fraction. These definitions are based on published guidelines from the American Society of Echocardiography and associations of thresholds for indexed LV mass with adverse outcomes in adults^{362,363,369}:

- LVH is defined as LV mass >51 g/m^{2.7} or LV mass >115 g per body surface area (BSA) for boys and LV mass >95 g/BSA for girls. (Note that the values for LVH are well above the 95th percentile for distributions of LV mass in children and adolescents.³⁶⁹ The clinical significance of values between the

95th percentile of a population-based distribution and these thresholds is uncertain³⁷²;

- An LV relative wall thickness >0.42 cm indicates concentric geometry. LV wall thickness >1.4 cm is abnormal³⁷³; and
- Decreased LV ejection fraction is a value <53%.

There are a number of additional evidence gaps related to the echocardiographic assessment of LV target organ injury. The value of LV mass assessment in risk reclassification independent of conventional risk assessment has not been established in adults.³⁶⁴ The costs and benefits of incorporation of echocardiography into HTN care has not been assessed. Quality control regarding reproducibility of measurements across laboratories may be suboptimal.³⁷⁴ The most accurate method to measure LV mass (M-mode; two-dimensional; or, in the near future, three-dimensional techniques) requires further research.

Key Action Statement 15

1. It is recommended that echocardiography be performed to assess for cardiac target organ damage (LV mass, geometry, and function) at the time of consideration of pharmacologic treatment of HTN;
2. LVH should be defined as LV mass >51 g/m^{2.7} (boys and girls) for children and adolescents older than 8 years and defined by LV mass >115 g/BSA for boys and LV mass >95 g/BSA for girls;
3. Repeat echocardiography may be performed to monitor improvement or progression of target organ damage at 6- to 12-month intervals. Indications to repeat echocardiography include persistent HTN despite treatment, concentric LV hypertrophy, or reduced LV ejection fraction; and

TABLE 16 DASH Diet Recommendations

Food	Servings per Day
Fruits and vegetables	4–5
Low-fat milk products	≥2
Whole grains	6
Fish, poultry, and lean red meats	≤2
Legumes and nuts	1
Oils and fats	2–3
Added sugar and sweets (including sweetened beverages)	≤1
Dietary sodium	<2300 mg per d

Adapted from Barnes TL, Crandell JL, Bell RA, Mayer-Davis EJ, Dabelea D, Liese AD. Change in DASH diet score and cardiovascular risk factors in youth with type 1 and type 2 diabetes mellitus: the SEARCH for Diabetes in Youth study. *Nutr Diabetes*. 2013;3:e91; US Department of Health and Human Services, US Department of Agriculture. Appendix 7. Nutritional goals for age-sex groups based on dietary reference intakes and dietary guidelines recommendations. In: *2015-2020 Dietary Guidelines for Americans*. Washington, DC: US Department of Health and Human Services, US Department of Agriculture; 2015; and Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report. *Pediatrics*. 2011;128 (suppl 5): S213–S256.

4. In patients without LV target organ injury at initial echocardiographic assessment, repeat echocardiography at yearly intervals may be considered in those with stage 2 HTN, secondary HTN, or chronic stage 1 HTN incompletely treated (noncompliance or drug resistance) to assess for the development of worsening LV

target organ injury (grade C, moderate recommendation).

6.7 Vascular Structure and Function

Emerging data demonstrate an association of higher levels of BP in youth with adverse changes in measures of vascular structure and function, including ultrasonography of the cIMT, PWV, a robust measure of central arterial stiffness⁶⁶ that is related to hard CV events in adults

Key Action Statement 15. It is recommended that echocardiography be performed to assess for cardiac target organ damage (LV mass, geometry, and function) at the time of consideration of pharmacologic treatment of HTN;

LVH should be defined as LV mass >51 g/m^{2.7} (boys and girls) for children and adolescents older than 8 years and defined by LV mass >115 g/BSA for boys and LV mass >95 g/BSA for girls;

Repeat echocardiography may be performed to monitor improvement or progression of target organ damage at 6- to 12-month intervals. Indications to repeat echocardiography include persistent HTN despite treatment, concentric LV hypertrophy, or reduced LV ejection fraction; and

In patients without LV target organ injury at initial echocardiographic assessment, repeat echocardiography at yearly intervals may be considered in those with stage 2 HTN, secondary HTN, or chronic stage 1 HTN incompletely treated (noncompliance or drug resistance) to assess for the development of worsening LV target organ injury (grade C, moderate recommendation).

Aggregate Evidence Quality	Grade C
Benefits	Severe LV target organ damage can only be identified with LV imaging. May improve risk stratification
Risks, harm, cost	Adds cost; improvement in outcomes from incorporating echocardiography into clinical care is not established
Benefit–harm assessment	Benefits exceed harms
Intentional vagueness	None
Role of patient preferences	Patients may elect to not to have the study
Exclusions	None
Strength	Moderate recommendation
Key references	361,363,364,367–369

(eg, stroke, myocardial infarction, etc),⁶⁹ and FMD, which assesses endothelial function and describes the ability of the endothelium to release nitric oxide in response to stress.³⁷⁵

Although there are multiple large studies of PWV in youth,^{376–381} they all suffer from notable limitations, primarily the lack of racial and ethnic diversity and differences in measurement devices and protocols. Researchers in the largest study of PWV in youth to date ($N = 6576$) only evaluated 10 and 11 year olds and measured only carotid-radial PWV across the arm; this measure has not been linked to CV events in adults.³⁸² Researchers in one large study of FMD performed in youth ($N = 5809$) only included 10- to 11-year-old children in England.³⁸² The largest set of data for cIMT included 1155 European youth who were 6 to 18 years of age.³⁸³ No racial and ethnic breakdown was provided for this study. The wide heterogeneity in the methods for cIMT measurement hinders the pooling of data. For instance, researchers in the aforementioned article only measured common carotid,³⁸³ although the bulb and internal carotid are the sites of earliest atherosclerotic disease.³⁸⁴

Many studies have had significant issues related to methodology. For example, carotid-femoral PWV is not measured identically with different devices and is not equivalent to other measures of PWV, such as brachial-femoral PWV.^{385,386} No direct comparisons have been made between carotid-femoral and brachial-ankle PWV, methods in which brachial-ankle PWV provide values considerably higher than carotid-femoral PWV.³⁷⁸ The brachial-ankle PWV measures stiffness along both a central elastic artery (aorta) and the medium muscular arteries of the leg.

Therefore, insufficient normative data are available to define clinically actionable cut-points between normal and abnormal for these

vascular parameters. The routine measurement of vascular structure and function to stratify risk in hypertensive youth cannot be recommended at this time.

6.8 Imaging for Renovascular Disease

There are no evidence-based criteria for the identification of children and adolescents who may be more likely to have RAS. Some experts will do a more extensive evaluation for RAS in children and adolescents with stage 2 HTN, those with significant diastolic HTN (especially on ABPM), those with HTN and hypokalemia on screening laboratories, and those with a notable size discrepancy between the kidneys on standard ultrasound imaging. Bruits over the renal arteries are also suggestive of RAS but are not always present. Consultation with a subspecialist is recommended to help decide which patients warrant further investigation and to aid in the selection of the appropriate imaging modality.

6.8a Renal Ultrasonography

The utility of Doppler renal ultrasonography as a noninvasive screening study for the identification of RAS in children and adolescents has been examined in at least 2 recent case series; sensitivity has been reported to be 64% to 90%, with a specificity of 68% to 70%.^{387,388} In another study that included both children and adults, sensitivity and specificity for the detection

of renal artery stenoses was 75% and 89%, respectively.³⁸⁹ Factors that may affect the accuracy of Doppler ultrasonography include patient cooperation, the technician's experience, the age of the child, and the child's BMI. Best results are obtained in older (≥ 8 years),³⁸⁸ nonobese ($\text{BMI} \leq 85\text{th percentile}$), cooperative children and adolescents who are examined in a facility with extensive pediatric vascular imaging experience. Doppler ultrasonography should probably not be obtained in patients who do not meet these criteria or in facilities that lack appropriate pediatric experience.

Key Action Statement 16

Doppler renal ultrasonography may be used as a noninvasive screening study for the evaluation of possible RAS in normal-weight children and adolescents ≥ 8 years of age who are suspected of having renovascular HTN and who will cooperate with the procedure (grade C, moderate recommendation).

6.8b Computed Tomographic Angiography, Magnetic Resonance Angiography, and Renography

Other noninvasive imaging studies that have been assessed for their ability to identify RAS include computed tomographic angiography (CTA), magnetic resonance angiography (MRA), and nuclear medicine studies. Each of these

Key Action Statement 16. Doppler renal ultrasonography may be used as a noninvasive screening study for the evaluation of possible RAS in normal-weight children and adolescents ≥ 8 years of age who are suspected of having renovascular HTN and who will cooperate with the procedure (grade C, moderate recommendation).

Aggregate Evidence Quality	Grade C
Benefits	Avoidance of complications of invasive procedure (angiography) or radiation from traditional or computed tomography angiography
Risks, harm, cost	Potential false-positive or false-negative results
Benefit-harm assessment	Potential for avoidance of an invasive procedure outweighs risk of false-negative or false-positive results
Intentional vagueness	None
Role of patient preferences	None
Exclusions	Children and adolescents without suspected renovascular HTN
Strength	Moderate recommendation
Key references	387–390

TABLE 17 Dosing Recommendations for the Initial Prescription of Antihypertensive Drugs for Outpatient Management of Chronic HTN

Drug	Age	Initial Dose	Maximal Dose	Dosing Interval	Formulations
ACE inhibitors					
Contraindications: pregnancy, angioedema					
Common adverse effects: cough, headache, dizziness, asthenia					
Severe adverse effects: hyperkalemia, acute kidney injury, angioedema, fetal toxicity					
Benazepril	≥6 y ^a	0.2 mg/kg per d (up to 10 mg per d)	0.6 mg/kg per d (up to 40 mg per d)	Daily	Tablet: 5, 10, 20, 40 mg (generic) Extemporaneous liquid: 2 mg/mL
Captopril	Infants	0.05 mg/kg per dose	6 mg/kg per d	Daily to 4 times a day	Tablet: 12.5, 25, 50, 100 mg (generic)
	Children	0.5 mg/kg per dose	6 mg/kg per d	Three times a day	Extemporaneous liquid: 1 mg/mL
Enalapril	≥1 mo ^a	0.08 mg/kg per d (up to 5 mg per d)	0.6 mg/kg per d (up to 40 mg per d)	Daily to twice a day	Tablet: 2.5, 5, 10, 20 mg (generic) Solution: 1 mg/mL Tablet: 10, 20, 40 mg (generic)
Fosinopril	≥6 y	0.1 mg/kg per d (up to 5 mg per d)	40 mg per d	Daily	
	<50 kg				
	≥50 kg ^a	5 mg per d	40 mg per d	Daily	Tablet: 2.5, 5, 10, 20, 30, 40 mg (generic)
Lisinopril	≥6 y ^a	0.07 mg/kg per d (up to 5 mg per d)	0.6 mg/kg per d (up to 40 mg per d)	Daily	Solution: 1 mg/mL Capsule: 1.25, 2.5, 5, 10 mg (generic)
Ramipril	—	1.6 mg/m ² per d	6 mg/m ² per d	Daily	Tablet: 5, 10, 20, 40 mg (generic)
Quinapril	—	5 mg per d	80 mg per d	Daily	
ARBs					
Contraindications: pregnancy					
Common adverse effects: headache, dizziness					
Severe adverse effects: hyperkalemia, acute kidney injury, fetal toxicity					
Candesartan	1–5 y ^a	0.02 mg/kg per d (up to 4 mg per d)	0.4 mg/kg per d (up to 16 mg per d)	Daily to twice a day	Tablet: 4, 8, 16, 32 mg
	≥6 y ^a				Extemporaneous liquid: 1 mg/mL
	<50 kg	4 mg per d	16 mg per d		
	≥50 kg	8 mg per d	32 mg per d		
Irbesartan	6–12 y	75 mg per d	150 mg per d	Daily	Tablet: 75, 150, 300 mg (generic)
	≥13	150 mg per d	300 mg per d		
Losartan	≥6 y ^a	0.7 mg/kg (up to 50 mg)	1.4 mg/kg (up to 100 mg)	Daily	Tablet: 25, 50, 100 (generic) Extemporaneous liquid: 2.5 mg/mL
	≥6 y ^a	—	—	Daily	Tablet: 5, 20, 40 mg Extemporaneous liquid: 2 mg/mL
Olmesartan	<35 kg	10 mg	20 mg		
	≥35 kg	20 mg	40 mg		
Valsartan	≥6 y ^a	1.3 mg/kg (up to 40 mg)	2.7 mg/kg (up to 160 mg)	Daily	Tablet: 40, 80, 160, 320 mg (generic) Extemporaneous liquid: 4 mg/mL
Thiazide diuretics					
Contraindications: anuria					
Common adverse effects: dizziness, hypokalemia					
Severe adverse effects: cardiac dysrhythmias, cholestatic jaundice, new onset diabetes mellitus, pancreatitis					
Chlorthalidone	Child	0.3 mg/kg	2 mg/kg per d (50 mg)	Daily	Tablet: 25, 50, 100 mg (generic)
Chlorothiazide	Child ^a	10 mg/kg per d	20 mg/kg per d (up to 375 mg per d)	Daily to twice a day	Tablet: 250, 500 mg (generic) Suspension: 250/5 mL
Hydrochlorothiazide	Child ^a	1 mg/kg per d	2 mg/kg per d (up to 37.5 mg per d)	Daily to twice a day	Extemporaneous liquid: 1 mg/mL Tablet: 12.5, 25, 50 mg

TABLE 17 Continued

Drug	Age	Initial Dose	Maximal Dose	Dosing Interval	Formulations
Calcium channel blockers					
Contraindications: hypersensitivity to CCBs					
Common adverse effects: flushing, peripheral edema, dizziness					
Severe adverse effects: angioedema					
Amlodipine	1–5 y	0.1 mg/kg	0.6 mg/kg (up to 5 mg per d)	Daily	Tablet: 2.5, 5, 10 mg
	≥6 y ^a	2.5 mg	10 mg		Extemporaneous liquid: 1 mg/mL
Felodipine	≥6 y	2.5 mg		Daily	Tablet (extended release): 2.5, 5, 10 mg (generic)
Isradipine	Child	0.05–0.1 mg/kg	0.6 mg/kg (up to 10 mg per d)	Capsule: twice daily to 3 times a day; extended-release tablet: daily	Capsule: 2.5, 5 mg
				Daily to twice a day	Extended-release tablet: 5, 10 mg (generic)
Nifedipine extended release	Child	0.2–0.5 mg/kg per d	3 mg/kg/d (up to 120 mg per d)		Tablet (extended-release): 30, 60, 90 mg (generic)

—, not applicable.

^a FDA pediatric labeling.

has been compared with the gold standard, renal arteriography. CTA and MRA have generally been found to be acceptable as noninvasive imaging modalities for the identification of hemodynamically significant vascular stenosis. One study that included both pediatric and adult patients showed that the sensitivity and specificity for the detection of RAS was 94% and 93% for CTA and 90% and 94% for MRA, respectively.³⁸⁹

Unfortunately, studies of either technique that include only pediatric patients are limited at best for CTA and are nonexistent for MRA. Despite this, expert opinion holds that either modality may be used for noninvasive screening for suspected RAS, but neither is a substitute for angiography.³⁹⁰ CTA typically involves significant radiation exposure, and MRA generally requires sedation or anesthesia in young children, which are factors that must be considered when deciding to use one of these modalities.

Nuclear renography is based on the principle that after the administration of an agent affecting the renin-angiotensin-aldosterone system (RAAS), there will be reduced blood flow to a kidney or kidney segment affected by hemodynamically significant RAS. Such reduced blood flow can be detected by a comparison of perfusion before and after the administration of the RAAS agent. Limited pediatric nuclear renography studies exist that show variable sensitivity and specificity, ranging from 48% to 85.7% and 73% to 92.3%, respectively.^{391–393} The utility of nuclear renography may be less in children than adults because children with RAS often have more complicated vascular abnormalities than adults.³⁹⁴ Given these issues, nuclear renography has generally been abandoned as a screening test for RAS in children and adolescents.³⁹⁰

Key Action Statement 17

In children and adolescents suspected of having RAS, either CTA or MRA may be performed as a noninvasive imaging study. Nuclear renography is less useful in pediatrics and should generally be avoided (grade D, weak recommendation).

6.9 Uric Acid

Cross-sectional data have suggested a relationship between elevated serum uric acid (UA) levels and HTN. Two recent studies of adolescents included in NHANES 1999–2000 and a small study conducted in Italy found that elevated UA levels were associated with higher BP.^{395–397} In the Italian study and in another US study of youth with obesity and HTN,^{397,398} elevated UA was also associated with other markers of CV risk. These findings suggest that the measurement of UA levels may best be viewed as 1 component of CV risk assessment, especially in those with obesity.

A causative role for elevated UA in the development of childhood HTN has not been definitively established, although recent studies suggest that it may be on the causal pathway. A longitudinal study in which researchers followed a group of children for an average of 12 years demonstrated that childhood UA levels were associated with adult BP levels even after controlling for baseline BP.³⁹⁹ A few small, single-center clinical trials have

also shown that lowering UA can decrease BP levels, and increased UA levels blunt the efficacy of lifestyle modifications on BP control.^{400–404} No large-scale, multicenter study has yet been conducted to confirm these preliminary findings. Hence, there is currently not sufficient evidence to support the routine measurement of serum UA in the evaluation and management of children with elevated BP.

6.10 Microalbuminuria

Microalbuminuria (MA), which should be differentiated from proteinuria in CKD, has been shown to be a marker of HTN-related kidney injury and a predictor of CVD in adults.^{405–408} MA has been shown to be effectively reduced via the use of ARBs and ACE inhibitors in adults. Lowering the degree of MA in adults has been associated with decreased CVD risk.

In contrast, data to support a clear relationship between HTN and MA in pediatric patients with primary HTN are limited.^{408–410} A single, retrospective study of children with primary HTN and WCH found that 20% of the former had MA versus 0% of the latter.⁴¹¹ MA appears to be a nonspecific finding in children that can occur in the absence of HTN; it can occur in children who have obesity, insulin resistance, diabetes, dyslipidemia, and even in those who have recently participated in vigorous physical activity.⁴¹² The previously mentioned study by

Seeman et al⁴¹¹ did not control for these potential confounders.

Limited, single-center data suggest that a reduction in the degree of MA, more than a reduction in BMI or SBP, is associated with a decrease in LVMI. In particular, researchers in this single-center, nonrandomized, prospective study of 64 hypertensive children without kidney disease who were 11 to 19 years of age evaluated the children at baseline and after 12 months of combination ACE and hydrochlorothiazide ($N = 59$) or ACE, hydrochlorothiazide, and ARB therapy ($N = 5$). Results found that lowering MA in children is associated with a regression of LVH.⁴¹³ Given the single-center design and lack of a control group, however, the applicability of these findings to the general population of children with primary HTN is unknown.

Key Action Statement 18

Routine testing for MA is not recommended for children and adolescents with primary HTN (grade C, moderate recommendation).

7. TREATMENT

7.1 Overall Goals

The overall goals for the treatment of HTN in children and adolescents, including both primary and secondary HTN, include achieving a BP level that not only reduces the risk for target organ damage in childhood but also reduces the risk for HTN and related CVD in adulthood. Several studies have shown that currently available treatment options can even reverse target organ damage in hypertensive youth.^{105,414,415}

The previous recommendations for HTN treatment target in children without CKD or diabetes were SBP and DBP <95th percentile. Since that recommendation was made, evidence has emerged that markers of target organ damage, such as increased LVMI, can be detected among some

Key Action Statement 17. In children and adolescents suspected of having RAS, either CTA or MRA may be performed as a noninvasive imaging study. Nuclear renography is less useful in pediatrics and should generally be avoided (grade D, weak recommendation).

Aggregate Evidence Quality	Grade D
Benefits	Avoidance of complications of an invasive procedure (angiography)
Risks, harm, cost	Potential false-positive or false-negative results
Benefit–harm assessment	Potential for avoidance of an invasive procedure outweighs risk of false-negative or false-positive results
Intentional vagueness	None
Role of patient preferences	None
Exclusions	Children and adolescents without suspected RAS
Strength	Weak recommendation; pediatric data are limited
Key references	389,390

Key Action Statement 18. Routine testing for MA is not recommended for children and adolescents with primary HTN (grade C, moderate recommendation).

Aggregate Evidence Quality	Grade C
Benefits	Avoid improper detection of MA in children with HTN. Detection of MA is strongly influenced by other factors, such as recent participation in rigorous physical activity, obesity, insulin resistance and diabetes. Hence, there is no clear benefit for testing for MA in the absence of other known comorbidities
Risks, harm, cost	No known risks given a lack of clear association between MA and primary HTN in children
Benefit–harm assessment	Limited data to support any real benefit for screening children for MA
Intentional vagueness	Screening of children with primary HTN versus screening of children with single kidney or CKD and HTN
Role of patient preferences	Unknown
Exclusions	None
Strength	Moderate recommendation
Key references	408,410,411,413

children with BP >90th percentile (or >120/80 mm Hg) but <95th percentile.^{66,416,417} Longitudinal studies on BP from childhood to adulthood that include indirect measures of CV injury indicate that the risk for subsequent CVD in early adulthood increases as the BP level in adolescence exceeds 120/80 mm Hg.^{11,103,418} In addition, there is some evidence that targeting a BP <90th percentile results in reductions in LVMI and prevalence of LVH.¹⁰⁴ Therefore, an optimal BP level to be achieved with treatment of childhood HTN is <90th percentile or <130/80 mm Hg, whichever is lower.

Treatment and management options are discussed below, including lifestyle modifications and pharmacologic therapy to achieve optimal BP levels in children and adolescents with HTN.

Key Action Statement 19. In children and adolescents diagnosed with HTN, the treatment goal with nonpharmacologic and pharmacologic therapy should be a reduction in SBP and DBP to <90th percentile and <130/80 mm Hg in adolescents ≥ 13 years old (grade C, moderate recommendation).

Aggregate Evidence Quality	Grade C
Benefits	Lower risk of childhood target organ damage, lower risk of adulthood HTN and CVD
Risk, harm, cost	Risk of drug adverse effects and polypharmacy
Benefit–harm assessment	Preponderance of benefit
Intentional vagueness	None
Role of patient preferences	Patient may have preference for nonpharmacologic or pharmacologic treatment
Exclusions	None
Strength	Moderate recommendation
Key references	11,66,103,104,416–418

Key Action Statement 19

In children and adolescents diagnosed with HTN, the treatment goal with nonpharmacologic and pharmacologic therapy should be a reduction in SBP and DBP to <90th percentile and <130/80 mm Hg in adolescents ≥ 13 years old (grade C, moderate recommendation).

7.2 Lifestyle and Nonpharmacologic Interventions

Lifestyle interventions are recommended to lower BP. There is good evidence from studies in adults showing that nutritional interventions lower BP,⁴¹⁹ including clinical trials demonstrating that reducing dietary sodium results in lower BP and CV mortality,³³⁸ and a diet high in olive oil polyphenols lowers BP.⁴²⁰ Studies of hypertensive youth suggest

that the relationship between diet, physical activity, and BP in childhood is similar to that observed in adults.

7.2a Diet

The Dietary Approaches to Stop Hypertension (DASH) approach and specific elements of that diet have been the primary dietary strategy tested in the literature. These elements include a diet that is high in fruits, vegetables, low-fat milk products, whole grains, fish, poultry, nuts, and lean red meats; it also includes a limited intake of sugar and sweets along with lower sodium intake (see Table 16). Cross-sectional studies demonstrate associations between elements of the DASH diet and BP. For example, population-based data from NHANES show correlations between dietary sodium and BP in childhood and elevated BP and HTN, particularly in people with excess weight.³³²

A high intake of fruits, vegetables, and legumes (ie, a plant-strong diet) is associated with lower BP.⁴²¹ A lack of fruit consumption in childhood has been linked to increases in cIMT in young adulthood in the Young Finns study.⁴²² Higher intake of low-fat dairy products has been associated with lower BP in childhood.⁴²³

Longitudinal, observational, and interventional data also support relationships between diet and BP in youth. The National Heart Lung and Blood Institute's Growth and Health Study, which followed 2185 girls over 10 years, demonstrated that consuming ≥2 servings of dairy and ≥3 servings of fruits and vegetables daily was associated with lower BP in childhood and a 36% lower risk of high BP by young adulthood.⁴²⁴ Similar associations have been demonstrated in children and adolescents with diabetes.⁴²⁵ Moreover, an improvement in diet

led to lower BP in some studies of adolescents with elevated BP,⁴²⁶ youth with overweight,⁴²⁷ girls with metabolic syndrome,⁴²⁸ and youth with T2DM.⁴²⁹ However, consuming a healthier diet may increase costs.⁴³⁰

7.2b Physical Activity

Observational data support a relationship between physical activity and lower BP, although the data are scant.³³⁹ Interventional data demonstrate increasing physical activity leads to lower BP. A review of 9 studies of physical activity interventions in children and adolescents with obesity suggested that 40 minutes of moderate to vigorous, aerobic physical activity at least 3 to 5 days per week improved SBP by an average of 6.6 mm Hg and prevented vascular dysfunction.³⁴⁰ A number of subsequent, additional studies with small sample sizes support a benefit of physical activity on BP.³⁴¹ A more recent analysis of 12 randomized controlled trials including 1266 subjects found reductions of 1% and 3% for resting SBP and DBP, respectively. These results did not reach statistical significance, however, and the authors suggested that longer studies with larger sample sizes are needed.³⁴⁴ Any type of exercise, whether it's aerobic training, resistance training, or combined training, appears to be beneficial³⁴² (see "HTN and the Athlete").

Programs that combine diet and physical activity can have a beneficial effect on SBP, as is shown in several studies designed to prevent childhood obesity and address cardiometabolic risk.⁴³¹

Key Action Statement 20

At the time of diagnosis of elevated BP or HTN in a child or adolescent, clinicians should provide advice on the DASH diet and recommend moderate to vigorous physical activity at least 3 to 5 days per

TABLE 18 OSAS Symptoms and Signs

History of frequent snoring (≥3 nights per week)
Labored breathing during sleep
Gasps, snorting noises, observed episodes of apnea
Sleep enuresis (especially secondary enuresis)
Sleeping in a seated position or with the neck hyperextended
Cyanosis
Headaches on awakening
Daytime sleepiness
Attention-deficit/hyperactivity disorder
Learning problems
Physical examination
Underweight or overweight
Tonsillar hypertrophy
Adenoidal facies
Micrognathia, retrognathia
High-arched palate
Failure to thrive
HTN

Adapted from Marcus CL, Brooks LJ, Draper KA, et al; American Academy of Pediatrics. Diagnosis and management of childhood obstructive sleep apnea syndrome. *Pediatrics*. 2012;130(3). Available at: www.pediatrics.org/cgi/content/full/130/3/e714.

week (30–60 minutes per session) to help reduce BP (grade C, weak recommendation).

7.2c Weight Loss and Related CV Risk Factors

As is true for children and adolescents with isolated HTN, a DASH diet^{426,432} and vigorous physical activity⁴³¹ are recommended in pediatric patients with multiple obesity-related risk factors as part of intensive weight-loss therapy.^{433,434} Motivational interviewing (MI) is a tool recommended for pediatricians' use by the AAP Expert Committee Statement on Obesity.⁴³⁵ MI may be a useful counseling tool to use in

combination with other behavioral techniques to address overweight and obesity in children.⁴³⁶ Studies in hypertensive adults support the use of MI to improve adherence to antihypertensive medications⁴³⁷ and decrease SBP.⁴³⁶ Although there are no trials investigating the use of MI in the care of hypertensive youth, a number of studies have shown that MI can be used successfully to address or prevent childhood obesity by promoting physical activity and dietary changes.^{438–441} However, other studies have been less promising.^{442,443} In addition to the standard lifestyle approaches, intensive weight-loss therapy

Key Action Statement 20. At the time of diagnosis of elevated BP or HTN in a child or adolescent, clinicians should provide advice on the DASH diet and recommend moderate to vigorous physical activity at least 3 to 5 days per week (30–60 minutes per session) to help reduce BP (grade C, weak recommendation).

Aggregate Evidence Quality	Grade C
Benefits	Potential to reduce BP
Risk, harm, cost	No or low potential for harm. Following a healthier diet may increase costs to patients and families
Benefit–harm assessment	Potential benefit outweighs lack of harm and minimal cost
Intentional vagueness	None
Role of patient preferences	Level of caregiver and patient concern may influence adoption of the DASH diet and physical activity. Patients may also have preferences around the use of a medication. These factors may influence the efficacy of lifestyle change
Exclusions	None
Strength	Weak recommendation
Key references	332,339–342,424–431

involving regular patient and/or family contact and at least 1 hour of moderate to vigorous physical activity on a daily basis should be offered to children and adolescents with obesity and HTN.⁴⁴⁴

7.2d Stress Reduction

Complimentary medicine interventions have shown some promise in studies in normotensive children and adolescents and in those with elevated BP. Breathing-awareness meditation, a component of the Mindfulness-Based Stress Reduction Program at the University of Massachusetts Memorial Medical Center,⁴⁴⁵ led to a reduction in daytime, nighttime, and 24-hour SBP (3–4 mm Hg) and DPB (1 mm Hg) in normotensive African American adolescents and African American adolescents with elevated BP.⁴⁴⁶ Another study of transcendental meditation showed no significant BP effect but did lead to a decrease in LVM in African American adolescents with elevated BP.⁴⁴⁷ Scant data suggest yoga may also be helpful.⁴⁴⁸

7.3 Pharmacologic Treatment

Children who remain hypertensive despite a trial of lifestyle modifications or who have symptomatic HTN, stage 2 HTN without a clearly modifiable factor (eg, obesity), or any stage of HTN associated with CKD or diabetes mellitus therapy should be initiated with a single medication at the low end of the dosing range (see Table 17). Depending on repeated BP measurements, the dose of the initial medication can be increased every 2 to 4 weeks until BP is controlled (eg, <90th percentile), the maximal dose is reached, or adverse effects occur. Although the dose can be titrated every 2 to 4 weeks using home BP measurements, the patient should be seen every 4 to 6 weeks until BP has normalized. If BP is not controlled with a single agent, a second agent can be added to the regimen and titrated as with the

initial drug. Because of the salt and water retention that occurs with many antihypertensive medications, a thiazide diuretic is often the preferred second agent.

Lifestyle modifications should be continued in children requiring pharmacologic therapy. An ongoing emphasis on a healthy, plant-strong diet rich in fruits and vegetables; reduced sodium intake; and increased exercise can improve the effectiveness of antihypertensive medications. The use of a combination product as initial treatment has been studied only for bisoprolol and hydrochlorothiazide,⁴⁴⁹ so the routine use of combination products to initiate treatment in children cannot be recommended. Once BP control has been achieved, a combination product can be considered as a means to improve adherence and reduce cost if the dose and formulation are appropriate.

7.3a Pharmacologic Treatment and Pediatric Exclusivity Studies

Studies completed in hypertensive children show that antihypertensive drugs decrease BP with few adverse effects.^{173,202,242–244,450–467} There are few studies in children in which researchers compare different antihypertensive agents.⁴⁵³ These studies do not show clinically significant differences in the degree of BP lowering between agents. There are no clinical trials in children that have CV end points as outcomes. Long-term studies on the safety of antihypertensive medications in children and their impact on future CVD are limited.⁴⁵⁵

Because of legislative acts that provide incentives and mandates for drug manufacturers to complete pediatric assessments,⁴⁶⁸ most of the newer antihypertensive medications have undergone some degree of efficacy and safety evaluation. Antihypertensive drugs without patent protection have not been, and are unlikely to be, studied in children

despite their continued widespread use.²³⁸

7.3b Pharmacologic Treatment: Choice of Agent

Pharmacologic treatment of HTN in children and adolescents should be initiated with an ACE inhibitor, ARB,⁴⁶⁹ long-acting calcium channel blocker, or a thiazide diuretic. Because African American children may not have as robust a response to ACE inhibitors,^{470,471} a higher initial dose for the ACE inhibitor may be considered; alternatively, therapy may be initiated with a thiazide diuretic or long-acting calcium channel blocker. In view of the expanded adverse effect profile and lack of association in adults with improved outcomes compared with other agents, β -blockers are not recommended as initial treatment in children. ACE inhibitors and ARBs are contraindicated in pregnancy because these agents can cause injury and death to the developing fetus. Adolescents of childbearing potential should be informed of the potential risks of these agents on the developing fetus; alternative medications (eg, calcium channel blocker, β -blocker) can be considered when appropriate.

In children with HTN and CKD, proteinuria, or diabetes mellitus, an ACE inhibitor or ARB is recommended as the initial antihypertensive agent unless there is an absolute contraindication. Other antihypertensive medications (eg, α -blockers, β -blockers, combination α - and β -blockers, centrally acting agents, potassium-sparing diuretics, and direct vasodilators) should be reserved for children who are not responsive to 2 or more of the preferred agents (see “Treatment in CKD”).

Key Action Statement 21

In hypertensive children and adolescents who have failed lifestyle modifications (particularly those

TABLE 19 Oral and Intravenous Antihypertensive Medications for Acute Severe HTN

Useful for Severely Hypertensive Patients With Life-Threatening Symptoms				
Drug	Class	Dose	Route	Comments
Esmolol	β -adrenergic blocker	100–500 $\mu\text{g/kg}$ per min	Intravenous infusion	Short acting, constant infusion preferred. May cause profound bradycardia
Hydralazine	Direct vasodilator	0.1–0.2 mg/kg per dose up to 0.4 mg/kg per dose	Intravenous, intramuscular	Causes tachycardia
Labetalol	α - and β -adrenergic blocker	Bolus: 0.20–1.0 mg/kg per dose up to 40 mg per dose Infusion: 0.25–3.0 mg/kg per h	Intravenous bolus or infusion	Give every 4 h when given intravenous bolus Asthma and overt heart failure are relative contraindications
Nicardipine	Calcium channel blocker	Bolus: 30 $\mu\text{g/kg}$ up to 2 mg per dose Infusion: 0.5–4 $\mu\text{g/kg}$ per min	Intravenous bolus or infusion	May cause reflex tachycardia. Increases cyclosporine and tacrolimus levels
Sodium nitroprusside	Direct vasodilator	Starting: 0–3 $\mu\text{g/kg}$ per min Maximum: 10 $\mu\text{g/kg}$ per min	Intravenous infusion	Monitor cyanide levels with prolonged (>72 h) use or in renal failure; or coadminister with sodium thiosulfate
Useful for Severely Hypertensive Patients With Less Significant Symptoms				
Clonidine	Central α -agonist	2–5 Mg/kg per dose up to 10 Mg/kg per dose given every 6–8 h	Oral	Adverse effects include dry mouth and drowsiness
Fenoldopam	Dopamine receptor agonist	0.2–0.5 Mg/kg per min up to 0.8 Mg/kg per min	Intravenous infusion	Higher doses worsen tachycardia without further reducing BP
Hydralazine	Direct vasodilator	0.25 mg/kg per dose up to 25 mg per dose given every 6–8 h	Oral	Half-life varies with genetically determined acetylation rates
Isradipine	Calcium channel blocker	0.05–0.1 mg/kg per dose up to 5 mg per dose given every 6–8 h	Oral	Exaggerated decrease in BP can be seen in patients receiving azole antifungal agents
Minoxidil	Direct vasodilator	0.1–0.2 mg/kg per dose up to 10 mg per dose given Q 8–12 h	Oral	Most potent oral vasodilator; long acting

who have LV hypertrophy on echocardiography, symptomatic HTN, or stage 2 HTN without a clearly modifiable factor [eg, obesity]), clinicians should initiate pharmacologic treatment with an ACE inhibitor, ARB, long-acting calcium channel blocker, or thiazide diuretic (grade B, moderate recommendation).

7.3c Treatment: Follow-Up and Monitoring

Treatment of a child or adolescent with HTN requires ongoing monitoring because goal BP can be difficult to achieve.⁴⁷² If the decision has been made to initiate treatment with medication, the patient should be seen frequently (every 4–6 weeks) for dose adjustments and/or addition of a second or third agent until goal BP has been achieved (see the preceding section). After that, the frequency of visits can be extended to every 3 to 4 months.

If the decision has been made to proceed with lifestyle changes only, then follow-up visits can occur at longer intervals (every 3–6 months) so that adherence to lifestyle change can be reinforced and the need for initiation of medication can be reassessed.

In patients treated with antihypertensive medications, home BP measurement is frequently used to get a better assessment of BP control (see “At-Home Measurement”). Repeat ABPM may also be used to assess BP control and is especially important in patients with CKD (see “Treatment: Use of ABPM and Assessment”).

At each follow-up visit, the patient should be assessed for adherence to prescribed therapy and for any adverse effects of the prescribed medication; such assessment may include laboratory testing depending on the medication (for example, electrolyte monitoring if the patient is on a diuretic). It is also important to continually reinforce adherence

Key Action Statement 21. In hypertensive children and adolescents who have failed lifestyle modifications (particularly those who have LV hypertrophy on echocardiography, symptomatic HTN, or stage 2 HTN without a clearly modifiable factor [eg, obesity]), clinicians should initiate pharmacologic treatment with an ACE inhibitor, ARB, long-acting calcium channel blocker, or thiazide diuretic (grade B, moderate recommendation).

Aggregate Evidence Quality	Grade B
Benefits	Potential prevention of progressive CVD; regression or avoidance of target organ damage; resolution of hypertensive symptoms; improved cognition; avoidance of worsening HTN; potential avoidance of stroke, heart failure, coronary artery disease, kidney failure
Risks, harm, cost	Potential for hypotension, financial cost, chronic medication treatment, adverse medication effects, impact on insurability (health and life)
Benefit–harm assessment	Preponderance of benefits over harms
Intentional vagueness	None
Role of patient preferences	The choice of which antihypertensive medication to use should be made in close discussion with the patient and parent regarding risk, benefits, and adverse effects
Exclusions	None
Strength	Moderate recommendation
Key references	452,455,467

to lifestyle changes because effective treatment will depend on the combination of effects from both medication and lifestyle measures. Finally, known hypertensive target organ damage (such as LVH) should be reassessed according to the recommendations in “Imaging Evaluation, Echocardiography: Coarctation of the Aorta and Detection of Target Organ Damage.”

7.3d Treatment: Use of ABPM to Assess Treatment

ABPM can be an objective method to evaluate treatment effect during antihypertensive drug therapy. Data obtained in a multicenter, single-blind, crossover study in which hypertensive children received a placebo or no treatment demonstrated no change in ABPM after receiving the placebo.⁴⁷³ A report from a single center found that among hypertensive children receiving antihypertensive drugs, BP data from ABPM resulted in medication changes in 63% of patients.⁴⁷⁴ Another study of 38 hypertensive children used ABPM to evaluate the effectiveness of antihypertensive therapy (nonpharmacologic and pharmacologic). After 1 year of

treatment, ABPM results indicated that treatment-goal BP was achieved in only one-third of children with HTN.¹⁷

Key Action Statement 22

ABPM may be used to assess treatment effectiveness in children and adolescents with HTN, especially when clinic and/or home BP measurements indicate insufficient BP response to treatment (grade B, moderate recommendation).

7.4 Treatment-Resistant HTN

Resistant HTN in adults is defined as persistently elevated BP

Key Action Statement 22. ABPM may be used to assess treatment effectiveness in children and adolescents with HTN, especially when clinic and/or home BP measurements indicate insufficient BP response to treatment (grade B, moderate recommendation).

Aggregate Evidence Quality	Grade B
Benefits	ABPM results can guide adjustment in medication. ABPM can facilitate achieving treatment-goal BP levels
Risks, harm, cost	Inconvenience and patient annoyance in wearing an ABPM monitor. Cost of ABPM monitors
Benefit–harm assessment	Overall benefit
Intentional vagueness	None
Role of patient preferences	Patients may choose not to wear the ambulatory BP monitor repeatedly, which may necessitate alternative approaches to evaluate treatment efficacy
Exclusions	Uncomplicated HTN with satisfactory BP control
Strength	Moderate recommendation
Key references	17,474,475

despite treatment with 3 or more antihypertensive agents of different classes. All of these drugs should be prescribed at maximally effective doses, and at least 1 should be a diuretic. Key to the identification of patients with true resistant HTN is correct office BP measurement, confirmation of adherence to current therapy, and confirmation of treatment resistance by ABPM.

The treatment of patients with resistant HTN includes dietary sodium restriction, the elimination of substances known to elevate BP, the identification of previously undiagnosed secondary causes of HTN, the optimization of current therapy, and the addition of additional agents as needed.⁴⁷⁵ Recent clinical trial data suggest that an aldosterone receptor antagonist (such as spironolactone) is the optimal additional agent in adults with resistant HTN; it helps address volume excess as well as untreated hyperaldosteronism, which is common in adult patients with true resistant HTN.^{476,477}

At present, there are no data on whether true treatment-resistant HTN exists in pediatric patients. Evaluation and management strategies similar to those proven effective in adults with resistant HTN would be reasonable in children and adolescents who present with apparent treatment resistance.

8. TREATMENT IN SPECIAL POPULATIONS

8.1 Treatment in Patients With CKD and Proteinuria

8.1a CKD

Children and adolescents with CKD often present with or develop HTN.⁴⁷⁸ HTN is a known risk factor for the progression of kidney disease in adults and children.^{173,479,480} Evidence suggests that the treatment of HTN in children with CKD might slow the progression of or reverse end organ damage.^{173,415} When evaluated by 24-hour ABPM, children and adolescents with CKD often have poor BP control even if BP measured in the clinic appears to be normal.⁴⁸ MH is associated with end organ damage, such as LVH.^{203,481} Threshold values that define HTN are not different in children with CKD, although there is some evidence that lower treatment goals might improve outcomes.

In the European Effect of Strict Blood Pressure Control and ACE-Inhibition on Progression of Chronic Renal Failure in Pediatric Patients study, researchers randomly assigned children with CKD to standard antihypertensive therapy (with a treatment goal of 24-hour MAP <90th percentile by ABPM) or

to intensive BP control (24-hour MAP <50th percentile by ABPM). The study demonstrated fewer composite CKD outcomes in children with the lower BP target.¹⁷³ Recent adult data from the Systolic Blood Pressure Intervention Trial suggest lower BP targets may be beneficial in preventing other, adverse CV outcomes as well.⁴⁸²

Key Action Statement 23

1. Children and adolescents with CKD should be evaluated for HTN at each medical encounter;
2. Children or adolescents with both CKD and HTN should be treated to lower 24-hour MAP to <50th percentile by ABPM; and
3. Regardless of apparent control of BP with office measures, children and adolescents with CKD and a history of HTN should have BP assessed by ABPM at least yearly to screen for MH (grade B; strong recommendation).

8.1b Proteinuria

Proteinuric renal disease is often associated with HTN and a rapid decline in glomerular filtration.⁴⁸³ Studies in both adults and children have indicated that both BP control and a reduction in proteinuria are

beneficial for preserving renal function. Researchers in multiple studies have evaluated the utility of RAAS blockade therapy in patients with CKD and HTN.^{452,464,465,484–487} These medications have been shown to benefit both BP and proteinuria.

The benefit of such therapies may not be sustained, however.^{173,488} The Effect of Strict Blood Pressure Control and ACE-Inhibition on Progression of Chronic Renal Failure in Pediatric Patients study demonstrated an initial 50% reduction in proteinuria in children with CKD after treatment with ramipril but with a rebound effect after 36 months.^{450,464,488} This study also showed that BP reduction with a ramipril-based antihypertensive regimen improved renal outcomes. In children with HTN related to underlying CKD, the assessment of proteinuria and institution of RAAS blockade therapy appears to have important prognostic implications.

Key Action Statement 24

Children and adolescents with CKD and HTN should be evaluated for proteinuria (grade B, strong recommendation).

Key Action Statement 25

Children and adolescents with CKD, HTN, and proteinuria should be treated with an ACE inhibitor or ARB (grade B, strong recommendation).

8.2. Treatment in Patients With Diabetes

Based on the Fourth Report criteria for the diagnosis of HTN,¹ between 4% and 16% of children and adolescents with T1DM are found to have HTN.^{14,489–491} In the SEARCH study of 3691 youth between the ages of 3 and 17 years, elevated BP was documented in 6% of children with T1DM, with the highest prevalence in Asian Pacific Islander and American Indian children followed by African American and Hispanic children and those with

Key Action Statement 23. Children and adolescents with CKD should be evaluated for HTN at each medical encounter;

Children or adolescents with both CKD and HTN should be treated to lower 24-hour MAP to <50th percentile by ABPM; and

Regardless of apparent control of BP with office measures, children and adolescents with CKD and a history of HTN should have BP assessed by ABPM at least yearly to screen for MH (grade B; strong recommendation).

Aggregate Evidence Quality	Grade B
Benefits	Control of BP in children and adolescents with CKD has been shown to decrease CKD progression and lead to resolution of LVH
Risks, harm, cost	Cost of ABPM and BP control, both financial and nonfinancial
Benefit–harm assessment	Benefits of BP control in patients with CKD outweigh treatment risks
Intentional vagueness	Threshold
Role of patient preferences	Patients may not want to wear the ambulatory BP monitor repeatedly, which should lead to detailed counseling regarding the benefits of this procedure in CKD
Exclusions	None
Strength	Strong recommendation
Key references	47,173,203,415,480–483

higher glycosylated hemoglobin A1c levels.¹⁴ An office-based study in Australia found much higher rates (16%) and a positive correlation with BMI.⁴⁹⁰ BP >130/90 mm Hg has been associated with a more-than-fourfold increase in the relative risk of coronary artery disease and mortality at 10-year follow-up of individuals with T1DM.⁴⁹²

The prevalence of HTN is higher in youth with T2DM compared with T1DM, ranging from 12% at baseline (*N* = 699) in the Treatment Options for Type 2 Diabetes in Adolescents and Youth study⁴⁹³ to 31% (*N* = 598) in the Pediatric Diabetes Consortium Type 2 Diabetes Clinic Registry.⁴⁹⁴ BP and arterial stiffness in cohort studies have correlated with BMI, male sex, African American race, and age of onset of diabetes.^{14,494,495} Unlike T1DM, HTN in T2DM is not correlated with glycosylated hemoglobin A1c levels or glycemic failure, and it develops early in the course of the disease.⁴⁹⁶ It is also associated with rapid onset of adverse cardiac changes^{111,497} and may not respond to diet changes.⁴²⁵ The concurrence of obesity and T2DM compounds the risks for target end organ damage.^{111,498}

Empirical evidence shows a poor awareness of HTN in youth with T1DM and T2DM.¹⁴ Additionally, only a fraction of children with HTN and diabetes were found to be on pharmacologic therapy^{14,490,498,499} despite treatment recommendations from the American Diabetes

Association,⁴⁹⁹ the International Society for Pediatric and Adolescent Diabetes,⁵⁰⁰ AHA,¹¹⁰ and the National Heart, Lung, and Blood Institute.⁵⁰¹

Key Action Statement 26

Children and adolescents with T1DM or T2DM should be evaluated for HTN at each medical encounter and treated if BP is \geq 95th percentile or >130/80 mm Hg in adolescents \geq 13 years of age (grade C, moderate recommendation).

9. COMORBIDITIES

9.1 Comorbidities: Dyslipidemia

Children and adolescents with HTN are at increased risk for lipid disorders attributable to the “common soil” phenomenon,⁵⁰² in which poor diet, inactivity, and obesity contribute to both disorders. Some observational pediatric data confirm this association.^{503–506} Furthermore, both HTN and dyslipidemias are associated with subclinical atherosclerosis²⁰⁶ and are risk factors for future CVD.⁵⁰³ Screening is recommended to identify those at increased risk for early atherosclerosis.⁵⁰³ Treatment of lipid disorders identified in the setting of HTN should follow existing pediatric lipid guidelines with lifestyle advice, including weight loss and pharmacotherapy, as necessary.⁵⁰³

9.2 Comorbidities: OSAS

Children with snoring, daytime sleepiness (in adolescents), or hyperactivity (in younger children)

may have OSAS and consequent HTN.⁵⁰⁷ The more severe the OSAS, the more likely a child is to have elevated BP^{44,45} (see Table 18). Children with moderate to severe OSAS are at increased risk for HTN. However, it is not known whether OSAS treatment with continuous positive airway pressure results in improved BP in all children.⁴⁴ Furthermore, adenotonsillectomy may not result in BP improvement in all children with OSAS. In particular, children who have obesity and OSAS may be less likely to experience a lowering of BP after an adenotonsillectomy.⁵⁰⁸

Therefore, children with signs of OSAS (eg, daytime fatigue, snoring, hyperactivity, etc) should undergo evaluation for elevated BP regardless of treatment status. Given that both nighttime and daytime BP is affected by OSAS, the use of ABPM is the recommended method for assessing the BP of children with suspected OSAS.

9.3 Comorbidities: Cognitive Impairment

Data from studies conducted in adults suggest that the central nervous system is a target organ that can be affected by HTN.⁴¹⁹ Preliminary studies suggest that this is true in children as well. Hypertensive children score lower on tests of neurocognition and on parental reports of executive function compared with normotensive controls.^{509,510} Adams et al⁵¹¹ found an increased prevalence of learning disabilities in children with primary HTN compared with normotensive controls. The postulated mechanism for these findings is impaired cerebrovascular reactivity.^{512–515} At the present time, these findings do not have specific clinical implications with respect to the diagnostic evaluation of childhood HTN, although they underscore the importance of early detection and treatment.

Key Action Statement 24. Children and adolescents with CKD and HTN should be evaluated for proteinuria (grade B, strong recommendation).

Aggregate Evidence Quality	Grade B
Benefits	Detection of proteinuria among children with CKD and HTN may foster early detection and treatment of children at risk for more advanced renal disease
Risks, harm, cost	Additional testing
Benefit–harm assessment	Benefit of detection of a higher-risk group exceeds the risk of testing
Intentional vagueness	Whether to screen children with HTN without CKD for proteinuria
Role of patient preferences	None
Exclusions	Children without CKD
Strength	Strong recommendation
Key references	47,484

Key Action Statement 25. Children and adolescents with CKD, HTN, and proteinuria should be treated with an ACE inhibitor or ARB (grade B, strong recommendation).

Aggregate Evidence Quality	Grade B
Benefits	ACE inhibitor and ARB therapy has been shown in the short-term to be effective in reducing urine proteinuria
Risks, harm, cost	Positive effect on urine protein concentrations after the receipt of an ACE inhibitor may not be sustained over time
Benefit–harm assessment	Treatment with an ACE inhibitor or ARB may lower the rate of progression of renal disease even if the effect is not sustained in the long-term
Intentional vagueness	Whether to aggressively treat the BP so that it is <90th percentile
Role of patient preferences	Patients may have concerns about the choice of medication, which should be addressed
Exclusions	Children without CKD
Strength	Strong recommendation
Key references	173,464,465,485,487,488

Key Action Statement 26. Children and adolescents with T1DM or T2DM should be evaluated for HTN at each medical encounter and treated if BP is ≥95th percentile or >130/80 mm Hg in adolescents ≥13 years of age (grade C, moderate recommendation).

Aggregate Evidence Quality	Grade C
Benefits	Early detection and treatment of HTN in children with T1DM and T2DM may reduce future CV and kidney disease
Risks, harm, cost	Risk of drug adverse effects and polypharmacy
Benefit–harm assessment	Preponderance of benefit
Intentional vagueness	None
Role of patient preferences	Family concerns about additional testing and/or medication may need to be addressed
Exclusions	None
Strength	Weak to moderate recommendation
Key references	14,110,111,494

10. SEX, RACIAL, AND ETHNIC DIFFERENCES IN BP AND MEDICATION CHOICE

BP differences between various ethnic groups are well described in the adult population.^{216,516} Large, cross-sectional studies have demonstrated that, per capita, minority ethnic groups have both a higher prevalence of HTN and more significant end organ damage and outcomes.^{517,518} Although a growing body of evidence indicates that racial and ethnic differences in BP appear during adolescence,^{519–521} the cause of these differences and when they develop in childhood are yet to be fully determined. The risk of HTN correlates more with obesity status than with ethnicity or race, although there may be some interaction.²¹⁶ At this time, although limited data suggest that there may be a racial difference

in response to ACE inhibitors in the pediatric age group,⁴⁷¹ the strength of available evidence is insufficient to recommend using racial, sex, or ethnic factors to inform the evaluation or management of HTN in children.

11. SPECIAL POPULATIONS AND SITUATIONS

11.1 Acute Severe HTN

There is a lack of robust evidence to guide the evaluation and management of children and adolescents with acute presentations of severe HTN. Thus, much of what is known is derived from studies conducted in adults, including medication choice.⁵²² The evidence base has been enhanced somewhat

over the past decade by the publication of several pediatric clinical trials and case series of antihypertensive agents that can be used to treat such patients.^{465,523–530}

Although children and adolescents can become symptomatic from HTN at lesser degrees of BP elevation, in general, patients who present with acute severe HTN will have BP elevation well above the stage 2 HTN threshold. In a study of 55 children presenting to a pediatric ED in Taiwan with hypertensive crisis, 96% had SBP greater than that of stage 2 HTN, and 76% had DBP greater than that of stage 2 HTN.⁵³¹ The major clinical issue in such children is that this level of BP elevation may produce acute target organ effects, including encephalopathy, acute kidney injury, and congestive heart failure. Clinicians should be concerned about the development of these complications when a child's BP increases 30 mm Hg or more above the 95th percentile.

Although a few children with primary HTN may present with features of acute severe HTN,⁵³² the vast majority will have an underlying secondary cause of HTN.^{532,533} Thus, for patients who present with acute severe HTN, an evaluation for secondary causes is appropriate and should be conducted expediently. Additionally, target organ effects should be assessed with renal function, echocardiography, and central nervous system imaging, among others.

Given the potential for the development of potentially life-threatening complications, expert opinion holds that children and adolescents who present with acute severe HTN require immediate treatment with short-acting antihypertensive medications that may abort such sequelae.^{533,534} Treatment may be initiated with oral agents if the patient is able to tolerate oral therapy and if

TABLE 20 Comparison of HTN Screening Strategies

Dimension	Option A (Clinic BP Alone)	Option B (Clinic BP Confirmed by ABPM)	Option C (ABPM Only)	Preferred Option	Assumptions Made
Population: 170 cardiology, nephrology referred patients; analyzed at single-patient level	Auscultatory or oscillatory BP >95%	Auscultatory or oscillatory BP >90% then ABPM	Patients referred to provider who only used ABPM	—	—
Operational factors					
Percent adherence to care (goal of 80%)	Assumes 100%	Assumes 100%	Assumes 100%	—	—
Care delivery team effects	Baseline	Additional work to arrange or interpret confirmatory ABPM	Additional work to arrange and interpret ABPM for all patients	—	Assumes ABPM can be arranged and interpreted correctly
Patient, family effects	Baseline	Less desirable to have more visits; more desirable to have better accuracy	Family opinion depends on family's values	—	—
Benefits					
Clinical significance	Baseline	If HTN, treatment improves long-term outcome	If HTN, treatment improves long-term outcome	C	WCH estimated at 35%, ABPM results in fewer false-positive screening results
Cost of options					
Visit, diagnosis costs (annual estimated cost for 1 patient)	\$1860 for visits and laboratory tests	\$1330 for visits, ABPM, and laboratory tests	\$1880 for visits, ABPM, and laboratory tests	B	—
Costs from complications, adverse events, nonoptimal treatment					
Likelihood of nonoptimal treatment	60% undiagnosed patients; 35% of those diagnosed with WCH	30% undiagnosed patients	All patients correctly diagnosed; fewer complications	C	Assumes treatment benefit for correctly diagnosed HTN has no complications
Costs of nonoptimal treatment					
Increased mortality for not treating undiagnosed HTN; inconvenience of treatment of patients with WCH	Increased mortality for not treating undiagnosed HTN; inconvenience of treatment of patients with WCH	Increased mortality for not treating undiagnosed HTN	All patients correctly diagnosed who are treated	C	—

—, none.

life-threatening complications have not yet developed. Intravenous agents are indicated when oral therapy is not possible because of the patient's clinical status or when a severe complication has developed (such as congestive heart failure) that warrants a more controlled BP reduction. In such situations, the BP should be reduced by no more than 25% of the planned reduction over the first 8 hours, with the remainder of the planned reduction over the next 12 to 24 hours.^{533,534} The ultimate short-term BP goal in such patients should generally be around the 95th percentile. Table 19 lists suggested doses for oral and intravenous antihypertensive medications that may be used to treat patients with acute severe HTN.

Key Action Statement 27

In children and adolescents with acute severe HTN and life-threatening symptoms, immediate treatment with short-acting antihypertensive medication should be initiated, and BP should be reduced by no more than 25% of the planned reduction over the first 8 hours (grade expert opinion D, weak recommendation).

11.2 HTN and the Athlete

Sports participation and increased physical activity should be encouraged in children with HTN. In adults, physical fitness is associated with lower all-cause mortality.⁵³⁶ Although meta-analyses and randomized controlled trials consistently show lower BP after exercise training in adults,⁵³⁵ the results are less robust in children.³⁴⁰ On the basis of this evidence, sports participation should improve BP over time. Additionally, there is evidence that exercise itself has a beneficial effect on cardiac structure in adolescents.⁵³⁷

The athlete interested in participating in competitive sports

and/or intense training presents a special circumstance. Existing guidelines present conflicting recommendations.^{1,538} Although increased LV wall dimension may be a consequence of athletic training,³⁶⁰ recommendations from AHA and ACC include the following: (1) limiting competitive athletic participation among athletes with LVH beyond that seen with athlete's heart until BP is normalized by appropriate antihypertensive drug therapy, and (2) restricting athletes with stage 2 HTN (even among those without evidence of target organ injury) from participating in high-static sports (eg, weight lifting, boxing, and wrestling) until HTN is controlled with either lifestyle modification or drug therapy.⁵³⁹

The AAP policy statement "Athletic Participation by Children and Adolescents Who Have Systemic Hypertension" recommends that children with stage 2 HTN be restricted from high-static sports (classes IIIA to IIIC) in the absence of end organ damage, including LVH or concomitant heart disease, until their BP is in the normal range after lifestyle modification and/or drug therapy.⁵³⁸ It is further recommended that athletes be promptly referred and evaluated by a qualified pediatric medical subspecialist within 1 week if they are asymptomatic or immediately if they are symptomatic. The subcommittee agrees with these recommendations.

Key Action Statement 27. In children and adolescents with acute severe HTN and life-threatening symptoms, immediate treatment with short-acting antihypertensive medication should be initiated, and BP should be reduced by no more than 25% of the planned reduction over the first 8 hours (grade expert opinion D, weak recommendation).

Aggregate Evidence Quality	Expert Opinion, D
Benefits	Avoidance of complications caused by rapid BP reduction
Risks, harm, cost	Severe BP elevation may persist
Benefit-harm assessment	Benefit outweighs harm
Intentional vagueness	None
Role of patient preferences	None
Exclusions	Patients without acute severe HTN and life-threatening symptoms
Strength	Weak recommendation because of expert opinion
Key references	240,533,535

It should be acknowledged that there are no data linking the presence of HTN to sudden death related to sports participation in children, although many cases of sudden death are of unknown etiology. That said, athletes identified as hypertensive (eg, during preparticipation sports screening) should undergo appropriate evaluation as outlined above. For athletes with more severe HTN (stage 2 or greater), treatment should be initiated before sports participation.

Key Action Statement 28

Children and adolescents with HTN may participate in competitive sports once hypertensive target organ effects and risk have been assessed (grade C, moderate recommendation).

Key Action Statement 29

Children and adolescents with HTN should receive treatment to lower BP below stage 2 thresholds before participating in competitive sports (grade C, weak recommendation).

11.3 HTN and the Posttransplant Patient

HTN is common in children after solid-organ transplants, with prevalence rates ranging from 50% to 90%.^{179,180,540,541} Contributing factors include the use of steroids, calcineurin inhibitors, and mTOR (mammalian target of rapamycin) inhibitors. In patients with renal

transplants, the presence of native kidneys, CKD, and transplant glomerulopathy are additional risk factors for HTN. HTN rates are higher by 24-hour ABPM compared with clinic BP measurements because these populations commonly have MH and nocturnal HTN.^{179–183,542} Control of HTN in renal-transplant patients has been improved with the use of annual ABPM.^{184,185} Therefore, ABPM should be used to identify and monitor nocturnal BP abnormalities and MH in pediatric kidney and heart-transplant recipients. The use of home BP assessment may provide a comparable alternative to ABPM for BP assessment after transplant as well.¹⁸⁶

The management of identified HTN in the pediatric transplant patient can be challenging. Rates of control of HTN in renal-transplant patients generally range from 33% to 55%.^{180,187} In studies by Seeman et al,¹⁸⁸ intensified antihypertensive treatment in pediatric renal-transplant recipients improved nocturnal SBP and significantly reduced proteinuria.⁵⁴³ Children in these studies who achieved normotension had stable graft function, whereas those who remained hypertensive at 2 years had a progression of renal disease.⁵⁴⁴

Antihypertensive medications have rarely been systematically studied in this population. There is limited evidence that ACE inhibitors and ARBs may be superior to other agents in achieving BP control and improving long-term graft survival in renal-transplant patients.^{185,543,544} However, the combination of ACE inhibitors and ARBs in renal-transplant patients has been associated with acidosis and hyperkalemia and is not recommended.⁵⁴⁵

12. LIFETIME HTN TREATMENT AND TRANSITION TO ADULTHOOD

For adolescents with HTN requiring ongoing treatment, the

Key Action Statement 28. Children and adolescents with HTN may participate in competitive sports once hypertensive target organ effects and risk have been assessed (grade C, moderate recommendation).

Aggregate Evidence Quality	Grade C
Benefits	Aerobic exercise improves CVD risk factors in children and adolescents with HTN
Risks, harm, cost	Unknown, but theoretical risk related to a rise in BP with strenuous exercise may exist
Benefit–harm assessment	The benefits of exercise likely outweigh the potential risk in the vast majority of children and adolescents with HTN
Intentional vagueness	None
Role of patient preferences	Families may have different opinions about sports participation in children with HTN
Exclusions	None
Strength	Moderate recommendation
Key references	341,360,538,540,541

Key Action Statement 29. Children and adolescents with HTN should receive treatment to lower BP below stage 2 thresholds before participating in competitive sports (grade C, weak recommendation).

Aggregate Evidence Quality	Grade C
Benefits	Aerobic exercise improves CVD risk factors in children and adolescents with HTN
Risks, harm, cost	Unknown, but theoretical risk related to a rise in BP with strenuous exercise may exist
Benefit–harm assessment	The benefits of exercise likely outweigh the potential risk in the vast majority of children and adolescents with HTN
Intentional vagueness	None
Role of patient preferences	None
Exclusions	None
Strength	Weak recommendation
Key references	341,360,538,540,541

transition from pediatric care to an adult provider is essential.⁵⁴⁶ HTN definition and treatment recommendations in this guideline are generally consistent with the forthcoming adult HTN treatment guideline, so diagnosis and treatment should not typically change with transition.

Key Action Statement 30

Adolescents with elevated BP or HTN (whether they are receiving antihypertensive treatment) should typically have their care transitioned to an appropriate adult care provider by 22 years of age (recognizing that there may be individual cases in which this upper age limit is exceeded, particularly in the case of youth with special health care needs). There should be a transfer

of information regarding HTN etiology and past manifestations and complications of the patient's HTN (grade X, strong recommendation).

13. PREVENTION OF HTN

13.1 Importance of Preventing HTN

BP levels tend to increase with time even after adult height is reached. The rate of progression to frank HTN in a study of more than 12 000 Japanese adults (20–35 years of age at baseline, followed for 9 years) was 36.5% and was greater with higher baseline BP category.⁵⁴⁸ The rate of progression may also be accelerated in African American individuals. Similarly, both the Bogalusa Heart⁶³ and Fels Longitudinal⁶⁰ studies have clearly

demonstrated that the risk of HTN in early adulthood is dependent on childhood BP, with greater numbers of elevated BP measurements in childhood conferring an increased risk of adult HTN.

Because the tracking of BP levels in children has also been well documented,¹⁰ it is not surprising that analyses of the National Childhood BP database found 7% of adolescents with elevated BP per year progressed to true hypertensive BP levels. Of note, initial BMI and change in BMI were major determinants of the development of HTN.²² Therefore, in both children and adults, efforts (discussed below) should be made to prevent progression to sustained HTN and to avoid the development of hypertensive CV diseases.

13.2 Strategies for Prevention

One of the largest trials of preventing progression to HTN in adults, the Trial of Preventing Hypertension study, proved that 2 years of treatment with candesartan reduced the number of subjects with elevated BP from developing stage 1 HTN even after the drug was withdrawn.⁵⁴⁷ However, no similar study has been conducted in youth; for this reason, prevention efforts to date have focused on lifestyle modification, especially dietary intervention,⁴²⁶ exercise,⁵⁴⁹ and treatment of obesity.⁵⁵⁰ The best evidence for the potential of such prevention strategies comes from epidemiologic evidence for risk factors for the development of HTN or from studies focused on the treatment of established HTN. These risk factors include positive family history, obesity, a high-sodium diet, the absence of a DASH-type diet, larger amounts of

Key Action Statement 30. Adolescents with elevated BP or HTN (whether they are receiving antihypertensive treatment) should typically have their care transitioned to an appropriate adult care provider by 22 years of age (recognizing that there may be individual cases in which this upper age limit is exceeded, particularly in the case of youth with special health care needs). There should be a transfer of information regarding HTN etiology and past manifestations and complications of the patient's HTN (grade X, strong recommendation).

Aggregate Evidence Quality	Grade X
Benefits	Provides continuity of care for patients
Risks, harm, cost	None
Benefit-harm assessment	No risk
Intentional vagueness	None
Role of patient preferences	Patient can pick adult care provider
Exclusions	None
Strength	Strong recommendation
Key references	547

sedentary time, and possibly other dietary factors.^{551–553}

Because family history is immutable, it is difficult to build a preventive strategy around it. However, a positive family history of HTN should suggest the need for closer BP monitoring to detect HTN if it occurs.

Appropriate energy balance with calories eaten balanced by calories expended in physical activity is important. This is the best strategy to maintain an appropriate BMI percentile for age and sex and to avoid the development of obesity.⁵⁵⁴ From a broader dietary perspective, a DASH-type diet (ie, high in fruits, vegetables, whole grains, and low-fat dairy, with decreased intake of foods high in saturated fat or sugar) may be beneficial (see Table 16).^{423,427} Avoiding high-sodium foods may prove helpful in preventing HTN, particularly for individuals who are more sensitive to dietary sodium intake.⁵⁵⁵

Adhering to recommendations for 60 minutes a day of moderate to vigorous physical activity can be important to maintaining an appropriate weight and may be independently helpful to maintaining a lower BP.³⁴⁴ The achievement of normal sleep habits

and avoidance of tobacco products are also reasonable strategies to reduce CV risk.

These preventive strategies can be implemented as part of routine primary health care for children and adolescents.

14. CHALLENGES IN THE IMPLEMENTATION OF PEDIATRIC HTN GUIDELINES

Many studies have shown that physicians fail to meet benchmarks with respect to screening, especially universal screening for high BP in children.^{7,115} Although the reasons for this failure likely vary from practice to practice, a number of common challenges can be identified.

The first challenge is determining how to identify every child in a clinic who merits a BP measurement. This could be accomplished through flags in an EHR, documentation rules for specific patients, and/or clinic protocols.

The second challenge is establishing a local clinic protocol for measuring BP correctly on the basis of the algorithms in this guideline. It is important to determine the optimal approach on the basis of the available equipment, the skills of clinic personnel, and the clinic's throughput needs.

The third challenge is for clinic personnel to be aware of what to do with high BP measurements when they occur. Knowing when to counsel patients, order tests or laboratory work, and reach out for help is essential. Making this part of standard practice so every child follows the prescribed pathway may be challenging.

The final diagnosis of HTN also relies on a number of sequential visits. Ensuring that patients return for all of these visits and are not lost to follow-up may require new clinic processes or mechanisms. Information technology may help remind providers to schedule these visits and remind patients to attend these visits; even with that assistance, however, completing all the visits may be difficult for some patients.

In addition, family medicine physicians and general pediatricians may face challenges in having normative pediatric BP values available for use at all times. Although adult BP cutoffs are easy to memorize, pediatric BP percentile cutoffs are greatly dependent on age and height. The BP tables in this guideline provide cutoffs to use for the proper diagnosis of HTN; their availability will simplify the recognition of abnormal BP values.

The AAP Education in Quality Improvement for Pediatric Practice module on HTN identification and management⁵⁵⁶ and its accompanying implementation guide⁵⁵⁷ should be of assistance to practitioners who wish to improve their approach to identifying and managing childhood HTN. This module is currently being updated to incorporate the new recommendations in this guideline.

15. OTHER TOPICS

15.1 Economic Impact of BP Management

Researchers in a small number of studies have examined the potential economic impacts related to pediatric BP management.^{208,558,559} Wang et al⁵⁵⁸ estimated both the effectiveness and cost-effectiveness of 3 screening strategies and interventions to normalize pediatric BP based on the literature and through a simulation of children ($n = 4017821$). The 3 screening strategies included the following: (1) no screening; (2) selected screening and treatment, as well as “treating everyone” (ie, with population-wide interventions, such as targeted programs for overweight adolescents [eg, weight-loss programs, exercise programs, and salt-reduction programs]); and (3) nontargeted programs for exercise and salt reduction.

The simulation suggested that these various strategies could reduce mortality, with a modest expected survival benefit of 0.5 to 8.6 days. The researchers also examined quality-adjusted life-years (QALYs) and the cost per QALY. Only 1 intervention, a nontargeted salt-reduction campaign, had a negative cost per QALY. This intervention and the other 2 described in that article support the concept that population-wide interventions may be the most cost-effective way to improve CV health. The article has serious limitations, however, including the fact that population-wide interventions for exercise and the reduction of sodium intake have not, thus far, been effective.

The accurate determination of those who actually have HTN (as opposed to WCH) is fundamental to providing sound care to patients. Researchers in two studies examined the effects of using ABPM in the diagnosis of HTN.^{208,559} Davis et al⁵⁵⁹ compared 3 HTN

screening strategies; these options are summarized in the following value-analysis framework (see Table 20).⁵⁶⁰ It appears that the implementation of ABPM for all patients is not ensured. The next best option, screening clinic BP with ABPM, is most likely to be implementable and has significant clinical benefit given the high prevalence of WCH.

Swartz et al²⁰⁸ conducted a retrospective review of 267 children with elevated clinic BP measurements referred for ABPM. Of the 126 patients who received ABPM, 46% had WCH, 49% had stage 1 HTN, and 5% had stage 2 HTN. This is consistent with the concept that screening with clinic BP alone results in high numbers of false-positive results for HTN. The diagnosis of HTN in this study resulted in an additional \$3420 for evaluation (includes clinic visit, facility fee, laboratory testing, renal ultrasound, and echocardiography) vs \$1265 (includes clinic visit, facility fee, and ABPM). This suggests that ABPM is cost-effective because of the reduction of unnecessary testing in patients with WCH.

When examining these costs, the availability of ABPM, and the availability of practitioners who are skilled in pediatric interpretation, the most cost-effective and implementable screening solution is to measure clinic BP and confirm elevated readings by ABPM.

15.2 Patient Perspective and Pediatric HTN

Children and adolescents are not just patients; they are active participants in their health management. If children and adolescents lack a clear understanding of what is happening inside their bodies, they will not be able to make informed choices in their daily activities. Better

choices lead to better decisions executed in self-care. For clear judgments to be made, there needs to be open communication between physicians and families, a provision of appropriate education on optimal HTN management, and a strong partnership assembled within a multidisciplinary health care team including physicians, advanced practice providers, dietitians, nurses, and medical and clinical assistants.

It is important for physicians to be mindful that children and adolescents want, and need, to be involved in their medical care. Pediatric HTN patients are likely to feel excluded when clinicians or other providers speak to their parents instead of including them in the conversation. When patients are neither included in the discussion nor encouraged to ask questions, their anxiety can increase, thus worsening their HTN. Keeping an open line of communication is important and is best done by using a team approach consisting of the patient, the family, health care support staff, and physicians. With practical education on HTN management provided in easily understandable terms, the patients will be more likely to apply the concepts presented to them. Education is important and should be given in a way that is appropriate for young children and their families to understand. Education should consist of suitable medication dosing, a proper diet and level of activity, the identification of symptoms, and appropriate BP monitoring (including cuff size).

15.3 Parental Perspective and Pediatric HTN

Parents play a key role in the management and care of their children's health. Parents and physicians should act as a cohesive unit to foster the best results. It

is vital for physicians to provide concise information in plain language and do so using a team approach. This will facilitate parents having a clear understanding of the required tests, medications, follow-ups, and outcomes.

Patient Perspective, by Matthew Goodwin

“I am not just a 13 year old, I am a teenager who has lived with hypertension, renal disease, and midaortic syndrome since I was 4 years old. I have experienced surgeries, extended hospitalizations, daily medications, procedures, tests, continued blood pressure monitoring, lifestyle changes, and dietary restrictions. Hypertension is a part of my everyday life. It will always be a component of me. I had to learn the effects of hypertension at a young age. I knew what would happen to me if I ate too much salt or did not fully hydrate, thus I became watchful. I did this so I could efficiently communicate with my physicians any changes I physically felt or any symptoms that were new or different regarding my illness. This has allowed me, my family, and my doctors to work effectively as one unit. I am grateful for my doctors listening to me as a person and not as a kid.”

Parents of children with hypertensive issues can encounter 1 or more specialists in addition to their pediatric clinician. This can prove to be overwhelming, frightening, and may fill the parent with anxiety. Taking these things into account and creating unified partners, built with the physician and family, will encourage the family to be more involved in the patient's health management. Plain language in a team approach will yield the most positive outcomes for the patient.

Understanding the family and patient's perception of HTN and any underlying disease that may be contributing to it is important to resolve any misconceptions and encourage adherence to the physician's recommendations. To attain therapeutic goals, proper education must be provided to the family as a whole. This education should include proper medication dosages, recommended sodium intake, any dietary changes, exercise expectations, and any other behavioral changes. It is equally important to stress to the family the short- and long-term effects of HTN if it is not properly managed. Parents with younger children will carry the ultimate burden of daily decisions as it applies to medications, food choices, and activity. Parents of older adolescents will partner with the children to encourage the right choices. Education as a family unit is important for everyone involved to understand the consequences.

A family-based approach is important for all pediatric diseases but plays a particular role in conditions that are substantially influenced by lifestyle behaviors. This has been shown in several pediatric populations, including those with T2DM and obesity.^{561–565}

16. EVIDENCE GAPS AND PROPOSED FUTURE DIRECTIONS

In general, the pediatric HTN literature is not as robust as the adult HTN literature. The reasons for this are many, but the 2 most important are as follows: (1) the lower prevalence of HTN in childhood compared with adults, and (2) the lack of adverse CV events (myocardial infarction, stroke, and death) attributable to HTN in young patients. These factors make it difficult to conduct

the types of clinical trials that are needed to produce high-quality evidence. For example, no large pediatric cohort has ever been assembled to answer the question of whether routine BP measurement in childhood is useful to prevent adult CVD.⁵⁶⁶ Given this, other types of evidence, such as from cross-sectional and observational cohort studies, must be examined to guide practice.⁵⁶⁷

From the standpoint of the primary care provider, the most significant evidence gaps relate to whether diagnosing elevated BP and HTN in children and adolescents truly has long-term health consequences, whether antihypertensive medications should be used in a child or adolescent with elevated BP, and what medications should be preferentially used. These evidence gaps have been alluded to previously in this document.

Other important evidence gaps should be highlighted, including the following:

- Is there a specific BP level in childhood that predicts adverse outcomes, and can a single number (or numbers) be used to define HTN, as in adults?
- Can and should ABPM ever replace auscultation in the diagnosis of childhood HTN?
- Are the currently used, normative standards for ABPM appropriate, or are new normative data needed?⁵⁶⁸
- What is the best diagnostic evaluation to confidently exclude secondary causes of HTN?
- Are other assessments of hypertensive target organ damage (such as urine MA or vascular studies) better than echocardiography?
- How confident can we be that a child or teenager with elevated BP

will have HTN and/or CVD disease as an adult?

Some of these questions may eventually be answered by research that is currently in progress, such as further analysis of the International Childhood Cardiovascular Cohort Consortium⁵⁶⁹ and the promising Adult Hypertension Onset in Youth study, which seeks to better define the level of BP in childhood that predicts the development of hypertensive target organ damage.⁵⁷⁰ Other studies will need to be performed in children and adolescents to fill in the remaining gaps, including more rigorous validation studies of automated BP devices in the pediatric population, expanded trials of lifestyle interventions, further comparative trials of antihypertensive medications, and studies of the clinical applicability of hypertensive target organ assessments.

Furthermore, and perhaps more crucially, there needs to be prospective assessment of the recommendations made in this document with regular updates based on new evidence as it is generated (generally, per AAP policy, these occur approximately every 5 years). With such ongoing reassessment and revision, it is hoped that this document and its future revisions will come to be viewed as an effective guide to practice and will improve the care of the young patients who are entrusted to us.

Implementation tools for this guideline are available on the AAP Web site (<https://www.aap.org/en-us/about-the-aap/Committees-Councils-Sections/coqips/Pages/Implementation-Guide.aspx>).

AUTHORS

Joseph T. Flynn, MD, MS, FAAP
David C. Kaelber, MD, PhD, MPH, FAAP, FACP, FACMI
Carissa M. Baker-Smith, MD, MS, MPH, FAAP, FAHA
Douglas Blowey, MD
Aaron E. Carroll, MD, MS, FAAP
Stephen R. Daniels, MD, PhD, FAAP
Sarah D. de Ferranti, MD, MPH, FAAP
Janis M. Dionne, MD, FRCPC

Susan K. Flinn, MA
Bonita Falkner, MD
Samuel S. Gidding, MD
Celeste Goodwin
Michael G. Leu, MD, MS, MHS, FAAP
Makia E. Powers, MD, MPH, FAAP
Corinna Rea, MD, MPH, FAAP
Joshua Samuels, MD, MPH, FAAP
Madeline Simasek, MD, MSCP, FAAP
Vidhu V. Thaker, MD, FAAP
Elaine M. Urbina, MD, MS, FAAP

SUBCOMMITTEE ON SCREENING AND MANAGEMENT OF HIGH BLOOD PRESSURE IN CHILDREN (OVERSIGHT BY THE COUNCIL ON QUALITY IMPROVEMENT AND PATIENT SAFETY)†

Joseph T. Flynn, MD, MS, FAAP, Co-chair, Section on Nephrology
David Kaelber, MD, MPH, PhD, FAAP, Co-chair, Section on Medicine-Pediatrics, Council on Clinical Information Technology
Carissa M. Baker-Smith, MD, MS, MPH, Epidemiologist and Methodologist
Aaron Carroll, MD, MS, FAAP, Partnership for Policy Implementation
Stephen R. Daniels, MD, PhD, FAAP, Committee on Nutrition
Sarah D. de Ferranti, MD, MPH, FAAP, Committee on Cardiology and Cardiac Surgery
Michael G. Leu, MD, MS, MHS, FAAP, Council on Quality Improvement and Patient Safety
Makia Powers, MD, MPH, FAAP, Committee on Adolescence
Corinna Rea, MD, MPH, FAAP, Section on Early Career Physicians
Joshua Samuels, MD, MPH, FAAP, Section on Nephrology
Madeline Simasek, MD, FAAP, Quality Improvement Innovation Networks
Vidhu Thaker, MD, FAAP, Section on Obesity

LIAISONS

Douglas Blowey, MD, *American Society of Pediatric Nephrology*
Janis Dionne, MD, FRCPC, *Canadian Association of Paediatric Nephrologists*
Bonita Falkner, MD, *International Pediatric Hypertension Association*
Samuel Gidding, MD, *American College of Cardiology, American Heart Association*
Celeste Goodwin, *National Pediatric Blood Pressure Awareness Foundation*
Elaine Urbina, MD, FAAP, *American Heart Association AHOY Committee*

MEDICAL WRITER

Susan K. Flinn, MA

STAFF

Kymika Okechukwu, MPA, Manager, Evidence-Based Practice Initiatives

ABBREVIATIONS

AAP: American Academy of Pediatrics
ABPM: ambulatory blood pressure monitoring
ACC: American College of Cardiology
ACE: angiotensin-converting enzyme
AHA: American Heart Association
ARB: angiotensin receptor blocker
ARR: aldosterone to renin ratio
BP: blood pressure
BSA: body surface area
cIMT: carotid intima-media thickness
CKD: chronic kidney disease
CTA: computed tomographic angiography
CV: cardiovascular
CVD: cardiovascular disease
DASH: Dietary Approaches to Stop Hypertension
DBP: diastolic blood pressure
ED: emergency department
EHR: electronic health record
FMD: flow-mediated dilation
HTN: hypertension
LVH: left ventricular hypertrophy
LVMI: left ventricular mass index
MA: microalbuminuria
MAP: mean arterial pressure
MH: masked hypertension
MI: motivational interviewing
MRA: magnetic resonance angiography
NF-1: neurofibromatosis type 1
OSAS: obstructive sleep apnea syndrome
PCC: pheochromocytoma
PICOT: Patient, Intervention/Indicator, Comparison, Outcome, and Time
PRA: plasma renin activity
PWV: pulse wave velocity
QALY: quality-adjusted life-year
RAAS: renin-angiotensin-aldosterone system
RAS: renal artery stenosis
SBP: systolic blood pressure
SDB: sleep-disordered breathing
T1DM: type 1 diabetes mellitus
T2DM: type 2 diabetes mellitus
UA: uric acid
WCH: white coat hypertension

Seattle, Washington; ^aDepartment of Pediatrics, School of Medicine, Morehouse College, Atlanta, Georgia; ^bAssociate Director, General Academic Pediatric Fellowship, Staff Physician, Boston's Children's Hospital Primary Care at Longwood, Instructor, Harvard Medical School, Boston, Massachusetts; Departments of ^cPediatrics and Internal Medicine, McGovern Medical School, University of Texas, Houston, Texas; ^dPediatric Education, University of Pittsburgh Medical Center Shadyside Family Medicine Residency, Clinical Associate Professor of Pediatrics, Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center; and School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania; ^eDivision of Molecular Genetics, Department of Pediatrics, Columbia University Medical Center, New York, New York; and ^fPreventive Cardiology, Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio

Drs Flynn and Kaelber served as the specialty and primary care chairs of the Subcommittee and had lead roles in developing the framework for the guidelines and coordinating the overall guideline development; Dr Baker-Smith served as the epidemiologist and led the evidence review and synthesis; Ms. Flinn compiled the first draft of the manuscript and coordinated manuscript revisions; All other authors were significantly involved in all aspects of the guideline creation including initial scoping, literature review and synthesis, draft manuscript creation and manuscript review; and all authors approved the final manuscript as submitted.

This document is copyrighted and is property of the American Academy of Pediatrics and its Board of Directors. All authors have filed conflict of interest statements with the American Academy of Pediatrics. Any conflicts have been resolved through a process approved by the Board of Directors. The American Academy of Pediatrics has neither solicited nor accepted any commercial involvement in the development of the content of this publication.

The guidance in this report does not indicate an exclusive course of treatment or serve as a standard of medical care. Variations, taking into account individual circumstances, may be appropriate.

All clinical practice guidelines from the American Academy of Pediatrics automatically expire 5 years after publication unless reaffirmed, revised, or retired at or before that time.

Endorsed by the American Heart Association.

DOI: <https://doi.org/10.1542/peds.2017-1904>

Address correspondence to Joseph T Flynn. Email: joseph.flynn@seattlechildrens.org

PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275).

Copyright © 2017 by the American Academy of Pediatrics

FINANCIAL DISCLOSURE: The authors have indicated that they have no financial relationships relevant to this article to disclose.

FUNDING: The American Academy of Pediatrics provided funding to cover travel costs for subcommittee members to attend subcommittee meetings, to pay for the epidemiologist (Dr Baker-Smith) and consultant (Susan Flynn), and to produce the revised normative blood pressure tables.

POTENTIAL CONFLICT OF INTEREST: The authors have indicated that they have no potential conflicts of interest to disclose.

REFERENCES

1. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. *Pediatrics*. 2004;114(2, suppl 4th Report):555–576
2. Institute of Medicine, Committee on Standards for Systematic Reviews of Comparative Effectiveness Research. In: Eden J, Levit L, Berg A, Morton S, eds. *Finding What Works in Health Care: Standards for Systematic Reviews*. Washington, DC: National Academies Press; 2011
3. American Academy of Pediatrics Steering Committee on Quality Improvement and Management. Classifying recommendations for clinical practice guidelines. *Pediatrics*. 2004;114(3):874–877
4. Rosner B, Cook NR, Daniels S, Falkner B. Childhood blood pressure trends and risk factors for high blood pressure: the NHANES experience 1988-2008. *Hypertension*. 2013;62(2):247–254
5. Din-Dzietham R, Liu Y, Bielo MV, Shamsa F. High blood pressure trends in children and adolescents in national surveys, 1963 to 2002. *Circulation*. 2007;116(13):1488–1496
6. Kit BK, Kuklina E, Carroll MD, Ostchega Y, Freedman DS, Ogden CL. Prevalence of and trends in dyslipidemia and blood pressure among US children and adolescents, 1999-2012. *JAMA Pediatr*. 2015;169(3):272–279
7. Hansen ML, Gunn PW, Kaelber DC. Underdiagnosis of hypertension in children and adolescents. *JAMA*. 2007;298(8):874–879
8. McNiece KL, Poffenbarger TS, Turner JL, Franco KD, Sorof JM, Portman RJ. Prevalence of hypertension and pre-hypertension among adolescents. *J Pediatr*. 2007;150(6):640–644.e1
9. Chioloro A, Cachat F, Burnier M, Paccaud F, Bovet P. Prevalence of hypertension in schoolchildren based on repeated measurements and association with overweight. *J Hypertens*. 2007;25(11):2209–2217
10. Chen X, Wang Y. Tracking of blood pressure from childhood to adulthood: a systematic review and meta-regression analysis. *Circulation*. 2008;117(25):3171–3180
11. Theodore RF, Broadbent J, Nagin D, et al. Childhood to early-midlife systolic blood pressure trajectories: early-life predictors, effect modifiers, and adult cardiovascular outcomes. *Hypertension*. 2015;66(6):1108–1115
12. Mozaffarian D, Benjamin EJ, Go AS, et al; Writing Group Members; American Heart Association Statistics Committee; Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics—2016 update: a report from the American Heart Association. *Circulation*. 2016;133(4):447–454
13. Liberman JN, Berger JE, Lewis M. Prevalence of antihypertensive, antidiabetic, and dyslipidemic prescription medication use among children and adolescents. *Arch Pediatr Adolesc Med*. 2009;163(4):357–364
14. Rodriguez BL, Dabelea D, Liese AD, et al; SEARCH Study Group. Prevalence and correlates of elevated blood pressure in youth with diabetes mellitus: the

- SEARCH for diabetes in youth study. *J Pediatr*. 2010;157(2):245–251.e1
15. Willi SM, Hirst K, Jago R, et al; HEALTHY Study Group. Cardiovascular risk factors in multi-ethnic middle school students: the HEALTHY primary prevention trial. *Pediatr Obes*. 2012;7(3):230–239
16. DiPietro A, Kees-Folts D, DesHarnais S, Camacho F, Wassner SJ. Primary hypertension at a single center: treatment, time to control, and extended follow-up. *Pediatr Nephrol*. 2009;24(12):2421–2428
17. Seeman T, Gilík J. Long-term control of ambulatory hypertension in children: improving with time but still not achieving new blood pressure goals. *Am J Hypertens*. 2013;26(7):939–945
18. Foglia CF, von Vigier RO, Fossali E, et al. A simplified antihypertensive drug regimen does not ameliorate control of childhood hypertension. *J Hum Hypertens*. 2005;19(8):653–654
19. Sorof J, Daniels S. Obesity hypertension in children: a problem of epidemic proportions. *Hypertension*. 2002;40(4):441–447
20. Sorof JM, Lai D, Turner J, Poffenbarger T, Portman RJ. Overweight, ethnicity, and the prevalence of hypertension in school-aged children. *Pediatrics*. 2004;113(3, pt 1):475–482
21. Koebrick C, Black MH, Wu J, et al. High blood pressure in overweight and obese youth: implications for screening. *J Clin Hypertens (Greenwich)*. 2013;15(11):793–805
22. Falkner B, Gidding SS, Ramirez-Garnica G, Wiltrout SA, West D, Rappaport EB. The relationship of body mass index and blood pressure in primary care pediatric patients. *J Pediatr*. 2006;148(2):195–200
23. Lurbe E, Invitti C, Torro I, et al. The impact of the degree of obesity on the discrepancies between office and ambulatory blood pressure values in youth [published correction appears in *J Hypertens*. 2007;25(1):258]. *J Hypertens*. 2006;24(8):1557–1564
24. Skinner AC, Perrin EM, Moss LA, Skelton JA. Cardiometabolic risks and severity of obesity in children and young adults. *N Engl J Med*. 2015;373(14):1307–1317
25. Zhang T, Zhang H, Li S, et al. Impact of adiposity on incident hypertension is modified by insulin resistance in adults: longitudinal observation from the Bogalusa Heart Study. *Hypertension*. 2016;67(1):56–62
26. So H-K, Yip GW-K, Choi K-C, et al; Hong Kong ABP Working Group. Association between waist circumference and childhood-masked hypertension: a community-based study. *J Paediatr Child Health*. 2016;52(4):385–390
27. Friedemann C, Heneghan C, Mahtani K, Thompson M, Perera R, Ward AM. Cardiovascular disease risk in healthy children and its association with body mass index: systematic review and meta-analysis. *BMJ*. 2012;345:e4759
28. Kelishadi R, Mirmoghtadaee P, Najafi H, Keikha M. Systematic review on the association of abdominal obesity in children and adolescents with cardio-metabolic risk factors. *J Res Med Sci*. 2015;20(3):294–307
29. Török K, Pálfi A, Szelényi Z, Molnár D. Circadian variability of blood pressure in obese children. *Nutr Metab Cardiovasc Dis*. 2008;18(6):429–435
30. Framme J, Dangardt F, Mårild S, Osika W, Währborg P, Friberg P. 24-h systolic blood pressure and heart rate recordings in lean and obese adolescents. *Clin Physiol Funct Imaging*. 2006;26(4):235–239
31. Westerståhl M, Marcus C. Association between nocturnal blood pressure dipping and insulin metabolism in obese adolescents. *Int J Obes*. 2010;34(3):472–477
32. Westerståhl M, Hedvall Kallerman P, Hagman E, Ek AE, Rössner SM, Marcus C. Nocturnal blood pressure non-dipping is prevalent in severely obese, prepubertal and early pubertal children. *Acta Paediatr*. 2014;103(2):225–230
33. Macumber IR, Weiss NS, Halbach SM, Hanevold CD, Flynn JT. The association of pediatric obesity with nocturnal non-dipping on 24-hour ambulatory blood pressure monitoring. *Am J Hypertens*. 2016;29(5):647–652
34. Perng W, Rifas-Shiman SL, Kramer MS, et al. Early weight gain, linear growth, and mid-childhood blood pressure: a prospective study in project viva. *Hypertension*. 2016;67(2):301–308
35. Parker ED, Sinaiko AR, Kharbanda EO, et al. Change in weight status and development of hypertension. *Pediatrics*. 2016;137(3):e20151662
36. Yip J, Facchini FS, Reaven GM. Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. *J Clin Endocrinol Metab*. 1998;83(8):2773–2776
37. Kashyap SR, DeFronzo RA. The insulin resistance syndrome: physiological considerations. *Diab Vasc Dis Res*. 2007;4(1):13–19
38. Lurbe E, Torro I, Aguilar F, et al. Added impact of obesity and insulin resistance in nocturnal blood pressure elevation in children and adolescents. *Hypertension*. 2008;51(3):635–641
39. Chinali M, de Simone G, Roman MJ, et al. Cardiac markers of pre-clinical disease in adolescents with the metabolic syndrome: the strong heart study. *J Am Coll Cardiol*. 2008;52(11):932–938
40. Archbold KH, Vasquez MM, Goodwin JL, Quan SF. Effects of sleep patterns and obesity on increases in blood pressure in a 5-year period: report from the Tucson Children's Assessment of Sleep Apnea Study. *J Pediatr*. 2012;161(1):26–30
41. Javaheri S, Storfer-Isser A, Rosen CL, Redline S. Sleep quality and elevated blood pressure in adolescents. *Circulation*. 2008;118(10):1034–1040
42. Hartzell K, Avis K, Lozano D, Feig D. Obstructive sleep apnea and periodic limb movement disorder in a population of children with hypertension and/or nocturnal nondipping blood pressures. *J Am Soc Hypertens*. 2016;10(2):101–107
43. Au CT, Ho CK, Wing YK, Lam HS, Li AM. Acute and chronic effects of sleep duration on blood pressure. *Pediatrics*. 2014;133(1). Available at: www.pediatrics.org/cgi/content/full/133/1/e64
44. Li AM, Au CT, Ng C, Lam HS, Ho CKW, Wing YK. A 4-year prospective follow-up study of childhood OSA

- and its association with BP. *Chest*. 2014;145(6):1255–1263
45. Li AM, Au CT, Sung RY, et al. Ambulatory blood pressure in children with obstructive sleep apnoea: a community based study. *Thorax*. 2008;63(9):803–809
 46. Flynn JT, Mitsnefes M, Pierce C, et al; Chronic Kidney Disease in Children Study Group. Blood pressure in children with chronic kidney disease: a report from the Chronic Kidney Disease in Children study. *Hypertension*. 2008;52(4):631–637
 47. Samuels J, Ng D, Flynn JT, et al; Chronic Kidney Disease in Children Study Group. Ambulatory blood pressure patterns in children with chronic kidney disease. *Hypertension*. 2012;60(1):43–50
 48. Shatat IF, Flynn JT. Hypertension in children with chronic kidney disease. *Adv Chronic Kidney Dis*. 2005;12(4):378–384
 49. Chavers BM, Solid CA, Daniels FX, et al. Hypertension in pediatric long-term hemodialysis patients in the United States. *Clin J Am Soc Nephrol*. 2009;4(8):1363–1369
 50. Seeman T. Hypertension after renal transplantation. *Pediatr Nephrol*. 2009;24(5):959–972
 51. Tkaczyk M, Nowicki M, Bałasz-Chmielewska I, et al. Hypertension in dialysed children: the prevalence and therapeutic approach in Poland—a nationwide survey. *Nephrol Dial Transplant*. 2006;21(3):736–742
 52. Kramer AM, van Stralen KJ, Jäger KJ, et al. Demographics of blood pressure and hypertension in children on renal replacement therapy in Europe. *Kidney Int*. 2011;80(10):1092–1098
 53. Halbach SM, Martz K, Mattoo T, Flynn J. Predictors of blood pressure and its control in pediatric patients receiving dialysis. *J Pediatr*. 2012;160(4):621–625.e1
 54. Kaelber DC. IBM explorys cohort discovery tool. Available at: www.ibm.com/watson/health/explorys. Accessed February 3, 2017
 55. Barker DJ. The fetal and infant origins of adult disease. *BMJ*. 1990;301(6761):1111
 56. Edvardsson VO, Steinhorsdottir SD, Eliasdottir SB, Indridason OS, Palsson R. Birth weight and childhood blood pressure. *Curr Hypertens Rep*. 2012;14(6):596–602
 57. Mhanna MJ, Iqbal AM, Kaelber DC. Weight gain and hypertension at three years of age and older in extremely low birth weight infants. *J Neonatal Perinatal Med*. 2015;8(4):363–369
 58. Di Salvo G, Castaldi B, Baldini L, et al. Masked hypertension in young patients after successful aortic coarctation repair: impact on left ventricular geometry and function. *J Hum Hypertens*. 2011;25(12):739–745
 59. Bayrakci US, Schaefer F, Duzova A, Yigit S, Bakkaloglu A. Abnormal circadian blood pressure regulation in children born preterm. *J Pediatr*. 2007;151(4):399–403
 60. Sun SS, Grave GD, Siervogel RM, Pickoff AA, Arslanian SS, Daniels SR. Systolic blood pressure in childhood predicts hypertension and metabolic syndrome later in life. *Pediatrics*. 2007;119(2):237–246
 61. Juhola J, Oikonen M, Magnussen CG, et al. Childhood physical, environmental, and genetic predictors of adult hypertension: the cardiovascular risk in young Finns study. *Circulation*. 2012;126(4):402–409
 62. Juhola J, Magnussen CG, Viikari JS, et al. Tracking of serum lipid levels, blood pressure, and body mass index from childhood to adulthood: the Cardiovascular Risk in Young Finns Study. *J Pediatr*. 2011;159(4):584–590
 63. Bao W, Threefoot SA, Srinivasan SR, Berenson GS. Essential hypertension predicted by tracking of elevated blood pressure from childhood to adulthood: the Bogalusa Heart Study. *Am J Hypertens*. 1995;8(7):657–665
 64. Falkner B, Gidding SS, Portman R, Rosner B. Blood pressure variability and classification of prehypertension and hypertension in adolescence. *Pediatrics*. 2008;122(2):238–242
 65. Tracy RE, Newman WP III, Wattigney WA, Srinivasan SR, Strong JP, Berenson GS. Histologic features of atherosclerosis and hypertension from autopsies of young individuals in a defined geographic population: the Bogalusa Heart Study. *Atherosclerosis*. 1995;116(2):163–179
 66. Urbina EM, Khoury PR, McCoy C, Daniels SR, Kimball TR, Dolan LM. Cardiac and vascular consequences of pre-hypertension in youth. *J Clin Hypertens (Greenwich)*. 2011;13(5):332–342
 67. de Simone G, Devereux RB, Daniels SR, Koren MJ, Meyer RA, Laragh JH. Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. *J Am Coll Cardiol*. 1995;25(5):1056–1062
 68. O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr; Cardiovascular Health Study Collaborative Research Group. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. *N Engl J Med*. 1999;340(1):14–22
 69. Mitchell GF, Hwang SJ, Vasan RS, et al. Arterial stiffness and cardiovascular events: the Framingham Heart Study. *Circulation*. 2010;121(4):505–511
 70. Lloyd-Jones DM, Hong Y, Labarthe D, et al; American Heart Association Strategic Planning Task Force and Statistics Committee. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association’s strategic impact goal through 2020 and beyond. *Circulation*. 2010;121(4):586–613
 71. Ning H, Labarthe DR, Shay CM, et al. Status of cardiovascular health in US children up to 11 years of age: the National Health and Nutrition Examination Surveys 2003–2010. *Circ Cardiovasc Qual Outcomes*. 2015;8(2):164–171
 72. Steinberger J, Daniels SR, Hagberg N, et al; American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Epidemiology and Prevention; Council on Functional Genomics and Translational Biology; Stroke Council. Cardiovascular health promotion in children: challenges and opportunities for 2020 and beyond: a

- scientific statement from the American Heart Association. *Circulation*. 2016;134(12):e236–e255
73. Ogden CL, Carroll MD, Lawman HG, et al. Trends in obesity prevalence among children and adolescents in the United States, 1988-1994 through 2013-2014. *JAMA*. 2016;315(21):2292–2299
 74. Skinner AC, Perrin EM, Skelton JA. Prevalence of obesity and severe obesity in US children, 1999-2014. *Obesity (Silver Spring)*. 2016;24(5):1116–1123
 75. Skinner AC, Skelton JA. Prevalence and trends in obesity and severe obesity among children in the United States, 1999-2012. *JAMA Pediatr*. 2014;168(6):561–566
 76. Shay CM, Ning H, Daniels SR, Rooks CR, Gidding SS, Lloyd-Jones DM. Status of cardiovascular health in US adolescents: prevalence estimates from the National Health and Nutrition Examination Surveys (NHANES) 2005-2010. *Circulation*. 2013;127(13):1369–1376
 77. Rosner B, Cook N, Portman R, Daniels S, Falkner B. Determination of blood pressure percentiles in normal-weight children: some methodological issues. *Am J Epidemiol*. 2008;167(6):653–666
 78. Kaelber DC, Pickett F. Simple table to identify children and adolescents needing further evaluation of blood pressure. *Pediatrics*. 2009;123(6). Available at: www.pediatrics.org/cgi/content/full/123/6/e972
 79. Dionne JM, Abitbol CL, Flynn JT. Hypertension in infancy: diagnosis, management and outcome [published correction appears in *Pediatr Nephrol*. 2012;27(1):159-60]. *Pediatr Nephrol*. 2012;27(1):17–32
 80. Kent AL, Chaudhari T. Determinants of neonatal blood pressure. *Curr Hypertens Rep*. 2013;15(5):426–432
 81. Report of the second task force on blood pressure control in children—1987. Task force on blood pressure control in children. National Heart, Lung, and Blood Institute, Bethesda, Maryland. *Pediatrics*. 1987;79(1):1–25
 82. Savoca MR, MacKey ML, Evans CD, Wilson M, Ludwig DA, Harshfield GA. Association of ambulatory blood pressure and dietary caffeine in adolescents. *Am J Hypertens*. 2005;18(1):116–120
 83. Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. *Circulation*. 2005;111(5):697–716
 84. Becton LJ, Egan BM, Hailpern SM, Shatat IF. Blood pressure reclassification in adolescents based on repeat clinic blood pressure measurements. *J Clin Hypertens (Greenwich)*. 2013;15(10):717–722
 85. Daley MF, Sinaiko AR, Reifler LM, et al. Patterns of care and persistence after incident elevated blood pressure. *Pediatrics*. 2013;132(2). Available at: www.pediatrics.org/cgi/content/full/132/2/e349
 86. Ostchega Y, Prineas RJ, Nwankwo T, Zipf G. Assessing blood pressure accuracy of an aneroid sphygmomanometer in a national survey environment. *Am J Hypertens*. 2011;24(3):322–327
 87. Ma Y, Temprowsa M, Fowler S, et al; Diabetes Prevention Program Research Group. Evaluating the accuracy of an aneroid sphygmomanometer in a clinical trial setting. *Am J Hypertens*. 2009;22(3):263–266
 88. Podoll A, Grenier M, Croix B, Feig DL. Inaccuracy in pediatric outpatient blood pressure measurement. *Pediatrics*. 2007;119(3). Available at: www.pediatrics.org/cgi/content/full/119/3/e538
 89. Mourad A, Carney S. Arm position and blood pressure: an audit. *Intern Med J*. 2004;34(5):290–291
 90. Mourad A, Carney S, Gillies A, Jones B, Nanra R, Trevillian P. Arm position and blood pressure: a risk factor for hypertension? *J Hum Hypertens*. 2003;17(6):389–395
 91. Zaheer S, Watson L, Webb NJ. Unmet needs in the measurement of blood pressure in primary care. *Arch Dis Child*. 2014;99(5):463–464
 92. Veiga EV, Arcuri EAM, Cloutier L, Santos JL. Blood pressure measurement: arm circumference and cuff size availability. *Rev Lat Am Enfermagem*. 2009;17(4):455–461
 93. Thomas M, Radford T, Dasgupta I. Unvalidated blood pressure devices with small cuffs are being used in hospitals. *BMJ*. 2001;323(7309):398
 94. Burke MJ, Towers HM, O'Malley K, Fitzgerald DJ, O'Brien ET. Sphygmomanometers in hospital and family practice: problems and recommendations. *Br Med J (Clin Res Ed)*. 1982;285(6340):469–471
 95. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey (NHANES) Anthropometry Procedures Manual. Available at: https://www.cdc.gov/nchs/data/nhanes/nhanes_07_08/manual_an.pdf. Published January 2013. Accessed May 9, 2016
 96. Prineas RJ, Ostchega Y, Carroll M, Dillon C, McDowell M. US demographic trends in mid-arm circumference and recommended blood pressure cuffs for children and adolescents: data from the National Health and Nutrition Examination Survey 1988-2004. *Blood Press Monit*. 2007;12(2):75–80
 97. Kimble KJ, Darnall RA Jr, Yelderman M, Ariagno RL, Ream AK. An automated oscillometric technique for estimating mean arterial pressure in critically ill newborns. *Anesthesiology*. 1981;54(5):423–425
 98. Sonesson SE, Broberger U. Arterial blood pressure in the very low birthweight neonate. Evaluation of an automatic oscillometric technique. *Acta Paediatr Scand*. 1987;76(2):338–341
 99. Duncan AF, Rosenfeld CR, Morgan JS, Ahmad N, Heyne RJ. Interrater reliability and effect of state on blood pressure measurements in infants 1 to 3 years of age. *Pediatrics*. 2008;122(3). Available at: www.pediatrics.org/cgi/content/full/122/3/e590
 100. Nwankwo MU, Lorenz JM, Gardiner JC. A standard protocol for blood pressure measurement in the newborn. *Pediatrics*. 1997;99(6). Available at: www.pediatrics.org/cgi/content/full/99/6/e10

101. Gupta-Malhotra M, Banker A, Shete S, et al. Essential hypertension vs. secondary hypertension among children. *Am J Hypertens*. 2015;28(1):73–80
102. Kelly RK, Thomson R, Smith KJ, Dwyer T, Venn A, Magnussen CG. Factors affecting tracking of blood pressure from childhood to adulthood: the Childhood Determinants of Adult Health Study. *J Pediatr*. 2015;167(6):1422–1428.e2
103. Juhola J, Magnussen CG, Berenson GS, et al. Combined effects of child and adult elevated blood pressure on subclinical atherosclerosis: the International Childhood Cardiovascular Cohort Consortium. *Circulation*. 2013;128(3):217–224
104. Sladowska-Kozłowska J, Litwin M, Niemirska A, Wierzbicka A, Wawer ZT, Janas R. Change in left ventricular geometry during antihypertensive treatment in children with primary hypertension. *Pediatr Nephrol*. 2011;26(12):2201–2209
105. Litwin M, Niemirska A, Sladowska-Kozłowska J, et al. Regression of target organ damage in children and adolescents with primary hypertension. *Pediatr Nephrol*. 2010;25(12):2489–2499
106. Meyer AA, Kundt G, Lenschow U, Schuff-Werner P, Kienast W. Improvement of early vascular changes and cardiovascular risk factors in obese children after a six-month exercise program. *J Am Coll Cardiol*. 2006;48(9):1865–1870
107. Juonala M, Magnussen CG, Berenson GS, et al. Childhood adiposity, adult adiposity, and cardiovascular risk factors. *N Engl J Med*. 2011;365(20):1876–1885
108. Lo JC, Chandra M, Sinaiko A, et al. Severe obesity in children: prevalence, persistence and relation to hypertension. *Int J Pediatr Endocrinol*. 2014;2014(1):3
109. Rademacher ER, Jacobs DR Jr, Moran A, Steinberger J, Prineas RJ, Sinaiko A. Relation of blood pressure and body mass index during childhood to cardiovascular risk factor levels in young adults. *J Hypertens*. 2009;27(9):1766–1774
110. Maahs DM, Daniels SR, de Ferranti SD, et al; American Heart Association Atherosclerosis, Hypertension and Obesity in Youth Committee of the Council on Cardiovascular Disease in the Young; Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on High Blood Pressure Research; Council on Lifestyle and Cardiometabolic Health. Cardiovascular disease risk factors in youth with diabetes mellitus: a scientific statement from the American Heart Association. *Circulation*. 2014;130(17):1532–1558
111. Levitt Katz L, Gidding SS, Bacha F, et al; TODAY Study Group. Alterations in left ventricular, left atrial, and right ventricular structure and function to cardiovascular risk factors in adolescents with type 2 diabetes participating in the TODAY clinical trial. *Pediatr Diabetes*. 2015;16(1):39–47
112. Hager A, Kanz S, Kaemmerer H, Schreiber C, Hess J. Coarctation Long-term Assessment (COALA): significance of arterial hypertension in a cohort of 404 patients up to 27 years after surgical repair of isolated coarctation of the aorta, even in the absence of restenosis and prosthetic material. *J Thorac Cardiovasc Surg*. 2007;134(3):738–745
113. O'Sullivan JJ, Derrick G, Darnell R. Prevalence of hypertension in children after early repair of coarctation of the aorta: a cohort study using casual and 24 hour blood pressure measurement. *Heart*. 2002;88(2):163–166
114. Becker AM, Goldberg JH, Henson M, et al. Blood pressure abnormalities in children with sickle cell anemia. *Pediatr Blood Cancer*. 2014;61(3):518–522
115. Brady TM, Solomon BS, Neu AM, Siberry GK, Parekh RS. Patient-, provider-, and clinic-level predictors of unrecognized elevated blood pressure in children. *Pediatrics*. 2010;125(6). Available at: www.pediatrics.org/cgi/content/full/125/6/e1286
116. Stabouli S, Sideras L, Vareta G, et al. Hypertension screening during healthcare pediatric visits. *J Hypertens*. 2015;33(5):1064–1068
117. Shapiro DJ, Hersh AL, Cabana MD, Sutherland SM, Patel AI. Hypertension screening during ambulatory pediatric visits in the United States, 2000-2009. *Pediatrics*. 2012;130(4):604–610
118. Bijlsma MW, Blufpand HN, Key Action Statementpers GJ, Bökenkamp A. Why pediatricians fail to diagnose hypertension: a multicenter survey. *J Pediatr*. 2014;164(1):173–177.e7
119. Chaudhry B, Wang J, Wu S, et al. Systematic review: impact of health information technology on quality, efficiency, and costs of medical care. *Ann Intern Med*. 2006;144(10):742–752
120. Shojania KG, Jennings A, Mayhew A, Ramsay CR, Eccles MP, Grimshaw J. The effects of on-screen, point of care computer reminders on processes and outcomes of care. *Cochrane Database Syst Rev*. 2009;(3):CD001096
121. Garg AX, Adhikari NKJ, McDonald H, et al. Effects of computerized clinical decision support systems on practitioner performance and patient outcomes: a systematic review. *JAMA*. 2005;293(10):1223–1238
122. Hicks LS, Sequist TD, Ayanian JZ, et al. Impact of computerized decision support on blood pressure management and control: a randomized controlled trial. *J Gen Intern Med*. 2008;23(4):429–441
123. Samal L, Linder JA, Lipsitz SR, Hicks LS. Electronic health records, clinical decision support, and blood pressure control. *Am J Manag Care*. 2011;17(9):626–632
124. Heymann AD, Hoch I, Valinsky L, Shalev V, Silber H, Kokia E. Mandatory computer field for blood pressure measurement improves screening. *Fam Pract*. 2005;22(2):168–169
125. Brady TM, Neu AM, Miller ER III, Appel LJ, Siberry GK, Solomon BS. Real-time electronic medical record alerts increase high blood pressure recognition in children. *Clin Pediatr (Phila)*. 2015;54(7):667–675
126. Romano MJ, Stafford RS. Electronic health records and clinical decision support systems: impact on national ambulatory care quality. *Arch Intern Med*. 2011;171(10):897–903

127. Alpert BS, Quinn D, Gallick D. Oscillometric blood pressure: a review for clinicians. *J Am Soc Hypertens*. 2014;8(12):930–938
128. Alpert BS. Oscillometric blood pressure values are algorithm-specific. *Am J Cardiol*. 2010;106(10):1524–1525, author reply 1524–1525
129. Flynn JT, Pierce CB, Miller ER III, et al; Chronic Kidney Disease in Children Study Group. Reliability of resting blood pressure measurement and classification using an oscillometric device in children with chronic kidney disease. *J Pediatr*. 2012;160(3):434–440.e1
130. Kamath N, Goud BR, Phadke KD, Iyengar A. Use of oscillometric devices for the measurement of blood pressure—comparison with the gold standard. *Indian J Pediatr*. 2012;79(9):1230–1232
131. Chiolerio A, Bovet P, Stergiou GS. Automated oscillometric blood pressure measurement in children. *J Clin Hypertens (Greenwich)*. 2014;16(6):468
132. Chiolerio A, Paradis G, Lambert M. Accuracy of oscillometric devices in children and adults. *Blood Press*. 2010;19(4):254–259
133. Chio SS, Urbina EM, Lapointe J, Tsai J, Berenson GS. Korotkoff sound versus oscillometric cuff sphygmomanometers: comparison between auscultatory and DynaPulse blood pressure measurements. *J Am Soc Hypertens*. 2011;5(1):12–20
134. Eliasdottir SB, Steinhorsdottir SD, Indridason OS, Palsson R, Edvardsson VO. Comparison of aneroid and oscillometric blood pressure measurements in children. *J Clin Hypertens (Greenwich)*. 2013;15(11):776–783
135. Urbina EM, Khoury PR, McCoy CE, Daniels SR, Dolan LM, Kimball TR. Comparison of mercury sphygmomanometry blood pressure readings with oscillometric and central blood pressure in predicting target organ damage in youth. *Blood Press Monit*. 2015;20(3):150–156
136. Negroni-Balasquide X, Bell CS, Samuel J, Samuels JA. Is one measurement enough to evaluate blood pressure among adolescents? A blood pressure screening experience in more than 9000 children with a subset comparison of auscultatory to mercury measurements. *J Am Soc Hypertens*. 2016;10(2):95–100
137. Leblanc M-É, Croteau S, Ferland A, et al. Blood pressure assessment in severe obesity: validation of a forearm approach. *Obesity (Silver Spring)*. 2013;21(12):E533–E541
138. Altunkan S, Genç Y, Altunkan E. A comparative study of an ambulatory blood pressure measuring device and a wrist blood pressure monitor with a position sensor versus a mercury sphygmomanometer. *Eur J Intern Med*. 2007;18(2):118–123
139. Uen S, Fimmers R, Brieger M, Nickenig G, Mengden T. Reproducibility of wrist home blood pressure measurement with position sensor and automatic data storage. *BMC Cardiovasc Disord*. 2009;9:20
140. Fania C, Benetti E, Palatini P. Validation of the A&D BP UB-543 wrist device for home blood pressure measurement according to the European Society of Hypertension International Protocol revision 2010. *Blood Press Monit*. 2015;20(4):237–240
141. Kang Y-Y, Chen Q, Li Y, Wang JG. Validation of the SCIAN LD-735 wrist blood pressure monitor for home blood pressure monitoring according to the European Society of Hypertension International Protocol revision 2010. *Blood Press Monit*. 2016;21(4):255–258
142. Xie P, Wang Y, Xu X, Huang F, Pan J. Validation of the Pangao PG-800A11 wrist device assessed according to the European Society of Hypertension and the British Hypertension Society protocols. *Blood Press Monit*. 2015;20(2):108–111
143. Zweiker R, Schumacher M, Fruhwald FM, Watzinger N, Klein W. Comparison of wrist blood pressure measurement with conventional sphygmomanometry at a cardiology outpatient clinic. *J Hypertens*. 2000;18(8):1013–1018
144. Altunkan S, Yildiz S, Azer S. Wrist blood pressure-measuring devices: a comparative study of accuracy with a standard auscultatory method using a mercury manometer. *Blood Press Monit*. 2002;7(5):281–284
145. Palatini P, Longo D, Toffanin G, Bertolo O, Zaetta V, Pessina AC. Wrist blood pressure overestimates blood pressure measured at the upper arm. *Blood Press Monit*. 2004;9(2):77–81
146. Stergiou GS, Christodoulakis GR, Nasothimiou EG, Giovvas PP, Kalogeropoulos PG. Can validated wrist devices with position sensors replace arm devices for self-home blood pressure monitoring? A randomized crossover trial using ambulatory monitoring as reference. *Am J Hypertens*. 2008;21(7):753–758
147. Khoshdel AR, Carney S, Gillies A. The impact of arm position and pulse pressure on the validation of a wrist-cuff blood pressure measurement device in a high risk population. *Int J Gen Med*. 2010;3:119–125
148. Kikuya M, Chonan K, Imai Y, Goto E, Ishii M; Research Group to Assess the Validity of Automated Blood Pressure Measurement Devices in Japan. Accuracy and reliability of wrist-cuff devices for self-measurement of blood pressure. *J Hypertens*. 2002;20(4):629–638
149. Westhoff TH, Schmidt S, Meissner R, Zidek W, van der Giet M. The impact of pulse pressure on the accuracy of wrist blood pressure measurement. *J Hum Hypertens*. 2009;23(6):391–395
150. Deutsch C, Krüger R, Saito K, et al. Comparison of the Omron RS6 wrist blood pressure monitor with the positioning sensor on or off with a standard mercury sphygmomanometer. *Blood Press Monit*. 2014;19(5):306–313
151. Yarows SA. Comparison of the Omron HEM-637 wrist monitor to the auscultation method with the wrist position sensor on or disabled. *Am J Hypertens*. 2004;17(1):54–58
152. Menezes AMB, Dumith SC, Noal RB, et al. Validity of a wrist digital monitor for blood pressure measurement in comparison to a mercury sphygmomanometer. *Arq Bras Cardiol*. 2010;94(3):345–349, 365–370
153. Wankum PC, Thurman TL, Holt SJ, Hall RA, Simpson PM, Heulitt MJ. Validation of a noninvasive blood pressure

- monitoring device in normotensive and hypertensive pediatric intensive care patients. *J Clin Monit Comput.* 2004;18(4):253–263
154. Cua CL, Thomas K, Zurakowski D, Laussen PC. A comparison of the Vasotrac with invasive arterial blood pressure monitoring in children after pediatric cardiac surgery. *Anesth Analg.* 2005;100(5):1289–1294
155. Flynn JT, Daniels SR, Hayman LL, et al; American Heart Association Atherosclerosis, Hypertension and Obesity in Youth Committee of the Council on Cardiovascular Disease in the Young. Update: ambulatory blood pressure monitoring in children and adolescents: a scientific statement from the American Heart Association. *Hypertension.* 2014;63(5):1116–1135
156. Siu AL; U.S. Preventive Services Task Force. Screening for high blood pressure in adults: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2015;163(10):778–786
157. Díaz LN, Garin EH. Comparison of ambulatory blood pressure and Task Force criteria to identify pediatric hypertension. *Pediatr Nephrol.* 2007;22(4):554–558
158. Salice P, Ardissino G, Zanchetti A, et al. Age-dependent differences in office (OBP) vs ambulatory blood pressure monitoring (ABPM) in hypertensive children and adolescents: 8C.03. *J Hypertens.* 2010;28:e423–e424
159. Stergiou GS, Alamara CV, Salgami EV, Vaindirlis IN, Dacou-Voutetakis C, Mountokalakis TD. Reproducibility of home and ambulatory blood pressure in children and adolescents. *Blood Press Monit.* 2005;10(3):143–147
160. Li Z, Snieder H, Harshfield GA, Treiber FA, Wang X. A 15-year longitudinal study on ambulatory blood pressure tracking from childhood to early adulthood. *Hypertens Res.* 2009;32(5):404–410
161. Seeman T, Palyzová D, Dusek J, Janda J. Reduced nocturnal blood pressure dip and sustained nighttime hypertension are specific markers of secondary hypertension. *J Pediatr.* 2005;147(3):366–371
162. Bjelakovic B, Jaddoe VW, Vukomanovic V, et al. The relationship between currently recommended ambulatory systolic blood pressure measures and left ventricular mass index in pediatric hypertension. *Curr Hypertens Rep.* 2015;17(4):534
163. Brady TM, Fivush B, Flynn JT, Parekh R. Ability of blood pressure to predict left ventricular hypertrophy in children with primary hypertension. *J Pediatr.* 2008;152(1):73–78, 78.e1
164. McNiece KL, Gupta-Malhotra M, Samuels J, et al; National High Blood Pressure Education Program Working Group. Left ventricular hypertrophy in hypertensive adolescents: analysis of risk by 2004 National High Blood Pressure Education Program Working Group staging criteria. *Hypertension.* 2007;50(2):392–395
165. Richey PA, Disessa TG, Hastings MC, Somes GW, Alpert BS, Jones DP. Ambulatory blood pressure and increased left ventricular mass in children at risk for hypertension. *J Pediatr.* 2008;152(3):343–348
166. Conkar S, Yılmaz E, Hacıkarar S, Bozabalı S, Mir S. Is daytime systolic load an important risk factor for target organ damage in pediatric hypertension? *J Clin Hypertens (Greenwich).* 2015;17(10):760–766
167. Flynn JT. Differentiation between primary and secondary hypertension in children using ambulatory blood pressure monitoring. *Pediatrics.* 2002;110(1, pt 1):89–93
168. Dursun H, Bayazit AK, Cengiz N, et al. Ambulatory blood pressure monitoring and renal functions in children with a solitary kidney. *Pediatr Nephrol.* 2007;22(4):559–564
169. Patzer L, Seeman T, Luck C, Wühl E, Janda J, Misselwitz J. Day- and night-time blood pressure elevation in children with higher grades of renal scarring. *J Pediatr.* 2003;142(2):117–122
170. Fidan K, Kandur Y, Buyukkaragoz B, Akdemir UO, Soylemezoglu O. Hypertension in pediatric patients with renal scarring in association with vesicoureteral reflux. *Urology.* 2013;81(1):173–177
171. Basiratnia M, Esteghamati M, Ajami GH, et al. Blood pressure profile in renal transplant recipients and its relation to diastolic function: tissue Doppler echocardiographic study. *Pediatr Nephrol.* 2011;26(3):449–457
172. Chaudhuri A, Sutherland SM, Begin B, et al. Role of twenty-four-hour ambulatory blood pressure monitoring in children on dialysis. *Clin J Am Soc Nephrol.* 2011;6(4):870–876
173. Wühl E, Trivelli A, Picca S, et al; ESCAPE Trial Group. Strict blood-pressure control and progression of renal failure in children. *N Engl J Med.* 2009;361(17):1639–1650
174. Chatterjee M, Speiser PW, Pellizzarri M, et al. Poor glycemic control is associated with abnormal changes in 24-hour ambulatory blood pressure in children and adolescents with type 1 diabetes mellitus. *J Pediatr Endocrinol Metab.* 2009;22(11):1061–1067
175. Darcan S, Goksen D, Mir S, et al. Alterations of blood pressure in type 1 diabetic children and adolescents. *Pediatr Nephrol.* 2006;21(5):672–676
176. Dost A, Klinkert C, Kapellen T, et al; DPV Science Initiative. Arterial hypertension determined by ambulatory blood pressure profiles: contribution to microalbuminuria risk in a multicenter investigation in 2,105 children and adolescents with type 1 diabetes. *Diabetes Care.* 2008;31(4):720–725
177. Ettinger LM, Freeman K, DiMartino-Nardi JR, Flynn JT. Microalbuminuria and abnormal ambulatory blood pressure in adolescents with type 2 diabetes mellitus. *J Pediatr.* 2005;147(1):67–73
178. Lurbe E, Redon J, Kesani A, et al. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. *N Engl J Med.* 2002;347(11):797–805
179. Nagasako SS, Nogueira PC, Machado PG, Pestana JO. Risk factors for hypertension 3 years after renal transplantation in children. *Pediatr Nephrol.* 2007;22(9):1363–1368
180. Roche SL, Kaufmann J, Dipchand AI, Kantor PF. Hypertension after pediatric heart transplantation is primarily associated with immunosuppressive

- regimen. *J Heart Lung Transplant*. 2008;27(5):501–507
181. Paripovic D, Kostic M, Spasojevic B, Krusic D, Peco-Antic A. Masked hypertension and hidden uncontrolled hypertension after renal transplantation. *Pediatr Nephrol*. 2010;25(9):1719–1724
182. Ferraris JR, Ghezzi L, Waisman G, Krmar RT. ABPM vs office blood pressure to define blood pressure control in treated hypertensive paediatric renal transplant recipients. *Pediatr Transplant*. 2007;11(1):24–30
183. McGlothlan KR, Wyatt RJ, Ault BH, et al. Predominance of nocturnal hypertension in pediatric renal allograft recipients. *Pediatr Transplant*. 2006;10(5):558–564
184. Balzano R, Lindblad YT, Vavilis G, Jogestrand T, Berg UB, Krmar RT. Use of annual ABPM, and repeated carotid scan and echocardiography to monitor cardiovascular health over nine yr in pediatric and young adult renal transplant recipients. *Pediatr Transplant*. 2011;15(6):635–641
185. Krmar RT, Berg UB. Blood pressure control in hypertensive pediatric renal transplants: role of repeated ABPM following transplantation. *Am J Hypertens*. 2008;21(10):1093–1099
186. Ambrosi P, Kreitmann B, Habib G. Home blood pressure monitoring in heart transplant recipients: comparison with ambulatory blood pressure monitoring. *Transplantation*. 2014;97(3):363–367
187. Seeman T, Simková E, Kreisinger J, et al. Reduction of proteinuria during intensified antihypertensive therapy in children after renal transplantation. *Transplant Proc*. 2007;39(10):3150–3152
188. Seeman T, Simková E, Kreisinger J, et al. Improved control of hypertension in children after renal transplantation: results of a two-yr interventional trial. *Pediatr Transplant*. 2007;11(5):491–497
189. Lurbe E, Alvarez V, Liao Y, et al. The impact of obesity and body fat distribution on ambulatory blood pressure in children and adolescents. *Am J Hypertens*. 1998;11(4, pt 1):418–424
190. Lurbe E, Alvarez V, Redon J. Obesity, body fat distribution, and ambulatory blood pressure in children and adolescents. *J Clin Hypertens (Greenwich)*. 2001;3(6):362–367
191. Marcovecchio ML, Patricelli L, Zito M, et al. Ambulatory blood pressure monitoring in obese children: role of insulin resistance. *J Hypertens*. 2006;24(12):2431–2436
192. Shatat IF, Freeman KD, Vuguin PM, Dimartino-Nardi JR, Flynn JT. Relationship between adiponectin and ambulatory blood pressure in obese adolescents. *Pediatr Res*. 2009;65(6):691–695
193. Amin RS, Carroll JL, Jeffries JL, et al. Twenty-four-hour ambulatory blood pressure in children with sleep-disordered breathing. *Am J Respir Crit Care Med*. 2004;169(8):950–956
194. Leung LC, Ng DK, Lau MW, et al. Twenty-four-hour ambulatory BP in snoring children with obstructive sleep apnea syndrome. *Chest*. 2006;130(4):1009–1017
195. Akyürek N, Atabek ME, Ekioglu BS, Alp H. Ambulatory blood pressure and subclinical cardiovascular disease in children with turner syndrome. *Pediatr Cardiol*. 2014;35(1):57–62
196. Salgado CM, Jardim PC, Teles FB, Nunes MC. Low birth weight as a marker of changes in ambulatory blood pressure monitoring. *Arq Bras Cardiol*. 2009;92(2):107–121
197. Gimpel C, Wühl E, Arbeiter K, et al; ESCAPE Trial Group. Superior consistency of ambulatory blood pressure monitoring in children: implications for clinical trials. *J Hypertens*. 2009;27(8):1568–1574
198. Suláková T, Feber J. Should mean arterial pressure be included in the definition of ambulatory hypertension in children? *Pediatr Nephrol*. 2013;28(7):1105–1112
199. Lurbe E, Torro I, Alvarez V, et al. Prevalence, persistence, and clinical significance of masked hypertension in youth. *Hypertension*. 2005;45(4):493–498
200. Stabouli S, Kotsis V, Toumanidis S, Papamichael C, Constantopoulos A, Zakopoulos N. White-coat and masked hypertension in children: association with target-organ damage. *Pediatr Nephrol*. 2005;20(8):1151–1155
201. Furusawa ÉA, Filho UD, Junior DM, Koch VH. Home and ambulatory blood pressure to identify white coat and masked hypertension in the pediatric patient. *Am J Hypertens*. 2011;24(8):893–897
202. Wells TG, Portman R, Norman P, Haertter S, Davidai G, Fei Wang. Safety, efficacy, and pharmacokinetics of telmisartan in pediatric patients with hypertension. *Clin Pediatr (Phila)*. 2010;49(10):938–946
203. Mitsnefes M, Flynn J, Cohn S, et al; CKiD Study Group. Masked hypertension associates with left ventricular hypertrophy in children with CKD. *J Am Soc Nephrol*. 2010;21(1):137–144
204. Lurbe E, Redon J. Discrepancies in office and ambulatory blood pressure in adolescents: help or hindrance? *Pediatr Nephrol*. 2008;23(3):341–345
205. Pogue V, Rahman M, Lipkowitz M, et al; African American Study of Kidney Disease and Hypertension Collaborative Research Group. Disparate estimates of hypertension control from ambulatory and clinic blood pressure measurements in hypertensive kidney disease. *Hypertension*. 2009;53(1):20–27
206. Urbina EM, Williams RV, Alpert BS, et al; American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee of the Council on Cardiovascular Disease in the Young. Noninvasive assessment of subclinical atherosclerosis in children and adolescents: recommendations for standard assessment for clinical research: a scientific statement from the American Heart Association. *Hypertension*. 2009;54(5):919–950
207. Kavey RE, Kveselis DA, Atallah N, Smith FC. White coat hypertension in childhood: evidence for end-organ effect. *J Pediatr*. 2007;150(5):491–497
208. Swartz SJ, Srivaths PR, Croix B, Feig DI. Cost-effectiveness of ambulatory blood pressure monitoring in the initial evaluation of hypertension in children. *Pediatrics*. 2008;122(6):1177–1181

209. Briasoulis A, Androulakis E, Palla M, Papaioannidis N, Tousoulis D. White-coat hypertension and cardiovascular events: a meta-analysis. *J Hypertens*. 2016;34(4):593–599
210. Valent-Morić B, Zigman T, Zaja-Franulović O, Malenica M, Cuk M. The importance of ambulatory blood pressure monitoring in children and adolescents. *Acta Clin Croat*. 2012;51(1):59–64
211. Palatini P, Parati G. Blood pressure measurement in very obese patients: a challenging problem. *J Hypertens*. 2011;29(3):425–429
212. Halm MA. Arm circumference, shape, and length: how interplaying variables affect blood pressure measurement in obese persons. *Am J Crit Care*. 2014;23(2):166–170
213. Ostchega Y, Hughes JP, Prineas RJ, Zhang G, Nwankwo T, Chiappa MM. Mid-arm circumference and recommended blood pressure cuffs for children and adolescents aged between 3 and 19 years: data from the National Health and Nutrition Examination Survey, 1999–2010. *Blood Press Monit*. 2014;19(1):26–31
214. Bonso E, Saladini F, Zanier A, Benetti E, Dorigatti F, Palatini P. Accuracy of a single rigid conical cuff with standard-size bladder coupled to an automatic oscillometric device over a wide range of arm circumferences. *Hypertens Res*. 2010;33(11):1186–1191
215. Palatini P, Benetti E, Fania C, Malipiero G, Saladini F. Rectangular cuffs may overestimate blood pressure in individuals with large conical arms. *J Hypertens*. 2012;30(3):530–536
216. Aguilar A, Ostrow V, De Luca F, Suarez E. Elevated ambulatory blood pressure in a multi-ethnic population of obese children and adolescents. *J Pediatr*. 2010;156(6):930–935
217. Ostrow V, Wu S, Aguilar A, Bonner R Jr, Suarez E, De Luca F. Association between oxidative stress and masked hypertension in a multi-ethnic population of obese children and adolescents. *J Pediatr*. 2011;158(4):628–633.e1
218. Woroniecki RP, Flynn JT. How are hypertensive children evaluated and managed? A survey of North American pediatric nephrologists. *Pediatr Nephrol*. 2005;20(6):791–797
219. Mengden T, Hernandez Medina RM, Beltran B, Alvarez E, Kraft K, Vetter H. Reliability of reporting self-measured blood pressure values by hypertensive patients. *Am J Hypertens*. 1998;11(12):1413–1417
220. Palatini P, Frick GN. Techniques for self-measurement of blood pressure: limitations and needs for future research. *J Clin Hypertens (Greenwich)*. 2012;14(3):139–143
221. Stergiou GS, Karpettas N, Kapoyiannis A, Stefanidis CJ, Vazeou A. Home blood pressure monitoring in children and adolescents: a systematic review. *J Hypertens*. 2009;27(10):1941–1947
222. Stergiou GS, Nasothimiou E, Giovas P, Kapoyiannis A, Vazeou A. Diagnosis of hypertension in children and adolescents based on home versus ambulatory blood pressure monitoring. *J Hypertens*. 2008;26(8):1556–1562
223. Furusawa EA, Filho UD, Koch VH. Home blood pressure monitoring in paediatric chronic hypertension. *J Hum Hypertens*. 2009;23(7):464–469
224. Stergiou GS, Nasothimiou EG, Giovas PP, Rarra VC. Long-term reproducibility of home vs. office blood pressure in children and adolescents: the Arsakeion school study. *Hypertens Res*. 2009;32(4):311–315
225. Wühl E, Hadtstein C, Mehls O, Schaefer F; Escape Trial Group. Home, clinic, and ambulatory blood pressure monitoring in children with chronic renal failure. *Pediatr Res*. 2004;55(3):492–497
226. Stergiou GS, Karpettas N, Panagiotakos DB, Vazeou A. Comparison of office, ambulatory and home blood pressure in children and adolescents on the basis of normalcy tables. *J Hum Hypertens*. 2011;25(4):218–223
227. Stergiou GS, Alamara CV, Kalkana CB, et al. Out-of-office blood pressure in children and adolescents: disparate findings by using home or ambulatory monitoring. *Am J Hypertens*. 2004;17(10):869–875
228. Stergiou GS, Rarra VC, Yiannes NG. Changing relationship between home and office blood pressure with increasing age in children: the Arsakeion School study. *Am J Hypertens*. 2008;21(1):41–46
229. Salgado CM, Jardim PC, Viana JK, Jardim TS, Velasquez PP. Home blood pressure in children and adolescents: a comparison with office and ambulatory blood pressure measurements. *Acta Paediatr*. 2011;100(10):e163–e168
230. Stergiou GS, Ntineri A, Kollias A, Destounis A, Nasothimiou E, Roussias L. Changing relationship among clinic, home, and ambulatory blood pressure with increasing age. *J Am Soc Hypertens*. 2015;9(7):544–552
231. Stergiou GS, Yiannes NG, Rarra VC, Panagiotakos DB. Home blood pressure normalcy in children and adolescents: the Arsakeion School study. *J Hypertens*. 2007;25(7):1375–1379
232. Sorof JM, Turner J, Franco K, Portman RJ. Characteristics of hypertensive children identified by primary care referral compared with school-based screening. *J Pediatr*. 2004;144(4):485–489
233. King CA, Meadows BB, Engelke MK, Swanson M. Prevalence of elevated body mass index and blood pressure in a rural school-aged population: implications for school nurses. *J Sch Health*. 2006;76(4):145–149
234. Underwood SM, Averhart L, Dean A, et al. Clinical evaluation and follow-up of body mass and blood pressure in pre-elementary school children: program review. *J Natl Black Nurses Assoc*. 2012;23(1):8–15
235. Kapur G, Ahmed M, Pan C, Mitsnefes M, Chiang M, Mattoo TK. Secondary hypertension in overweight and stage 1 hypertensive children: a Midwest Pediatric Nephrology Consortium report. *J Clin Hypertens (Greenwich)*. 2010;12(1):34–39
236. Flynn JT, Alderman MH. Characteristics of children with primary hypertension seen at a referral center. *Pediatr Nephrol*. 2005;20(7):961–966
237. Gomes RS, Quirino IG, Pereira RM, et al. Primary versus secondary

- hypertension in children followed up at an outpatient tertiary unit. *Pediatr Nephrol*. 2011;26(3):441–447
238. Welch WP, Yang W, Taylor-Zapata P, Flynn JT. Antihypertensive drug use by children: are the drugs labeled and indicated? *J Clin Hypertens (Greenwich)*. 2012;14(6):388–395
 239. Flynn J, Zhang Y, Solar-Yohay S, Shi V. Clinical and demographic characteristics of children with hypertension. *Hypertension*. 2012;60(4):1047–1054
 240. Baracco R, Kapur G, Mattoo T, et al. Prediction of primary vs secondary hypertension in children. *J Clin Hypertens (Greenwich)*. 2012;14(5):316–321
 241. Silverstein DM, Champoux E, Aviles DH, Vehaskari VM. Treatment of primary and secondary hypertension in children. *Pediatr Nephrol*. 2006;21(6):820–827
 242. Flynn JT, Meyers KEC, Neto JP, et al; Pediatric Valsartan Study Group. Efficacy and safety of the angiotensin receptor blocker valsartan in children with hypertension aged 1 to 5 years. *Hypertension*. 2008;52(2):222–228
 243. Schaefer F, van de Walle J, Zurowska A, et al; Candesartan in Children with Hypertension Investigators. Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age. *J Hypertens*. 2010;28(5):1083–1090
 244. Webb NJ, Wells TG, Shahinfar S, et al. A randomized, open-label, dose-response study of losartan in hypertensive children. *Clin J Am Soc Nephrol*. 2014;9(8):1441–1448
 245. Coleman DM, Eliason JL, Ohye RG, Stanley JC. Long-segment thoracoabdominal aortic occlusions in childhood. *J Vasc Surg*. 2012;56(2):482–485
 246. Lee MG, Kowalski R, Galati JC, et al. Twenty-four-hour ambulatory blood pressure monitoring detects a high prevalence of hypertension late after coarctation repair in patients with hypoplastic arches. *J Thorac Cardiovasc Surg*. 2012;144(5):1110–1116
 247. Agnoletti G, Bonnet C, Bonnet D, Sidi D, Aggoun Y. Mid-term effects of implanting stents for relief of aortic recoarctation on systemic hypertension, carotid mechanical properties, intimal medial thickness and reflection of the pulse wave. *Cardiol Young*. 2005;15(3):245–250
 248. Young WF. Endocrine hypertension. In: Melmed S, Polonsky KS, Larsen R, Kronenberg HM, eds. *Williams Textbook of Endocrinology*. 13th ed. Philadelphia, PA: Elsevier Inc; 2016:556–588
 249. Bausch B, Wellner U, Bausch D, et al. Long-term prognosis of patients with pediatric pheochromocytoma. *Endocr Relat Cancer*. 2013;21(1):17–25
 250. Waguespack SG, Rich T, Grubbs E, et al. A current review of the etiology, diagnosis, and treatment of pediatric pheochromocytoma and paraganglioma. *J Clin Endocrinol Metab*. 2010;95(5):2023–2037
 251. Fishbein L, Merrill S, Fraker DL, Cohen DL, Nathanson KL. Inherited mutations in pheochromocytoma and paraganglioma: why all patients should be offered genetic testing. *Ann Surg Oncol*. 2013;20(5):1444–1450
 252. Barontini M, Levin G, Sanso G. Characteristics of pheochromocytoma in a 4- to 20-year-old population. *Ann N Y Acad Sci*. 2006;1073:30–37
 253. Welander J, Söderkvist P, Gimm O. Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. *Endocr Relat Cancer*. 2011;18(6):R253–R276
 254. Eisenhofer G, Peitzsch M. Laboratory evaluation of pheochromocytoma and paraganglioma. *Clin Chem*. 2014;60(12):1486–1499
 255. Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2016;101(5):1889–1916
 256. Stowasser M, Gordon RD. Monogenic mineralocorticoid hypertension. *Best Pract Res Clin Endocrinol Metab*. 2006;20(3):401–420
 257. White PC, Dupont J, New MI, Leiberman E, Hochberg Z, Rösler A. A mutation in CYP11B1 (Arg-448---His) associated with steroid 11 beta-hydroxylase deficiency in Jews of Moroccan origin. *J Clin Invest*. 1991;87(5):1664–1667
 258. Parsa AA, New MI. Low-renin hypertension of childhood. *Endocrinol Metab Clin North Am*. 2011;40(2):369–377, viii
 259. Parajes S, Loidi L, Reisch N, et al. Functional consequences of seven novel mutations in the CYP11B1 gene: four mutations associated with nonclassic and three mutations causing classic 11beta-hydroxylase deficiency. *J Clin Endocrinol Metab*. 2010;95(2):779–788
 260. New MI, Geller DS, Fallo F, Wilson RC. Monogenic low renin hypertension. *Trends Endocrinol Metab*. 2005;16(3):92–97
 261. Imai T, Yanase T, Waterman MR, Simpson ER, Pratt JJ. Canadian Mennonites and individuals residing in the Friesland region of The Netherlands share the same molecular basis of 17 alpha-hydroxylase deficiency. *Hum Genet*. 1992;89(1):95–96
 262. Dhir V, Reisch N, Bleicken CM, et al. Steroid 17alpha-hydroxylase deficiency: functional characterization of four mutations (A174E, V178D, R440C, L465P) in the CYP17A1 gene. *J Clin Endocrinol Metab*. 2009;94(8):3058–3064
 263. Aglony M, Martínez-Aguayo A, Carvajal CA, et al. Frequency of familial hyperaldosteronism type 1 in a hypertensive pediatric population: clinical and biochemical presentation. *Hypertension*. 2011;57(6):1117–1121
 264. Speiser PW, White PC. Congenital adrenal hyperplasia. *N Engl J Med*. 2003;349(8):776–788
 265. Funder JW. Genetic disorders in primary aldosteronism — familial and somatic. *J Steroid Biochem Mol Biol*. 2017;165(pt A):154–157
 266. Carss KJ, Stowasser M, Gordon RD, O'Shaughnessy KM. Further study of chromosome 7p22 to identify the molecular basis of familial hyperaldosteronism type II. *J Hum Hypertens*. 2011;25(9):560–564

267. So A, Duffy DL, Gordon RD, et al. Familial hyperaldosteronism type II is linked to the chromosome 7p22 region but also shows predicted heterogeneity. *J Hypertens*. 2005;23(8):1477–1484
268. Geller DS, Zhang J, Wisgerhof MV, Shackleton C, Key Action Statementhgarian M, Lifton RP. A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism. *J Clin Endocrinol Metab*. 2008;93(8):3117–3123
269. Boulkroun S, Beuschlein F, Rossi GP, et al. Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism. *Hypertension*. 2012;59(3):592–598
270. Scholl UI, Nelson-Williams C, Yue P, et al. Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5. *Proc Natl Acad Sci USA*. 2012;109(7):2533–2538
271. Scholl UI, Goh G, Stölting G, et al. Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. *Nat Genet*. 2013;45(9):1050–1054
272. Scholl UI, Stölting G, Nelson-Williams C, et al. Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism. *Elife*. 2015;4:e06315
273. Rothenbuhler A, Stratakis CA. Clinical and molecular genetics of Carney complex. *Best Pract Res Clin Endocrinol Metab*. 2010;24(3):389–399
274. Stratakis CA, Salpea P, Raygada M. *Carney Complex*. Seattle, WA: University of Washington; 2015
275. Lietman SA, Schwindinger WF, Levine MA. Genetic and molecular aspects of McCune-Albright syndrome. *Pediatr Endocrinol Rev*. 2007;4(suppl 4):380–385
276. Lumbroso S, Paris F, Sultan C. McCune-Albright syndrome: molecular genetics. *J Pediatr Endocrinol Metab*. 2002;15(suppl 3):875–882
277. Malchoff CD, Javier EC, Malchoff DM, et al. Primary cortisol resistance presenting as isosexual precocity. *J Clin Endocrinol Metab*. 1990;70(2):503–507
278. Nicolaidis NC, Charmandari E. Crousos syndrome: from molecular pathogenesis to therapeutic management. *Eur J Clin Invest*. 2015;45(5):504–514
279. Malchoff DM, Brufsky A, Reardon G, et al. A mutation of the glucocorticoid receptor in primary cortisol resistance. *J Clin Invest*. 1993;91(5):1918–1925
280. Ferrari P. The role of 11 β -hydroxysteroid dehydrogenase type 2 in human hypertension. *Biochim Biophys Acta*. 2010;1802(12):1178–1187
281. Morineau G, Sulmont V, Salomon R, et al. Apparent mineralocorticoid excess: report of six new cases and extensive personal experience. *J Am Soc Nephrol*. 2006;17(11):3176–3184
282. Nesterov V, Krueger B, Bertog M, Dahlmann A, Palmisano R, Korbmacher C. In Liddle syndrome, epithelial sodium channel is hyperactive mainly in the early part of the aldosterone-sensitive distal nephron. *Hypertension*. 2016;67(6):1256–1262
283. Hanukoglu I, Hanukoglu A. Epithelial sodium channel (ENaC) family: Phylogeny, structure-function, tissue distribution, and associated inherited diseases. *Gene*. 2016;579(2):95–132
284. Geller DS, Farhi A, Pinkerton N, et al. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. *Science*. 2000;289(5476):119–123
285. Wilson FH, Disse-Nicodème S, Choate KA, et al. Human hypertension caused by mutations in WNK kinases. *Science*. 2001;293(5532):1107–1112
286. Boyden LM, Choi M, Choate KA, et al. Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities. *Nature*. 2012;482(7383):98–102
287. Stowasser M, Pimenta E, Gordon RD. Familial or genetic primary aldosteronism and Gordon syndrome. *Endocrinol Metab Clin North Am*. 2011;40(2):343–368, viii
288. Sacerdote A, Weiss K, Tran T, Rokeya Noor B, McFarlane SI. Hypertension in patients with Cushing's disease: pathophysiology, diagnosis, and management. *Curr Hypertens Rep*. 2005;7(3):212–218
289. Baid S, Nieman LK. Glucocorticoid excess and hypertension. *Curr Hypertens Rep*. 2004;6(6):493–499
290. Michalkiewicz E, Sandrini R, Figueiredo B, et al. Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry. *J Clin Oncol*. 2004;22(5):838–845
291. Danzi S, Klein I. Thyroid hormone and blood pressure regulation. *Curr Hypertens Rep*. 2003;5(6):513–520
292. Bahn RS, Burch HB, Cooper DS, et al; American Thyroid Association; American Association of Clinical Endocrinologists. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. *Endocr Pract*. 2011;17(3):456–520
293. Heyliger A, Tangpricha V, Weber C, Sharma J. Parathyroidectomy decreases systolic and diastolic blood pressure in hypertensive patients with primary hyperparathyroidism. *Surgery*. 2009;146(6):1042–1047
294. Rydberg E, Birgander M, Bondeson AG, Bondeson L, Willenheimer R. Effect of successful parathyroidectomy on 24-hour ambulatory blood pressure in patients with primary hyperparathyroidism. *Int J Cardiol*. 2010;142(1):15–21
295. Gambelunghie A, Sallsten G, Borné Y, et al. Low-level exposure to lead, blood pressure, and hypertension in a population-based cohort. *Environ Res*. 2016;149:157–163
296. Lee BK, Ahn J, Kim NS, Lee CB, Park J, Kim Y. Association of blood pressure with exposure to lead and cadmium: analysis of data from the 2008-2013 Korean National Health and Nutrition Examination Survey. *Biol Trace Elem Res*. 2016;174(1):40–51
297. Rapisarda V, Ledda C, Ferrante M, et al. Blood pressure and occupational

- exposure to noise and lead (Pb): a cross-sectional study. *Toxicol Ind Health*. 2016;32(10):1729–1736
298. Hara A, Thijs L, Asayama K, et al. Blood pressure in relation to environmental lead exposure in the national health and nutrition examination survey 2003 to 2010. *Hypertension*. 2015;65(1):62–69
 299. Gump BB, Reihman J, Stewart P, Lonky E, Darvill T, Matthews KA. Blood lead (Pb) levels: a potential environmental mechanism explaining the relation between socioeconomic status and cardiovascular reactivity in children. *Health Psychol*. 2007;26(3):296–304
 300. Chen A, Rhoads GG, Cai B, Salganik M, Rogan WJ. The effect of chelation on blood pressure in lead-exposed children: a randomized study. *Environ Health Perspect*. 2006;114(4):579–583
 301. Chen X, Zhu G, Lei L, Jin T. The association between blood pressure and blood cadmium in a Chinese population living in cadmium polluted area. *Environ Toxicol Pharmacol*. 2013;36(2):595–599
 302. Tellez-Plaza M, Navas-Acien A, Crainiceanu CM, Guallar E. Cadmium exposure and hypertension in the 1999-2004 National Health and Nutrition Examination Survey (NHANES). *Environ Health Perspect*. 2008;116(1):51–56
 303. Gallagher CM, Meliker JR. Blood and urine cadmium, blood pressure, and hypertension: a systematic review and meta-analysis. *Environ Health Perspect*. 2010;118(12):1676–1684
 304. Swaddiwudhipong W, Mahasakpan P, Jeekeeree W, et al. Renal and blood pressure effects from environmental cadmium exposure in Thai children. *Environ Res*. 2015;136:82–87
 305. Cao Y, Chen A, Radcliffe J, et al. Postnatal cadmium exposure, neurodevelopment, and blood pressure in children at 2, 5, and 7 years of age. *Environ Health Perspect*. 2009;117(10):1580–1586
 306. Park JD, Zheng W. Human exposure and health effects of inorganic and elemental mercury. *J Prev Med Public Health*. 2012;45(6):344–352
 307. Weidemann DK, Weaver VM, Fadrowski JJ. Toxic environmental exposures and kidney health in children. *Pediatr Nephrol*. 2016;31(11):2043–2054
 308. Torres AD, Rai AN, Hardiek ML. Mercury intoxication and arterial hypertension: report of two patients and review of the literature. *Pediatrics*. 2000;105(3). Available at: www.pediatrics.org/cgi/content/full/105/3/e34
 309. Brannan EH, Su S, Alverson BK. Elemental mercury poisoning presenting as hypertension in a young child. *Pediatr Emerg Care*. 2012;28(8):812–814
 310. Mercer JJ, Bercovitch L, Muglia JJ. Acrodynia and hypertension in a young girl secondary to elemental mercury toxicity acquired in the home. *Pediatr Dermatol*. 2012;29(2):199–201
 311. Valvi D, Casas M, Romaguera D, et al. Prenatal phthalate exposure and childhood growth and blood pressure: evidence from the Spanish INMA-Sabadell Birth Cohort Study. *Environ Health Perspect*. 2015;123(10):1022–1029
 312. Trasande L, Sathyanarayana S, Spanier AJ, Trachtman H, Attina TM, Urbina EM. Urinary phthalates are associated with higher blood pressure in childhood. *J Pediatr*. 2013;163(3):747–753.e1
 313. Trasande L, Attina TM. Association of exposure to di-2-ethylhexylphthalate replacements with increased blood pressure in children and adolescents. *Hypertension*. 2015;66(2):301–308
 314. Saif I, Seriki D, Moore R, Woywodt A. Midaortic syndrome in neurofibromatosis type 1 resulting in bilateral renal artery stenosis. *Am J Kidney Dis*. 2010;56(6):1197–1201
 315. Kimura M, Kakizaki S, Kawano K, Sato S, Kure S. Neurofibromatosis type 1 complicated by atypical coarctation of the thoracic aorta. *Case Rep Pediatr*. 2013;2013:458543
 316. Malav IC, Kothari SS. Renal artery stenosis due to neurofibromatosis. *Ann Pediatr Cardiol*. 2009;2(2):167–169
 317. Mavani G, Kesar V, Devita MV, Rosenstock JL, Michelis MF, Schwimmer JA. Neurofibromatosis type 1-associated hypertension secondary to coarctation of the thoracic aorta. *Clin Kidney J*. 2014;7(4):394–395
 318. Duan L, Feng K, Tong A, Liang Z. Renal artery stenosis due to neurofibromatosis type 1: case report and literature review. *Eur J Med Res*. 2014;19:17
 319. Srinivasan A, Krishnamurthy G, Fontalvo-Herazo L, et al. Spectrum of renal findings in pediatric fibromuscular dysplasia and neurofibromatosis type 1. *Pediatr Radiol*. 2011;41(3):308–316
 320. Dubov T, Toledano-Alhadeff H, Chernin G, Constantini S, Cleper R, Ben-Shachar S. High prevalence of elevated blood pressure among children with neurofibromatosis type 1. *Pediatr Nephrol*. 2016;31(1):131–136
 321. Erem C, Onder Ersöz H, Ukinç K, et al. Neurofibromatosis type 1 associated with pheochromocytoma: a case report and a review of the literature. *J Endocrinol Invest*. 2007;30(1):59–64
 322. Zinnamosca L, Petramala L, Cotesta D, et al. Neurofibromatosis type 1 (NF1) and pheochromocytoma: prevalence, clinical and cardiovascular aspects. *Arch Dermatol Res*. 2011;303(5):317–325
 323. Nawrot TS, Den Hond E, Fağard RH, Hoppenbrouwers K, Staessen JA. Blood pressure, serum total cholesterol and contraceptive pill use in 17-year-old girls. *Eur J Cardiovasc Prev Rehabil*. 2003;10(6):438–442
 324. Le-Ha C, Beilin LJ, Burrows S, et al. Oral contraceptive use in girls and alcohol consumption in boys are associated with increased blood pressure in late adolescence. *Eur J Prev Cardiol*. 2013;20(6):947–955
 325. Du Y, Rosner BM, Knopf H, Schwarz S, Dören M, Scheidt-Nave C. Hormonal contraceptive use among adolescent girls in Germany in relation to health behavior and biological cardiovascular risk factors. *J Adolesc Health*. 2011;48(4):331–337
 326. Samuels JA, Franco K, Wan F, Sorof JM. Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial. *Pediatr Nephrol*. 2006;21(1):92–95
 327. Covar RA, Leung DY, McCormick D, Steelman J, Zeitler P, Spahn JD. Risk

- factors associated with glucocorticoid-induced adverse effects in children with severe asthma. *J Allergy Clin Immunol*. 2000;106(4):651–659
328. Vehaskari VM. Heritable forms of hypertension. *Pediatr Nephrol*. 2009;24(10):1929–1937
 329. Halperin F, Dluhy RG. Glucocorticoid-remediable aldosteronism. *Endocrinol Metab Clin North Am*. 2011;40(2):333–341, viii
 330. Staley JR, Bradley J, Silverwood RJ, et al. Associations of blood pressure in pregnancy with offspring blood pressure trajectories during childhood and adolescence: findings from a prospective study. *J Am Heart Assoc*. 2015;4(5):e001422
 331. Daniels SD, Meyer RA, Loggie JM. Determinants of cardiac involvement in children and adolescents with essential hypertension. *Circulation*. 1990;82(4):1243–1248
 332. Yang Q, Zhang Z, Kuklina EV, et al. Sodium intake and blood pressure among US children and adolescents. *Pediatrics*. 2012;130(4):611–619
 333. He FJ, MacGregor GA. Importance of salt in determining blood pressure in children: meta-analysis of controlled trials. *Hypertension*. 2006;48(5):861–869
 334. Aeberli I, Spinaz GA, Lehmann R, l'Allemand D, Molinari L, Zimmermann MB. Diet determines features of the metabolic syndrome in 6- to 14-year-old children. *Int J Vitam Nutr Res*. 2009;79(1):14–23
 335. Colín-Ramírez E, Castillo-Martínez L, Orea-Tejeda A, Villa Romero AR, Vergara Castañeda A, Asensio Lafuente E. Waist circumference and fat intake are associated with high blood pressure in Mexican children aged 8 to 10 years. *J Am Diet Assoc*. 2009;109(6):996–1003
 336. Niinikoski H, Jula A, Viikari J, et al. Blood pressure is lower in children and adolescents with a low-saturated-fat diet since infancy: the special turku coronary risk factor intervention project. *Hypertension*. 2009;53(6):918–924
 337. Institute of Medicine. *Strategies to Reduce Sodium Intake in the United States*. Washington, DC: National Academies Press; 2010
 338. Adler AJ, Taylor F, Martin N, Gottlieb S, Taylor RS, Ebrahim S. Reduced dietary salt for the prevention of cardiovascular disease. *Cochrane Database Syst Rev*. 2014;(12):CD009217
 339. Rebholz CM, Gu D, Chen J, et al; GenSalt Collaborative Research Group. Physical activity reduces salt sensitivity of blood pressure: the Genetic Epidemiology Network of Salt Sensitivity study. *Am J Epidemiol*. 2012;176(suppl 7):S106–S113
 340. Torrance B, McGuire KA, Lewanczuk R, McGavock J. Overweight, physical activity and high blood pressure in children: a review of the literature. *Vasc Health Risk Manag*. 2007;3(1):139–149
 341. Chen HH, Chen YL, Huang CY, Lee SD, Chen SC, Kuo CH. Effects of one-year swimming training on blood pressure and insulin sensitivity in mild hypertensive young patients. *Chin J Physiol*. 2010;53(3):185–189
 342. Farpour-Lambert NJ, Aggoun Y, Marchand LM, Martin XE, Herrmann FR, Beghetti M. Physical activity reduces systemic blood pressure and improves early markers of atherosclerosis in pre-pubertal obese children. *J Am Coll Cardiol*. 2009;54(25):2396–2406
 343. Cai L, Wu Y, Cheskin LJ, Wilson RF, Wang Y. Effect of childhood obesity prevention programmes on blood lipids: a systematic review and meta-analysis. *Obes Rev*. 2014;15(12):933–944
 344. Kelley GA, Kelley KS, Tran ZV. The effects of exercise on resting blood pressure in children and adolescents: a meta-analysis of randomized controlled trials. *Prev Cardiol*. 2003;6(1):8–16
 345. van Dijk AE, van Eijsden M, Stronks K, Gemke RJ, Vrijkotte TG. The association between prenatal psychosocial stress and blood pressure in the child at age 5-7 years. *PLoS One*. 2012;7(8):e43548
 346. Stein DJ, Scott K, Haro Abad JM, et al. Early childhood adversity and later hypertension: data from the World Mental Health Survey. *Ann Clin Psychiatry*. 2010;22(1):19–28
 347. Halonen JI, Stenholm S, Pentti J, et al. Childhood psychosocial adversity and adult neighborhood disadvantage as predictors of cardiovascular disease: a cohort study. *Circulation*. 2015;132(5):371–379
 348. Maggio AB, Martin XE, Saunders Gasser C, et al. Medical and non-medical complications among children and adolescents with excessive body weight. *BMC Pediatr*. 2014;14:232
 349. Yun M, Li S, Sun D, et al. Tobacco smoking strengthens the association of elevated blood pressure with arterial stiffness: the Bogalusa Heart Study. *J Hypertens*. 2015;33(2):266–274
 350. Priest JR, Nead KT, Wehner MR, Cooke JP, Leeper NJ. Self-reported history of childhood smoking is associated with an increased risk for peripheral arterial disease independent of lifetime smoking burden. *PLoS One*. 2014;9(2):e88972
 351. Hagan JFSJ, Duncan PM. *Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents*. 3rd ed. Elk Grove Village, IL: American Academy of Pediatrics; 2008
 352. Benson L, Baer HJ, Greco PJ, Kaelber DC. When is family history obtained? - Lack of timely documentation of family history among overweight and hypertensive paediatric patients. *J Paediatr Child Health*. 2010;46(10):600–605
 353. Flynn JT. Evaluation and management of hypertension in childhood. *Prog Pediatr Cardiol*. 2001;12(2):177–188
 354. Wiesen J, Adkins M, Fortune S, et al. Evaluation of pediatric patients with mild-to-moderate hypertension: yield of diagnostic testing. *Pediatrics*. 2008;122(5). Available at: www.pediatrics.org/cgi/content/full/122/5/e988
 355. Yoon EY, Cohn L, Rocchini A, et al. Use of diagnostic tests in adolescents with essential hypertension. *Arch Pediatr Adolesc Med*. 2012;166(9):857–862
 356. Killian L, Simpson JM, Savis A, Rawlins D, Sinha MD. Electrocardiography is a poor screening test to detect left ventricular hypertrophy in children. *Arch Dis Child*. 2010;95(10):832–836

357. Ramaswamy P, Patel E, Fahey M, Mahgerefteh J, Lytrivi ID, Kupferman JC. Electrocardiographic predictors of left ventricular hypertrophy in pediatric hypertension. *J Pediatr*. 2009;154(1):106–110
358. Rijnbeek PR, van Herpen G, Kapusta L, Ten Harkel AD, Witsenburg M, Kors JA. Electrocardiographic criteria for left ventricular hypertrophy in children. *Pediatr Cardiol*. 2008;29(5):923–928
359. Grossman A, Prokupertz A, Koren-Morag N, Grossman E, Shamiss A. Comparison of usefulness of Sokolow and Cornell criteria for left ventricular hypertrophy in subjects aged <20 years versus >30 years. *Am J Cardiol*. 2012;110(3):440–444
360. Caselli S, Maron MS, Urbano-Moral JA, Pandian NG, Maron BJ, Pelliccia A. Differentiating left ventricular hypertrophy in athletes from that in patients with hypertrophic cardiomyopathy. *Am J Cardiol*. 2014;114(9):1383–1389
361. Urbina EM, Gidding SS, Bao W, Pickoff AS, Berdusis K, Berenson GS. Effect of body size, ponderosity, and blood pressure on left ventricular growth in children and young adults in the Bogalusa Heart Study. *Circulation*. 1995;91(9):2400–2406
362. Kuznetsova T, Haddad F, Tikhonoff V, et al; European Project On Genes in Hypertension (EPOGH) Investigators. Impact and pitfalls of scaling of left ventricular and atrial structure in population-based studies. *J Hypertens*. 2016;34(6):1186–1194
363. Armstrong AC, Gidding S, Gjesdal O, Wu C, Bluemke DA, Lima JA. LV mass assessed by echocardiography and CMR, cardiovascular outcomes, and medical practice. *JACC Cardiovasc Imaging*. 2012;5(8):837–848
364. Armstrong AC, Jacobs DR Jr, Gidding SS, et al. Framingham score and LV mass predict events in young adults: CARDIA study. *Int J Cardiol*. 2014;172(2):350–355
365. Gidding SS, Palermo RA, DeLoach SS, Keith SW, Falkner B. Associations of cardiac structure with obesity, blood pressure, inflammation, and insulin resistance in African-American adolescents. *Pediatr Cardiol*. 2014;35(2):307–314
366. Hanevold C, Waller J, Daniels S, Portman R, Sorof J; International Pediatric Hypertension Association. The effects of obesity, gender, and ethnic group on left ventricular hypertrophy and geometry in hypertensive children: a collaborative study of the International Pediatric Hypertension Association. *Pediatrics*. 2004;113(2):328–333
367. Daniels SR, Loggie JM, Khoury P, Kimball TR. Left ventricular geometry and severe left ventricular hypertrophy in children and adolescents with essential hypertension. *Circulation*. 1998;97(19):1907–1911
368. Devereux RB, Wachtell K, Gerdts E, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. *JAMA*. 2004;292(19):2350–2356
369. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*. 2015;28(1):1–39.e14
370. Daniels SR, Kimball TR, Morrison JA, Khoury P, Witt S, Meyer RA. Effect of lean body mass, fat mass, blood pressure, and sexual maturation on left ventricular mass in children and adolescents. Statistical, biological, and clinical significance. *Circulation*. 1995;92(11):3249–3254
371. Lopez L, Colan SD, Frommelt PC, et al. Recommendations for quantification methods during the performance of a pediatric echocardiogram: a report from the Pediatric Measurements Writing Group of the American Society of Echocardiography Pediatric and Congenital Heart Disease Council. *J Am Soc Echocardiogr*. 2010;23(5):465–495, quiz 576–577
372. Foster BJ, Khoury PR, Kimball TR, Mackie AS, Mitsnefes M. New reference centiles for left ventricular mass relative to lean body mass in children. *J Am Soc Echocardiogr*. 2016;29(5):441–447.e2
373. Khoury PR, Mitsnefes M, Daniels SR, Kimball TR. Age-specific reference intervals for indexed left ventricular mass in children. *J Am Soc Echocardiogr*. 2009;22(6):709–714
374. Lipshultz SE, Easley KA, Orav EJ, et al. Reliability of multicenter pediatric echocardiographic measurements of left ventricular structure and function: the prospective P(2)C(2) HIV study. *Circulation*. 2001;104(3):310–316
375. Urbina EM. Abnormalities of vascular structure and function in pediatric hypertension. *Pediatr Nephrol*. 2016;31(7):1061–1070
376. Elmenhorst J, Hulpke-Wette M, Barta C, Dalla Pozza R, Springer S, Oberhoffer R. Percentiles for central blood pressure and pulse wave velocity in children and adolescents recorded with an oscillometric device. *Atherosclerosis*. 2015;238(1):9–16
377. Hidvégi EV, Illyés M, Benczúr B, et al. Reference values of aortic pulse wave velocity in a large healthy population aged between 3 and 18 years. *J Hypertens*. 2012;30(12):2314–2321
378. Miyai N, Utsumi M, Gowa Y, et al. Age-specific nomogram of brachial-ankle pulse wave velocity in Japanese adolescents. *Clin Exp Hypertens*. 2013;35(2):95–101
379. Urbina EM, Khoury PR, McCoy CE, Dolan LM, Daniels SR, Kimball TR. Triglyceride to HDL-C ratio and increased arterial stiffness in children, adolescents, and young adults [published correction appears in *Pediatrics*. 2013;132(4):780]. *Pediatrics*. 2013;131(4). Available at: www.pediatrics.org/cgi/content/full/131/4/e1082
380. Lurbe E, Torro I, Garcia-Vicent C, Alvarez J, Fernández-Fornoso JA, Redon J. Blood pressure and obesity exert independent influences on pulse wave velocity in youth. *Hypertension*. 2012;60(2):550–555
381. Zhu H, Yan W, Ge D, et al. Relationships of cardiovascular phenotypes with healthy weight, at risk of overweight, and overweight in US youths. *Pediatrics*. 2008;121(1):115–122
382. Charakida M, Jones A, Falaschetti E, et al. Childhood obesity and vascular

- phenotypes: a population study. *J Am Coll Cardiol*. 2012;60(25):2643–2650
383. Doyon A, Kracht D, Bayazit AK, et al; 4C Study Consortium. Carotid artery intima-media thickness and distensibility in children and adolescents: reference values and role of body dimensions. *Hypertension*. 2013;62(3):550–556
 384. Urbina EM, Kimball TR, McCoy CE, Khoury PR, Daniels SR, Dolan LM. Youth with obesity and obesity-related type 2 diabetes mellitus demonstrate abnormalities in carotid structure and function. *Circulation*. 2009;119(22):2913–2919
 385. Keehn L, Milne L, McNeill K, Chowieniczky P, Sinha MD. Measurement of pulse wave velocity in children: comparison of volumetric and tonometric sensors, brachial-femoral and carotid-femoral pathways. *J Hypertens*. 2014;32(7):1464–1469, discussion 1469
 386. Kis E, Cseprekál O, Kerti A, et al. Measurement of pulse wave velocity in children and young adults: a comparative study using three different devices. *Hypertens Res*. 2011;34(11):1197–1202
 387. Chhadia S, Cohn RA, Vural G, Donaldson JS. Renal Doppler evaluation in the child with hypertension: a reasonable screening discriminator? *Pediatr Radiol*. 2013;43(12):1549–1556
 388. Castelli PK, Dillman JR, Kershaw DB, Khalatbari S, Stanley JC, Smith EA. Renal sonography with Doppler for detecting suspected pediatric renin-mediated hypertension - is it adequate? *Pediatr Radiol*. 2014;44(1):42–49
 389. Rountas C, Vlychou M, Vassiou K, et al. Imaging modalities for renal artery stenosis in suspected renovascular hypertension: prospective intraindividual comparison of color Doppler US, CT angiography, GD-enhanced MR angiography, and digital subtraction angiography. *Ren Fail*. 2007;29(3):295–302
 390. Marks SD, Tullus K. Update on imaging for suspected renovascular hypertension in children and adolescents. *Curr Hypertens Rep*. 2012;14(6):591–595
 391. Lagomarsino E, Orellana P, Muñoz J, Velásquez C, Cavagnaro F, Valdés F. Captopril scintigraphy in the study of arterial hypertension in pediatrics. *Pediatr Nephrol*. 2004;19(1):66–70
 392. Abdulsamea S, Anderson P, Biassoni L, et al. Pre- and postcaptopril renal scintigraphy as a screening test for renovascular hypertension in children. *Pediatr Nephrol*. 2010;25(2):317–322
 393. Günay EC, Öztürk MH, Ergün EL, et al. Losartan renography for the detection of renal artery stenosis: comparison with captopril renography and evaluation of dose and timing. *Eur J Nucl Med Mol Imaging*. 2005;32(9):1064–1074
 394. Reusz GS, Kis E, Cseprekál O, Szabó AJ, Kis E. Captopril-enhanced renal scintigraphy in the diagnosis of pediatric hypertension. *Pediatr Nephrol*. 2010;25(2):185–189
 395. Loeffler LF, Navas-Acien A, Brady TM, Miller ER III, Fadrowski JJ. Uric acid level and elevated blood pressure in US adolescents: National Health and Nutrition Examination Survey, 1999–2006. *Hypertension*. 2012;59(4):811–817
 396. Shatat IF, Abdallah RT, Sas DJ, Hailpern SM. Serum uric acid in U.S. adolescents: distribution and relationship to demographic characteristics and cardiovascular risk factors. *Pediatr Res*. 2012;72(1):95–100
 397. Viazzi F, Antolini L, Giussani M, et al. Serum uric acid and blood pressure in children at cardiovascular risk. *Pediatrics*. 2013;132(1). Available at: www.pediatrics.org/cgi/content/full/132/1/e93
 398. Reschke LD, Miller ER III, Fadrowski JJ, et al. Elevated uric acid and obesity-related cardiovascular disease risk factors among hypertensive youth. *Pediatr Nephrol*. 2015;30(12):2169–2176
 399. Alper AB Jr, Chen W, Yau L, Srinivasan SR, Berenson GS, Hamm LL. Childhood uric acid predicts adult blood pressure: the Bogalusa Heart Study. *Hypertension*. 2005;45(1):34–38
 400. Soletsky B, Feig DI. Uric acid reduction rectifies prehypertension in obese adolescents. *Hypertension*. 2012;60(5):1148–1156
 401. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. *JAMA*. 2008;300(8):924–932
 402. Assadi F. Allopurinol enhances the blood pressure lowering effect of enalapril in children with hyperuricemic essential hypertension. *J Nephrol*. 2014;27(1):51–56
 403. Feig DI, Nakagawa T, Karumanchi SA, et al. Hypothesis: uric acid, nephron number, and the pathogenesis of essential hypertension. *Kidney Int*. 2004;66(1):281–287
 404. Viazzi F, Rebora P, Giussani M, et al. Increased serum uric acid levels blunt the antihypertensive efficacy of lifestyle modifications in children at cardiovascular risk. *Hypertension*. 2016;67(5):934–940
 405. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. *Circulation*. 2004;110(1):32–35
 406. Bigazzi R, Bianchi S, Baldari D, Campese VM. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. *J Hypertens*. 1998;16(9):1325–1333
 407. Chugh A, Bakris GL. Microalbuminuria: what is it? Why is it important? What should be done about it? An update. *J Clin Hypertens (Greenwich)*. 2007;9(3):196–200
 408. Flynn JT. Microalbuminuria in children with primary hypertension. *J Clin Hypertens (Greenwich)*. 2016;18(10):962–965
 409. Radhakishun NN, van Vliet M, von Rosenstiel IA, Beijnen JH, Diamant M. Limited value of routine microalbuminuria assessment in multi-ethnic obese children. *Pediatr Nephrol*. 2013;28(7):1145–1149
 410. Tsioufis C, Mazaraki A, Dimitriadis K, Stefanidis CJ, Stefanadis C. Microalbuminuria in the paediatric age: current knowledge and

- emerging questions. *Acta Paediatr.* 2011;100(9):1180–1184
411. Seeman T, Pohl M, Palyzova D, John U. Microalbuminuria in children with primary and white-coat hypertension. *Pediatr Nephrol.* 2012;27(3):461–467
 412. Sanad M, Gharib A. Evaluation of microalbuminuria in obese children and its relation to metabolic syndrome. *Pediatr Nephrol.* 2011;26(12):2193–2199
 413. Assadi F. Effect of microalbuminuria lowering on regression of left ventricular hypertrophy in children and adolescents with essential hypertension. *Pediatr Cardiol.* 2007;28(1):27–33
 414. Niemirska A, Litwin M, Feber J, Jurkiewicz E. Blood pressure rhythmicity and visceral fat in children with hypertension. *Hypertension.* 2013;62(4):782–788
 415. Kupferman JC, Paterno K, Mahgerefteh J, et al. Improvement of left ventricular mass with antihypertensive therapy in children with hypertension. *Pediatr Nephrol.* 2010;25(8):1513–1518
 416. Falkner B, DeLoach S, Keith SW, Gidding SS. High risk blood pressure and obesity increase the risk for left ventricular hypertrophy in African-American adolescents. *J Pediatr.* 2013;162(1):94–100
 417. Stabouli S, Kotsis V, Rizos Z, et al. Left ventricular mass in normotensive, prehypertensive and hypertensive children and adolescents. *Pediatr Nephrol.* 2009;24(8):1545–1551
 418. Tirosh A, Afek A, Rudich A, et al. Progression of normotensive adolescents to hypertensive adults: a study of 26,980 teenagers. *Hypertension.* 2010;56(2):203–209
 419. Chobanian AV, Bakris GL, Black HR; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report [published correction appears in *JAMA*. 2003;290(2):197]. *JAMA.* 2003;289(19):2560–2571
 420. Moreno-Luna R, Muñoz-Hernandez R, Miranda ML, et al. Olive oil polyphenols decrease blood pressure and improve endothelial function in young women with mild hypertension. *Am J Hypertens.* 2012;25(12):1299–1304
 421. Damasceno MM, de Araújo MF, de Freitas RW, de Almeida PC, Zanetti ML. The association between blood pressure in adolescents and the consumption of fruits, vegetables and fruit juice—an exploratory study. *J Clin Nurs.* 2011;20(11–12):1553–1560
 422. Juonala M, Viikari JS, Kähönen M, et al. Life-time risk factors and progression of carotid atherosclerosis in young adults: the Cardiovascular Risk in Young Finns study. *Eur Heart J.* 2010;31(14):1745–1751
 423. Yuan WL, Kakinami L, Gray-Donald K, Czernichow S, Lambert M, Paradis G. Influence of dairy product consumption on children's blood pressure: results from the QUALITY cohort. *J Acad Nutr Diet.* 2013;113(7):936–941
 424. Moore LL, Bradlee ML, Singer MR, Qureshi MM, Buendia JR, Daniels SR. Dietary approaches to stop hypertension (DASH) eating pattern and risk of elevated blood pressure in adolescent girls. *Br J Nutr.* 2012;108(9):1678–1685
 425. Günther AL, Liese AD, Bell RA, et al. Association between the dietary approaches to hypertension diet and hypertension in youth with diabetes mellitus. *Hypertension.* 2009;53(1):6–12
 426. Couch SC, Saelens BE, Levin L, Dart K, Falciglia G, Daniels SR. The efficacy of a clinic-based behavioral nutrition intervention emphasizing a DASH-type diet for adolescents with elevated blood pressure. *J Pediatr.* 2008;152(4):494–501
 427. Davis JN, Ventura EE, Cook LT, Gyllenhammer LE, Gatto NMLA. LA Sprouts: a gardening, nutrition, and cooking intervention for Latino youth improves diet and reduces obesity. *J Am Diet Assoc.* 2011;111(8):1224–1230
 428. Saneei P, Hashemipour M, Kelishadi R, Rajaei S, Esmaillzadeh A. Effects of recommendations to follow the dietary approaches to stop hypertension (DASH) diet v. usual dietary advice on childhood metabolic syndrome: a randomised cross-over clinical trial. *Br J Nutr.* 2013;110(12):2250–2259
 429. Barnes TL, Crandell JL, Bell RA, Mayer-Davis EJ, Dabelea D, Liese AD. Change in DASH diet score and cardiovascular risk factors in youth with type 1 and type 2 diabetes mellitus: the SEARCH for Diabetes in Youth study. *Nutr Diabetes.* 2013;3:e91
 430. Rao M, Afshin A, Singh G, Mozaffarian D. Do healthier foods and diet patterns cost more than less healthy options? A systematic review and meta-analysis. *BMJ Open.* 2013;3(12):e004277
 431. Monzavi R, Dreimane D, Geffner ME, et al. Improvement in risk factors for metabolic syndrome and insulin resistance in overweight youth who are treated with lifestyle intervention. *Pediatrics.* 2006;117(6). Available at: www.pediatrics.org/cgi/content/full/117/6/e1111
 432. Asghari G, Yuzbashian E, Mirmiran P, Hooshmand F, Najafi R, Azizi F. Dietary approaches to stop hypertension (DASH) dietary pattern is associated with reduced incidence of metabolic syndrome in children and adolescents. *J Pediatr.* 2016;174:178–184.e1
 433. Pacifico L, Anania C, Martino F, et al. Management of metabolic syndrome in children and adolescents. *Nutr Metab Cardiovasc Dis.* 2011;21(6):455–466
 434. Puri M, Flynn JT. Management of hypertension in children and adolescents with the metabolic syndrome. *J Cardiometab Syndr.* 2006;1(4):259–268
 435. Davis MM, Gance-Cleveland B, Hassink S, Johnson R, Paradis G, Resnicow K. Recommendations for prevention of childhood obesity. *Pediatrics.* 2007;120(suppl 4):S229–S253
 436. Ogedegbe G, Chaplin W, Schoenthaler A, et al. A practice-based trial of motivational interviewing and adherence in hypertensive African Americans. *Am J Hypertens.* 2008;21(10):1137–1143

437. Bosworth HB, Olsen MK, Neary A, et al. Take Control of Your Blood Pressure (TCYB) study: a multifactorial tailored behavioral and educational intervention for achieving blood pressure control. *Patient Educ Couns*. 2008;70(3):338–347
438. Resnicow K, McMaster F, Bocian A, et al. Motivational interviewing and dietary counseling for obesity in primary care: an RCT. *Pediatrics*. 2015;135(4):649–657
439. Davoli AM, Broccoli S, Bonvicini L, et al. Pediatrician-led motivational interviewing to treat overweight children: an RCT. *Pediatrics*. 2013;132(5). Available at: www.pediatrics.org/cgi/content/full/132/5/e1236
440. Broccoli S, Davoli AM, Bonvicini L, et al. Motivational interviewing to treat overweight children: 24-month follow-up of a randomized controlled trial. *Pediatrics*. 2016;137(1):e20151979
441. Flattum C, Friend S, Neumark-Sztainer D, Story M. Motivational interviewing as a component of a school-based obesity prevention program for adolescent girls. *J Am Diet Assoc*. 2009;109(1):91–94
442. Schwartz RP, Hamre R, Dietz WH, et al. Office-based motivational interviewing to prevent childhood obesity: a feasibility study. *Arch Pediatr Adolesc Med*. 2007;161(5):495–501
443. Döring N, Ghaderi A, Bohman B, et al. Motivational interviewing to prevent childhood obesity: a cluster RCT. *Pediatrics*. 2016;137(5):1–10
444. Spear BA, Barlow SE, Ervin C, et al. Recommendations for treatment of child and adolescent overweight and obesity. *Pediatrics*. 2007;120(4, suppl 4):S254–S288
445. Kabat-Zinn J, Hanh TN. *Full Catastrophe Living: Using the Wisdom of Your Body and Mind to Face Stress, Pain, and Illness*. New York, NY: Delta; 1990
446. Gregoski MJ, Barnes VA, Tingen MS, Harshfield GA, Treiber FA. Breathing awareness meditation and LifeSkills Training programs influence upon ambulatory blood pressure and sodium excretion among African American adolescents. *J Adolesc Health*. 2011;48(1):59–64
447. Barnes VA, Kapuku GK, Treiber FA. Impact of transcendental meditation on left ventricular mass in African American adolescents. *Evid Based Complement Alternat Med*. 2012;2012:923153
448. Sieverdes JC, Mueller M, Gregoski MJ, et al. Effects of Hatha yoga on blood pressure, salivary α -amylase, and cortisol function among normotensive and prehypertensive youth. *J Altern Complement Med*. 2014;20(4):241–250
449. Sorof JM, Cargo P, Graepel J, et al. β -blocker/thiazide combination for treatment of hypertensive children: a randomized double-blind, placebo-controlled trial. *Pediatr Nephrol*. 2002;17(5):345–350
450. Trachtman H, Hainer JW, Sugg J, Teng R, Sorof JM, Radcliffe J; Candesartan in Children with Hypertension (CINCH) Investigators. Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years. *J Clin Hypertens (Greenwich)*. 2008;10(10):743–750
451. Herder SD, Weber E, Winkemann A, Herder C, Morck H. Efficacy and safety of angiotensin II receptor type 1 antagonists in children and adolescents. *Pediatr Nephrol*. 2010;25(5):801–811
452. Schaefer F, Litwin M, Zachwieja J, et al. Efficacy and safety of valsartan compared to enalapril in hypertensive children: a 12-week, randomized, double-blind, parallel-group study. *J Hypertens*. 2011;29(12):2484–2490
453. Gartenmann AC, Fossali E, von Vigier RO, et al. Better renoprotective effect of angiotensin II antagonist compared to dihydropyridine calcium channel blocker in childhood. *Kidney Int*. 2003;64(4):1450–1454
454. Chaturvedi S, Lipszyc DH, Licht C, Craig JC, Parekh R. Pharmacological interventions for hypertension in children. *Evid Based Child Health*. 2014;9(3):498–580
455. Flynn JT. Efficacy and safety of prolonged amlodipine treatment in hypertensive children. *Pediatr Nephrol*. 2005;20(5):631–635
456. Schaefer F, Coppo R, Bagga A, et al. Efficacy and safety of valsartan in hypertensive children 6 months to 5 years of age. *J Hypertens*. 2013;31(5):993–1000
457. Batisky DL, Sorof JM, Sugg J, et al; Toprol-XL Pediatric Hypertension Investigators. Efficacy and safety of extended release metoprolol succinate in hypertensive children 6 to 16 years of age: a clinical trial experience. *J Pediatr*. 2007;150(2):134–139, 139.e1
458. Wells T, Blumer J, Meyers KE, et al; Valsartan Pediatric Hypertension Study Group. Effectiveness and safety of valsartan in children aged 6 to 16 years with hypertension. *J Clin Hypertens (Greenwich)*. 2011;13(5):357–365
459. Trachtman H, Frank R, Mahan JD, et al. Clinical trial of extended-release felodipine in pediatric essential hypertension. *Pediatr Nephrol*. 2003;18(6):548–553
460. Shahinfar S, Cano F, Soffer BA, et al. A double-blind, dose-response study of losartan in hypertensive children. *Am J Hypertens*. 2005;18(2, pt 1):183–190
461. Hazan L, Hernández Rodríguez OA, Bhorat AE, Miyazaki K, Tao B, Heyrman R; Assessment of Efficacy and Safety of Olmesartan in Pediatric Hypertension Study Group. A double-blind, dose-response study of the efficacy and safety of olmesartan medoxomil in children and adolescents with hypertension. *Hypertension*. 2010;55(6):1323–1330
462. Flynn JT, Newburger JW, Daniels SR, et al; PATH-1 Investigators. A randomized, placebo-controlled trial of amlodipine in children with hypertension. *J Pediatr*. 2004;145(3):353–359
463. Simonetti GD, Rizzi M, Donadini R, Bianchetti MG. Effects of antihypertensive drugs on blood pressure and proteinuria in childhood. *J Hypertens*. 2007;25(12):2370–2376
464. Seeman T, Dusek J, Vondrák K, Flögelová H, Geier P, Janda J. Ramipril in the treatment of hypertension and proteinuria in children with chronic kidney diseases. *Am J Hypertens*. 2004;17(5, pt 1):415–420
465. Hammer GB, Verghese ST, Drover DR, Yaster M, Tobin JR. Pharmacokinetics and pharmacodynamics of fenoldopam mesylate for blood pressure control

- in pediatric patients. *BMC Anesthesiol.* 2008;8:6
466. Blowey DL. Update on the pharmacologic treatment of hypertension in pediatrics. *J Clin Hypertens (Greenwich).* 2012;14(6):383–387
 467. Li JS, Flynn JT, Portman R, et al. The efficacy and safety of the novel aldosterone antagonist eplerenone in children with hypertension: a randomized, double-blind, dose-response study. *J Pediatr.* 2010;157(2):282–287
 468. U.S. Food and Drug Administration. Pediatric product development. Available at: www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm049867.htm. Accessed February 6, 2017
 469. Croxtall JD. Valsartan: in children and adolescents with hypertension. *Paediatr Drugs.* 2012;14(3):201–207
 470. Menon S, Berezny KY, Kilaru R, et al. Racial differences are seen in blood pressure response to fosinopril in hypertensive children. *Am Heart J.* 2006;152(2):394–399
 471. Li JS, Baker-Smith CM, Smith PB, et al. Racial differences in blood pressure response to angiotensin-converting enzyme inhibitors in children: a meta-analysis. *Clin Pharmacol Ther.* 2008;84(3):315–319
 472. Seeman T, Dostálek L, Gilík J. Control of hypertension in treated children and its association with target organ damage. *Am J Hypertens.* 2012;25(3):389–395
 473. Redwine K, Howard L, Simpson P, et al; Network of Pediatric Pharmacology Research Units. Effect of placebo on ambulatory blood pressure monitoring in children. *Pediatr Nephrol.* 2012;27(10):1937–1942
 474. Halbach SM, Hamman R, Yonekawa K, Hanevold C. Utility of ambulatory blood pressure monitoring in the evaluation of elevated clinic blood pressures in children. *J Am Soc Hypertens.* 2016;10(5):406–412
 475. White WB, Turner JR, Sica DA, et al. Detection, evaluation, and treatment of severe and resistant hypertension: proceedings from an American Society of Hypertension Interactive forum held in Bethesda, MD, U.S.A., October 10th, 2013. *J Am Soc Hypertens.* 2014;8(10):743–757
 476. Narayan H, Webb DJ. New evidence supporting the use of mineralocorticoid receptor blockers in drug-resistant hypertension. *Curr Hypertens Rep.* 2016;18(5):34
 477. Williams B, MacDonald TM, Morant S, et al; British Hypertension Society's PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. *Lancet.* 2015;386(10008):2059–2068
 478. Mitsnefes M, Ho PL, McEnery PT. Hypertension and progression of chronic renal insufficiency in children: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). *J Am Soc Nephrol.* 2003;14(10):2618–2622
 479. Dionne JM. Evidence-based guidelines for the management of hypertension in children with chronic kidney disease. *Pediatr Nephrol.* 2015;30(11):1919–1927
 480. VanDeVoorde RG, Mitsnefes MM. Hypertension and CKD. *Adv Chronic Kidney Dis.* 2011;18(5):355–361
 481. Mitsnefes MM, Kimball TR, Kartal J, et al. Progression of left ventricular hypertrophy in children with early chronic kidney disease: 2-year follow-up study. *J Pediatr.* 2006;149(5):671–675
 482. Wright JT Jr, Williamson JD, Whelton PK, et al; SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. *N Engl J Med.* 2015;373(22):2103–2116
 483. Wong H, Mylrea K, Feber J, Drukker A, Filler G. Prevalence of complications in children with chronic kidney disease according to KDOQI. *Kidney Int.* 2006;70(3):585–590
 484. Simonetti GD, von Vigier RO, Konrad M, Rizzi M, Fossali E, Bianchetti MG. Candesartan cilexetil in children with hypertension or proteinuria: preliminary data. *Pediatr Nephrol.* 2006;21(10):1480–1482
 485. White CT, Macpherson CF, Hurley RM, Matsell DG. Antiproteinuric effects of enalapril and losartan: a pilot study. *Pediatr Nephrol.* 2003;18(10):1038–1043
 486. Webb NJ, Lam C, Loeys T, et al. Randomized, double-blind, controlled study of losartan in children with proteinuria. *Clin J Am Soc Nephrol.* 2010;5(3):417–424
 487. Webb NJ, Shahinfar S, Wells TG, et al. Losartan and enalapril are comparable in reducing proteinuria in children. *Kidney Int.* 2012;82(7):819–826
 488. Wühl E, Mehls O, Schaefer F; ESCAPE Trial Group. Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure. *Kidney Int.* 2004;66(2):768–776
 489. Eppens MC, Craig ME, Cusumano J, et al. Prevalence of diabetes complications in adolescents with type 2 compared with type 1 diabetes. *Diabetes Care.* 2006;29(6):1300–1306
 490. Mayer-Davis EJ, Ma B, Lawson A, et al; SEARCH for Diabetes in Youth Study Group. Cardiovascular disease risk factors in youth with type 1 and type 2 diabetes: implications of a factor analysis of clustering. *Metab Syndr Relat Disord.* 2009;7(2):89–95
 491. Margeirsdottir HD, Larsen JR, Brunborg C, Overby NC, Dahl-Jørgensen K; Norwegian Study Group for Childhood Diabetes. High prevalence of cardiovascular risk factors in children and adolescents with type 1 diabetes: a population-based study. *Diabetologia.* 2008;51(4):554–561
 492. Orchard TJ, Forrest KY, Kuller LH, Becker DJ; Pittsburgh Epidemiology of Diabetes Complications Study. Lipid and blood pressure treatment goals for type 1 diabetes: 10-year incidence data from the Pittsburgh Epidemiology of Diabetes Complications Study. *Diabetes Care.* 2001;24(6):1053–1059
 493. Copeland KC, Zeitler P, Geffner M, et al; TODAY Study Group. Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline. *J Clin Endocrinol Metab.* 2011;96(1):159–167
 494. Klingensmith GJ, Connor CG, Ruedy KJ, et al; Pediatric Diabetes Consortium. Presentation of youth with type 2

- diabetes in the Pediatric Diabetes Consortium. *Pediatr Diabetes*. 2016;17(4):266–273
495. Shah AS, Dolan LM, Gao Z, Kimball TR, Urbina EM. Racial differences in arterial stiffness among adolescents and young adults with type 2 diabetes. *Pediatr Diabetes*. 2012;13(2):170–175
496. TODAY Study Group. Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: the TODAY clinical trial. *Diabetes Care*. 2013;36(6):1735–1741
497. Shah AS, Khoury PR, Dolan LM, et al. The effects of obesity and type 2 diabetes mellitus on cardiac structure and function in adolescents and young adults. *Diabetologia*. 2011;54(4):722–730
498. Nambam B, DuBose SN, Nathan BM, et al; T1D Exchange Clinic Network. Therapeutic inertia: underdiagnosed and undertreated hypertension in children participating in the T1D Exchange Clinic Registry. *Pediatr Diabetes*. 2016;17(1):15–20
499. American Diabetes Association. Supplemental issue: standards of medical care in diabetes - 2016. *Diabetes Care*. 2016;39(suppl 1):S1–S2
500. Donaghue KC, Chiarelli F, Trotta D, Allgrove J, Dahl-Jørgensen K. Microvascular and macrovascular complications associated with diabetes in children and adolescents. *Pediatr Diabetes*. 2009;10(suppl 12):195–203
501. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. *Pediatrics*. 2011;128(suppl 5):S213–S256
502. Stern MP. Diabetes and cardiovascular disease. The “common soil” hypothesis. *Diabetes*. 1995;44(4):369–374
503. Martino F, Puddu PE, Pannarale G, et al. Hypertension in children and adolescents attending a lipid clinic. *Eur J Pediatr*. 2013;172(12):1573–1579
504. Rodríguez-Morán M, Guerrero-Romero F, Aradillas-García C, et al. Atherogenic indices and prehypertension in obese and non-obese children. *Diab Vasc Dis Res*. 2013;10(1):17–24
505. Li J, Motsko SP, Goehring EL Jr, Vendiola R, Maneno M, Jones JK. Longitudinal study on pediatric dyslipidemia in population-based claims database. *Pharmacoepidemiol Drug Saf*. 2010;19(1):90–98
506. Liao CC, Su TC, Chien KL, et al. Elevated blood pressure, obesity, and hyperlipidemia. *J Pediatr*. 2009;155(1):79–83, 83.e1
507. Marcus CL, Brooks LJ, Draper KA, et al; American Academy of Pediatrics. Diagnosis and management of childhood obstructive sleep apnea syndrome. *Pediatrics*. 2012;130(3). Available at: www.pediatrics.org/cgi/content/full/130/3/e714
508. Kuo YL, Kang KT, Chiu SN, Weng WC, Lee PL, Hsu WC. Blood pressure after surgery among obese and nonobese children with obstructive sleep apnea. *Otolaryngol Head Neck Surg*. 2015;152(5):931–940
509. Lande MB, Adams HR, Kupferman JC, Hooper SR, Szilagyi PG, Batisky DL. A multicenter study of neurocognition in children with hypertension: methods, challenges, and solutions. *J Am Soc Hypertens*. 2013;7(5):353–362
510. Lande MB, Adams H, Falkner B, et al. Parental assessments of internalizing and externalizing behavior and executive function in children with primary hypertension. *J Pediatr*. 2009;154(2):207–212
511. Adams HR, Szilagyi PG, Gebhardt L, Lande MB. Learning and attention problems among children with pediatric primary hypertension. *Pediatrics*. 2010;126(6). Available at: www.pediatrics.org/cgi/content/full/126/6/e1425
512. Settakis G, Páll D, Molnár C, Katona E, Bereczki D, Fülesdi B. Hyperventilation-induced cerebrovascular reactivity among hypertensive and healthy adolescents. *Kidney Blood Press Res*. 2006;29(5):306–311
513. Wong LJ, Kupferman JC, Prohovnik I, et al. Hypertension impairs vascular reactivity in the pediatric brain. *Stroke*. 2011;42(7):1834–1838
514. Lande MB, Kupferman JC, Adams HR. Neurocognitive alterations in hypertensive children and adolescents. *J Clin Hypertens (Greenwich)*. 2012;14(6):353–359
515. Ostrovskaya MA, Rojas M, Kupferman JC, et al. Executive function and cerebrovascular reactivity in pediatric hypertension. *J Child Neurol*. 2015;30(5):543–546
516. Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. *Hypertension*. 2007;49(1):69–75
517. Guo F, He D, Zhang W, Walton RG. Trends in prevalence, awareness, management, and control of hypertension among United States adults, 1999 to 2010. *J Am Coll Cardiol*. 2012;60(7):599–606
518. Hajjar J, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. *JAMA*. 2003;290(2):199–206
519. Daniels SR, McMahon RP, Obarzanek E, et al. Longitudinal correlates of change in blood pressure in adolescent girls. *Hypertension*. 1998;31(1):97–103
520. Wang X, Poole JC, Treiber FA, Harshfield GA, Hanevold CD, Snieder H. Ethnic and gender differences in ambulatory blood pressure trajectories: results from a 15-year longitudinal study in youth and young adults. *Circulation*. 2006;114(25):2780–2787
521. Rosner B, Cook N, Portman R, Daniels S, Falkner B. Blood pressure differences by ethnic group among United States children and adolescents. *Hypertension*. 2009;54(3):502–508
522. Peacock WF IV, Hilleman DE, Levy PD, Rhoney DH, Varon J. A systematic review of nicardipine vs labetalol for the management of hypertensive crises. *Am J Emerg Med*. 2012;30(6):981–993
523. Wiest DB, Garner SS, Uber WE, Sade RM. Esmolol for the management of pediatric hypertension after cardiac operations. *J Thorac Cardiovasc Surg*. 1998;115(4):890–897

524. Flynn JT, Mottes TA, Brophy PD, Kershaw DB, Smoyer WE, Bunchman TE. Intravenous nicardipine for treatment of severe hypertension in children. *J Pediatr*. 2001;139(1):38–43
525. Tabbutt S, Nicolson SC, Adamson PC, et al. The safety, efficacy, and pharmacokinetics of esmolol for blood pressure control immediately after repair of coarctation of the aorta in infants and children: a multicenter, double-blind, randomized trial. *J Thorac Cardiovasc Surg*. 2008;136(2):321–328
526. Miyashita Y, Peterson D, Rees JM, Flynn JT. Isradipine for treatment of acute hypertension in hospitalized children and adolescents. *J Clin Hypertens (Greenwich)*. 2010;12(11):850–855
527. Thomas CA, Moffett BS, Wagner JL, Mott AR, Feig DI. Safety and efficacy of intravenous labetalol for hypertensive crisis in infants and small children. *Pediatr Crit Care Med*. 2011;12(1):28–32
528. Kako H, Gable A, Martin D, et al. A prospective, open-label trial of clevidipine for controlled hypotension during posterior spinal fusion. *J Pediatr Pharmacol Ther*. 2015;20(1):54–60
529. Hammer GB, Lewandowski A, Drover DR, et al. Safety and efficacy of sodium nitroprusside during prolonged infusion in pediatric patients. *Pediatr Crit Care Med*. 2015;16(5):397–403
530. Flynn JT, Bradford MC, Harvey EM. Intravenous hydralazine in hospitalized children and adolescents with hypertension. *J Pediatr*. 2016;168:88–92
531. Yang WC, Zhao LL, Chen CY, Wu YK, Chang YJ, Wu HP. First-attack pediatric hypertensive crisis presenting to the pediatric emergency department. *BMC Pediatr*. 2012;12:200
532. Baracco R, Mattoo TK. Pediatric hypertensive emergencies. *Curr Hypertens Rep*. 2014;16(8):456
533. Flynn JT, Tullus K. Severe hypertension in children and adolescents: pathophysiology and treatment [published correction appears in *Pediatr Nephrol*. 2012;27(3):503–504]. *Pediatr Nephrol*. 2009;24(6):1101–1112
534. Patel NH, Romero SK, Kaelber DC. Evaluation and management of pediatric hypertensive crises: hypertensive urgency and hypertensive emergencies. *Open Access Emerg Med*. 2012;4:85–92
535. Chen YL, Liu YF, Huang CY, et al. Normalization effect of sports training on blood pressure in hypertensives. *J Sports Sci*. 2010;28(4):361–367
536. Hupin D, Roche F, Gremeaux V, et al. Even a low-dose of moderate-to-vigorous physical activity reduces mortality by 22% in adults aged ≥ 60 years: a systematic review and meta-analysis. *Br J Sports Med*. 2015;49(19):1262–1267
537. Di Paolo FM, Schmied C, Zerguini YA, et al. The athlete's heart in adolescent Africans: an electrocardiographic and echocardiographic study. *J Am Coll Cardiol*. 2012;59(11):1029–1036
538. McCambridge TM, Benjamin HJ, Brenner JS, et al; Council on Sports Medicine and Fitness. Athletic participation by children and adolescents who have systemic hypertension. *Pediatrics*. 2010;125(6):1287–1294
539. Black HR, Sica D, Ferdinand K, White WB. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 6: hypertension: a scientific statement from the American Heart Association and the American College of Cardiology. *J Am Coll Cardiol*. 2015;66(21):2393–2397
540. Tainio J, Qvist E, Miettinen J, et al. Blood pressure profiles 5 to 10 years after transplant in pediatric solid organ recipients. *J Clin Hypertens (Greenwich)*. 2015;17(2):154–161
541. Seeman T, Simková E, Kreisinger J, et al. Control of hypertension in children after renal transplantation. *Pediatr Transplant*. 2006;10(3):316–322
542. Gülhan B, Topaloğlu R, Karabulut E, et al. Post-transplant hypertension in pediatric kidney transplant recipients. *Pediatr Nephrol*. 2014;29(6):1075–1080
543. Arbeiter K, Pichler A, Stemberger R, et al. ACE inhibition in the treatment of children after renal transplantation. *Pediatr Nephrol*. 2004;19(2):222–226
544. Suszynski TM, Rizzari MD, Gillingham KJ, et al. Antihypertensive pharmacotherapy and long-term outcomes in pediatric kidney transplantation. *Clin Transplant*. 2013;27(3):472–480
545. Sakallı H, Baskın E, Bayrakçı US, Moray G, Haberal M. Acidosis and hyperkalemia caused by losartan and enalapril in pediatric kidney transplant recipients. *Exp Clin Transplant*. 2014;12(4):310–313
546. Cooley WC, Sagerman PJ; American Academy of Pediatrics; American Academy of Family Physicians; American College of Physicians; Transitions Clinical Report Authoring Group. Supporting the health care transition from adolescence to adulthood in the medical home. *Pediatrics*. 2011;128(1):182–200
547. Julius S, Nesbitt SD, Egan BM, et al; Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. *N Engl J Med*. 2006;354(16):1685–1697
548. Kurioka S, Horie S, Inoue A, Mafune K, Tsuda Y, Otsuji Y. Risk of progression to hypertension in nonhypertensive Japanese workers aged 20–64 years. *J Hypertens*. 2014;32(2):236–244
549. Stabouli S, Papakatsika S, Kotsis V. The role of obesity, salt and exercise on blood pressure in children and adolescents. *Expert Rev Cardiovasc Ther*. 2011;9(6):753–761
550. Holm JC, Gamborg M, Neland M, et al. Longitudinal changes in blood pressure during weight loss and regain of weight in obese boys and girls. *J Hypertens*. 2012;30(2):368–374
551. Gillman MW, Ellison RC. Childhood prevention of essential hypertension. *Pediatr Clin North Am*. 1993;40(1):179–194
552. Krousel-Wood MA, Muntner P, He J, Whelton PK. Primary prevention of essential hypertension. *Med Clin North Am*. 2004;88(1):223–238
553. Whelton PK, He J, Appel LJ, et al; National High Blood Pressure Education Program Coordinating Committee. Primary prevention of

- hypertension: clinical and public health advisory from the National High Blood Pressure Education Program. *JAMA*. 2002;288(15):1882–1888
554. Kim N, Seo DC, King MH, Lederer AM, Sovinski D. Long-term predictors of blood pressure among adolescents during an 18-month school-based obesity prevention intervention. *J Adolesc Health*. 2014;55(4):521–527
 555. Aburto NJ, Ziolkovska A, Hooper L, Elliott P, Cappuccio FP, Meerpohl JJ. Effect of lower sodium intake on health: systematic review and meta-analyses. *BMJ*. 2013;346:f1326
 556. American Academy of Pediatrics. EQIPP: hypertension recognition and management. Available at: <http://shop.aap.org/eqipp-hypertension-identification-and-management>. Accessed February 6, 2017
 557. American Academy of Pediatrics, Council on Quality Improvement and Patient Safety. Implementation guide. Available at: <https://www.aap.org/en-us/about-the-aap/Committees-Councils-Sections/coqips/Pages/Implementation-Guide.aspx>. Accessed July 28, 2017
 558. Wang YC, Cheung AM, Bibbins-Domingo K, et al. Effectiveness and cost-effectiveness of blood pressure screening in adolescents in the United States. *J Pediatr*. 2011;158(2):257–264. e1–e7
 559. Davis ML, Ferguson MA, Zachariah JP. Clinical predictors and impact of ambulatory blood pressure monitoring in pediatric hypertension referrals. *J Am Soc Hypertens*. 2014;8(9):660–667
 560. Leu MG, Austin E, Foti JL, et al. A framework for evaluating value of new clinical recommendations. *Hosp Pediatr*. 2016;6(10):578–586
 561. Bradshaw B. The role of the family in managing therapy in minority children with type 2 diabetes mellitus. *J Pediatr Endocrinol Metab*. 2002;15(suppl 1):547–551
 562. Pinhas-Hamiel O, Standiford D, Hamiel D, Dolan LM, Cohen R, Zeitler PS. The type 2 family: a setting for development and treatment of adolescent type 2 diabetes mellitus. *Arch Pediatr Adolesc Med*. 1999;153(10):1063–1067
 563. Mulvaney SA, Schlundt DG, Mudasiru E, et al. Parent perceptions of caring for adolescents with type 2 diabetes. *Diabetes Care*. 2006;29(5):993–997
 564. Summerbell CD, Ashton V, Campbell KJ, Edmunds L, Kelly S, Waters E. Interventions for treating obesity in children. *Cochrane Database Syst Rev*. 2003;(3):CD001872
 565. Skinner AC, Weinberger M, Mulvaney S, Schlundt D, Rothman RL. Accuracy of perceptions of overweight and relation to self-care behaviors among adolescents with type 2 diabetes and their parents. *Diabetes Care*. 2008;31(2):227–229
 566. Thompson M, Dana T, Bougatsos C, Blazina I, Norris SL. Screening for hypertension in children and adolescents to prevent cardiovascular disease. *Pediatrics*. 2013;131(3):490–525
 567. Urbina EM, de Ferranti S, Steinberger J. Observational studies may be more important than randomized clinical trials: weaknesses in US Preventive Services Task Force recommendation on blood pressure screening in youth. *Hypertension*. 2014;63(4):638–640
 568. Flynn JT. Ambulatory blood pressure monitoring in children: imperfect yet essential. *Pediatr Nephrol*. 2011;26(12):2089–2094
 569. Juonala M, Magnussen CG, Venn A, et al. Influence of age on associations between childhood risk factors and carotid intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study, the Childhood Determinants of Adult Health Study, the Bogalusa Heart Study, and the Muscatine Study for the International Childhood Cardiovascular Cohort (i3C) Consortium. *Circulation*. 2010;122(24):2514–2520
 570. Muntner P, Becker RC, Calhoun D, et al. Introduction to the American Heart Association's hypertension strategically focused research network. *Hypertension*. 2016;67(4):674–680

Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents

Joseph T. Flynn, David C. Kaelber, Carissa M. Baker-Smith, Douglas Blowey, Aaron E. Carroll, Stephen R. Daniels, Sarah D. de Ferranti, Janis M. Dionne, Bonita Falkner, Susan K. Flinn, Samuel S. Gidding, Celeste Goodwin, Michael G. Leu, Makia E. Powers, Corinna Rea, Joshua Samuels, Madeline Simasek, Vidhu V. Thaker, Elaine M. Urbina and SUBCOMMITTEE ON SCREENING AND MANAGEMENT OF

HIGH BLOOD PRESSURE IN CHILDREN

Pediatrics; originally published online August 21, 2017;

DOI: 10.1542/peds.2017-1904

Updated Information & Services

including high resolution figures, can be found at:
</content/early/2017/08/21/peds.2017-1904.full.html>

References

This article cites 559 articles, 142 of which can be accessed free at:
</content/early/2017/08/21/peds.2017-1904.full.html#ref-list-1>

Subspecialty Collections

This article, along with others on similar topics, appears in the following collection(s):

Cardiology

/cgi/collection/cardiology_sub

Cardiovascular Disorders

/cgi/collection/cardiovascular_disorders_sub

Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
</site/misc/Permissions.xhtml>

Reprints

Information about ordering reprints can be found online:
</site/misc/reprints.xhtml>

PEDIATRICS is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since 1948. PEDIATRICS is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2017 by the American Academy of Pediatrics. All rights reserved. Print ISSN: 0031-4005. Online ISSN: 1098-4275.

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™



PEDIATRICS®

OFFICIAL JOURNAL OF THE AMERICAN ACADEMY OF PEDIATRICS

Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents

Joseph T. Flynn, David C. Kaelber, Carissa M. Baker-Smith, Douglas Blowey, Aaron E. Carroll, Stephen R. Daniels, Sarah D. de Ferranti, Janis M. Dionne, Bonita Falkner, Susan K. Flinn, Samuel S. Gidding, Celeste Goodwin, Michael G. Leu, Makia E. Powers, Corinna Rea, Joshua Samuels, Madeline Simasek, Vidhu V. Thaker, Elaine M. Urbina and SUBCOMMITTEE ON SCREENING AND MANAGEMENT OF HIGH BLOOD PRESSURE IN CHILDREN

Pediatrics; originally published online August 21, 2017;
DOI: 10.1542/peds.2017-1904

The online version of this article, along with updated information and services, is located on the World Wide Web at:

</content/early/2017/08/21/peds.2017-1904.full.html>

PEDIATRICS is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since 1948. PEDIATRICS is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2017 by the American Academy of Pediatrics. All rights reserved. Print ISSN: 0031-4005. Online ISSN: 1098-4275.

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™

